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Abstract 
 
Light-based therapies, including photodynamic therapy (PDT), for acne are gaining 
popularity in dermatology. Based largely upon in vitro data, their beneficial outcome 
in acne is thought to be related to their bactericidal effects on Propionibacterium 
acnes. This randomised controlled study sought to determine the efficacy and 
tolerability of 610-950 nm IPL (administered as IPL-Placebo) and IPL-assisted 
methyl aminolaevulinate PDT (IPL-MAL) vs. adapalene 0.1% gel in the treatment of 
acne and to identify their mode of action, looking specifically at the effect on surface 
density of P. acnes. 
 
Thirty seven patients (31% of target due to slow recruitment) with mild to moderate 
facial acne were randomly allocated to IPL-MAL treatment, IPL-Placebo or 
adapalene. Both IPL groups received four treatments to the whole face, 2 weeks 
apart, while the third group was given adapalene nightly for 12 weeks. Assessments 
performed at baseline and weeks 8, 11, and 16 included inflamed, noninflamed and 
total lesion counts, Leeds grading, follicular porphyrin fluorescence, the Family 
Dermatology Life Quality Index and Dermatology Life Quality Index scores, and 
patient’s perspective of clinical improvement by the visual analogue scale (VAS). 
Cutaneous microflora was collected from all patients at similar intervals. 
 
Of the 37 patients randomised, only 30 completed the trial (10 in each group) and 
were included in the final analyses. Adapalene was found to be significantly superior 
to IPL-MAL and IPL-Placebo in reducing the noninflamed (adapalene 37.6% vs. 
IPL-MAL 3.4% vs. IPL-Placebo −9.7%) and total lesion counts (adapalene 35.7% 
vs. IPL-MAL 4.3% vs. IPL-Placebo −8.4%) at week 16. This was accompanied by a 
significant decrease (52.9%) in the DLQI score in this group (p = 0.031). The 
maximum improvement in inflamed lesion counts from baseline was seen at week 11 
in the IPL-MAL (20.7%) and IPL-Placebo (13.4%) groups but occurred at week 16 
in the adapalene group (26.5%). Statistical significance, however, was not reached in 
any group. There was no significant difference within or between the groups in the 
VAS, Leeds, FDLQI and porphyrin fluorescence results pre- and post- treatment. A 
significant increase in the density of propionibacteria (p = 0.021) and
xxi  
coagulase-negative staphylococci (p = 0.039) was seen in the IPL-Placebo and IPL- 
MAL groups at week 16 and week 8, respectively; however, there was no significant 
difference between the groups. All the treatments were well tolerated. 
 
Adapalene remains an effective first line treatment in mild to moderate facial acne. 
However, the present study has remained indecisive (due to being underpowered) in 
drawing any firm conclusions regarding the efficacy of IPL and IPL-MAL on 
inflamed acne lesions. Further research is therefore warranted before their use can be 
advocated for acne treatment. An alternative mode of action for IPL and IPL-assisted 
MAL-PDT other than photodynamic destruction of P. acnes is suggested from the 
results of this study. 
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Chapter 1 
 
 
 
 
 
 
 
 
 
 
 
BACKGROUND 1: Microbiology of Acne 
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Error! 
1. Microbiology of Acne 
 
1.1 Introduction 
 
Acne vulgaris is a multifactorial, pleomorphic skin disease of the pilosebaceous 
follicles (units) characterised by a variety of noninflamed (open and closed 
comedones) and inflamed (macules, papules, pustules, and nodules) lesions. It is 
estimated to affect up to 80% of individuals aged 11-30 [1]. Of the three types of 
pilosebaceous follicles (PSFs) found on the face (terminal, vellus, and sebaceous), 
acne only affects the sebaceous follicles which are characterised by widely dilated 
follicular canals with small inconspicuous vellus hairs and a large sebaceous gland 
(Figure 1.1) [2]. Comedones represent acne-affected follicles filled with horny 
lamellated material and are typical of, but not peculiar to, acne [2, 3]. 
 
 
 
 
Figure 1.1: Sebaceous follicle. Adapted from Williams et al. [4]. 
 
 
 
Vellus hair 
 
 
 
 
 
 
 
 
 
Sebaceous gland 
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Although a common disease, the aetiology of acne is not yet fully elucidated and is 
thought to be a multifactorial process. Hormonally influenced excessive sebum 
production (seborrhoea), comedogenesis (comedone formation), Propionibacterium 
acnes colonisation, genetic susceptibility, as well as inflammation are considered the 
major contributors to acne pathogenesis [5-8]. Various acne treatments target one or 
more of these aetiological factors and include topical and systemic 
antibiotics/retinoids, antimicrobials, and hormonal therapy (e.g. oral contraceptives, 
antiandrogens) [9]. These are successful in some, but not all, patients. Moreover, a 
slow onset of action and undesirable effects such as dryness, bleaching of hair and 
clothing, birth defects and issue of antibiotic resistance result in poor patient 
compliance [10]. 
 
 
It has long been observed that many patients describe an improvement in their acne 
following sun exposure [11]. In recent years, a technological explosion has resulted 
in the development of numerous laser and non-laser light-based treatments which has 
given us an opportunity to examine the role of light in the treatment of acne. Indeed, 
visible light has been shown to have a beneficial effect on acne [12]. The possible 
mechanism of action of these optical therapies in acne has been a subject of debate. It 
is known that P. acnes produces porphyrins [13]. Based largely upon in vitro data, 
the beneficial effect of optical therapies in acne is assumed to be due to the 
photodynamic eradication of P. acnes owing to activation of its endogenous 
porphyrins [14-16]. However, the role of P. acnes in acne has long been a 
controversial topic and it is still unclear whether this micro-organism has a causal 
role in the pathogenesis of acne. 
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1.2 Propionibacterium acnes 
 
1.2.1 P. acnes: Causal or bystander? 
 
Propionibacterium acnes, an aerotolerant anaerobic Gram-positive bacillus that 
produces propionic acid as a metabolic byproduct [17], has been implicated in the 
pathogenesis of acne since the beginning of the last century. Alexander [18], in 
1909, claimed successful treatment of acne with vaccines containing the ‘acne 
bacillus’. However, Lovejoy and Hastings [19] in 1911 isolated the organism from 
sebaceous secretions of normal skin, casting doubt on its significance in the aetiology 
of acne. It was not until 1950 that P. acnes came to be regarded as a normal and 
ubiquitous member of the resident cutaneous microflora and its reputation as a 
pathogen subsequently declined [20]. Interest in the microbial aetiology of acne 
again developed after the observation that the P. acnes population increased greatly 
at puberty [21]. This was observed to coincide with the onset of acne, and treatment 
with antibiotics was found to be beneficial in the majority of patients. Moreover, 
acne patients were observed to carry higher densities of P. acnes compared with 
normal controls [22]. The presence of significantly higher levels of antibodies to P. 
acnes in patients with cystic and pustular acne compared with mild comedopapular 
acne and persons with healthy skin further strengthened the belief that P. acnes is 
important in the aetiopathogenesis of acne [23]. This also led to the hypothesis that 
hypersensitivity to P. acnes may account for the variation in acne severity [24]. 
 
 
Thus, there is evidence, although largely circumstantial, which suggests that micro- 
organisms, particularly P. acnes, are important in the pathogenesis of acne vulgaris. 
Despite an abundance of data, it is still unclear whether P. acnes is actually a causal  
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agent in the development of various acne lesions (noninflamed and inflamed), as 
it is a normal and ubiquitous member of the resident cutaneous microflora [25]. 
 
 
The clinical study in this thesis attempted to evaluate the effect of intense pulsed light 
(a polychromatic adjustable incoherent light source), used alone and in combination 
with a photosensitiser, on the cutaneous microflora in acne patients. A review of 
the literature surrounding the microbiological data on normal and acne-affected skin 
was conducted, with a view to revisiting the unresolved controversy of the role of 
P. acnes in the initiation of acne. The discussion from this section will act as the 
basis for next chapter, in which the pathogenesis of acne will be discussed in the 
context of findings from this review. 
 
 
1.2.2 Microbial colonisation of normal skin 
 
Various micro-organisms normally reside on human skin. Propionibacterium acnes 
is one of four species of propionibacteria (the other three being P. granulosum, P. 
avidum, and P. propionicum) which form part of the resident commensal flora in 
humans [26]. Two further species, formerly known as P. innocuum and P. 
lymphophilum, have been reclassified as Propioniferax innocua [27] and 
Propionimicrobium lymphophilum [28], respectively. Among these commensal 
propionibacteria, P. acnes is found to be present on the skin in nearly 100% of adults 
[25]. Although the organism is isolated from the skin surface, its normal habitat is 
the PSF. Propionibacterium acnes shares this habitat with the yeast Malassezia 
(formerly known as Pityrosporum [29]), along with the Gram-positive, coagulase- 
negative cocci, namely staphylococci and micrococci [30]. 
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1.2.2.1 Skin surface microflora 
 
Various techniques have been used over the years to study the cutaneous microflora. 
The surface scrub technique of Williamson and Kligman [31], which has been 
extensively used, gives useful information about the surface flora but yields little or 
no information about the microbial ecology of an individual PSF. This method 
involves scrubbing the surface of a defined area of skin, using a mild detergent (0.1 
% Triton X-100 in 0.075 M phosphate buffer, pH 7.9) and a Teflon rod [31]. By 
using this technique, it has been shown that propionibacteria colonisation of normal 
skin shows significant body site and age-related differences [21, 25, 32]. 
Propionibacterium acnes density as well as prevalence is highest in the oily regions 
of skin such as the face and upper trunk. Body sites with few sebaceous glands such 
as lower trunk and extremities have a lower prevalence and much lower mean 
densities [32]. Propionibacterium acnes counts on scalp and face can be as high as 
105 organisms per cm2 [25]. Propionibacterium granulosum is also found in the oily 
regions but at a lower density and prevalence, while P. avidum is normally isolated 
from wet areas of the body such as the axilla, groin and rectum [25]. It is well 
recognised that P. acnes uses triglycerides in sebum as a carbon and energy source 
with the resultant liberation of free fatty acids (FFA). The evidence in favour of this 
process includes the following observations: (i) Marples et al. [33] established that P. 
acnes lipase is responsible for the cleavage of sebaceous triglycerides into FFA; (ii) 
Rebillo and Hawk [34] demonstrated an inverse correlation between skin surface 
glycerol levels (an end product of lipolysis of sebaceous triglycerides along with 
FFA) and the P. acnes population, suggesting that glycerol may be a substrate for P. 
acnes; and (iii) results of two studies in which drugs were used to either increase or 
decrease sebum production resulting in a concomitant increase or decrease in the 
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numbers of propionibacteria, helped to strengthen this hypothesis further [35, 36]. 
Thus a high density and prevalence of P. acnes at skin sites with large numbers of 
sebaceous glands is not unexpected. 
 
 
Likewise, age- related differences have been found in P. acnes colonisation, with 
infants and young children up to the age of five carrying significantly higher 
numbers than older children up to age 10 [21]. Sebum production by the sebaceous 
glands is androgen-dependent; at puberty there is an increase in the sebum excretion 
rate (SER) [37, 38] which is accompanied by a rise in the population density of 
cutaneous propionibacteria [21]. The population density keeps increasing until the 
age of 25 years, remaining constant thereafter through adulthood and middle age 
[21]. A declining trend is seen after age 70 years [21], which is consistent with 
decreasing sebaceous secretion at that time [38]. After age 20 years, men carry 
significantly higher numbers of P. acnes compared to women [21]. This is in 
accordance with the observation that normal men over the age of 20 years produce 
greater quantities of sebum than women [38]. No significant racial difference in the 
population density of P. acnes has been found in healthy black and white individuals 
[21]. Moreover, the pattern for aerobic bacterial population, particularly cocci, in 
relation to age, sex and race has been found to be the same as for P. acnes [21]. 
 
 
1.2.2.2 Microbial ecology of normal pilosebaceous follicles 
 
The surface scrub technique is useful for removing micro-organisms that are located 
on or near the skin surface, but it is likely that most of the follicular inhabitants are 
not removed. As acne is a disease of the PSFs, it is obvious that the microbial 
ecology of individual follicles is more relevant when dealing with acne-affected skin 
8  
and gaining this knowledge could yield more information about the role of micro- 
organisms in acne vulgaris (Table 1.1). Leeming et al. [39] used punch biopsies to 
separate the epidermis with intact follicles from the dermis after CaCl2 treatment, in 
order to study the microbiology of normal follicles from the upper back of patients 
with acne. This technique enables quantification of bacteria from a single PSF but 
has the drawback that it is dependent on obtaining biopsies of skin for sampling.    Of 
140 normal follicles isolated from 54 patients, only 12% of the follicles were 
colonised by propionibacteria (with P. acnes the only colonising species), with a 
mean population density of 2.6×105 per follicle [39]. Similarly the incidence of 
Staphylococcus and Pityrosporum was 4% and 13% respectively. The geometric 
mean density of staphylococci was found to be 5.5103, with S. epidermidis 
(formerly known as S. albus [40]) being the major colonising species (approximately 
50% of all staphylococci) followed by other coagulase-negative staphylococci 
(CoNS). Colonised follicles, in this study, were described as those containing high 
densities of bacteria, and PSFs with low numbers were considered to have 
contaminants [39]. Intriguingly, approximately 34% of the normal follicles were 
found to be sterile even if the micro-organisms thought to be contaminants were 
included as colonists [41]. Likewise Till et al. [42], by using the same technique, 
found propionibacteria (exclusively P. acnes) and Staphylococcus (exclusively S. 
epidermidis) to colonise only 17% and 10% of 48 normal follicles from the back of 
patients with persistent and late-onset acne, respectively. They were, however, 
unable to detect any viable Malassezia in these follicles. Moreover, like Leeming et 
al. [39], they also found 90% of these normal PSFs to be sterile. 
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Despite the scarcity of data on the microbiology of normal PSFs, based on the 
findings of Leeming et al. [39] and Till et al. [42] it can be concluded that only a 
proportion of normal PSFs is colonised by bacteria. Furthermore, Leeming et al. [39] 
observed the proportion of follicles colonised by micro-organisms to vary widely 
among patients, which can probably explain individual differences in microbial 
densities found at the skin surface. The slightly higher prevalence of propionibacteria 
and staphylococci in the study of Till et al. [42] may be explained by the fact that no 
attempt   was   made   to   differentiate   colonised   follicles   by   bacterial    density. 
  
 
 
Table 1.1: Studies on the microbial ecology of normal pilosebaceous follicles (PSFs) 
 
Study 
(first author 
and year) 
Age range 
(years) 
Type of lesions 
sampled 
Number 
of lesions 
sampled 
Abstinence 
from 
antibiotics 
presampling 
(weeks) 
Sampling 
technique 
Culture 
medium/ 
incubation 
period for P. 
acnes 
Microbiology 
(percentage of lesions 
colonised/sterile) 
Conclusion 
 
Leeming 
(1984) [39] 
 
14-37 
 
Normal PSFs 
from the back of 
patients with 
acne 
 
140 
 
6 
 
Punch biopsy 
with micro- 
dissection of 
PSFs from 
unprepared skin 
 
 Reinforced    
 clostridial   
 medium  
 supplemented  
 with 0.2%  
 Tween-80/6 days 
 
Propionibacteria 
(exclusively P. acnes) 
12 
Staphylococci 
(predominantly 
S. epidermidis ) 4 
Pityrosporum spp. 13 
Sterile 34 
 
A proportion of 
normal PSFs is 
colonised by three 
major genera of 
micro-organisms i.e. 
Propionibacterium, 
Staphylococcus, and 
Pityrosporum. 
Follicular 
microenvironment 
may be responsible for 
the colonisation of 
these normal follicles 
 
Till 
(2000) [42] 
 
Female 26-51 
(19)a 
Male 25-50 
(17)a 
Female 26-54 
(12)a 
 
Normal PSFs 
from the back of 
patients with 
acne 
 
48 
 
6 
 
Punch biopsy 
with micro- 
dissection of 
PSFs 
 
Brain-heart 
infusion agar 
with 
furazolidone/
7 days 
 
Propionibacteria 
(exclusively P. acnes) 
17 
Staphylococci 
(exclusively 
S. epidermidis) 10 
Malassezia 0 
Sterile 90 
 
Only a proportion of 
normal PSFs is 
colonised by 
propionibacteria, 
therefore, validating 
the results of Leeming 
et al. 
 
P. acnes, Propionibacterium acnes; S. epidermidis, Staphylococcus epidermidis. aNumber of patients in each group in parentheses. 
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1.2.3 Microbiology of acne lesions 
 
In the hope of establishing a microbial aetiology for acne, various investigators have 
studied the microbiology of noninflamed [41, 43-47] (Table 1.2) and inflamed acne 
lesions [42, 43, 48-51] (Tables 1.3). The sampling technique varied with the type 
of lesion being studied. 
 
 
1.2.3.1 Microbiology of comedones 
 
1.2.3.1.1 Microbial ecology of extracted comedones 
 
A sampling method involving expression of the comedonal material, with the help of 
a comedone extractor or stylet, and culturing it for bacteriological examination has 
been used by various investigators to study the microbial ecology of comedones [43-
46]. This method has the drawback that there can be no assurance of complete 
sampling [52]. 
 
Shehadeh and Kligman [43] examined (Gram-stained smears) and cultured a total of 
71 comedones (45 open; 26 closed), from over 100 adolescent boys and girls, and 
found Corynebacterium acnes (synonymous with P. acnes) and C. acnes along   with 
S. albus in 96% and 92% of the lesions, respectively. Likewise, S. albus was isolated 
from 96% of the lesions while none of the comedones was found to be sterile. 
Similarly, Ganor and Sacks [44] compared the microbial flora of acne and senile 
comedones (seen on the sun-damaged faces of the elderly) and found corynebacteria 
(synonymous with propionibacteria) and staphylococci in 65% and 51% of the acne 
comedones respectively. Moreover, yeasts were seen in 67% of these lesions. The 
investigators failed to culture all the corynebacteria identified microscopically and, 
therefore, corynebacteria from only 20% of the acne comedones were identified as C. 
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acnes. Similarly staphylococci from only 41% of the comedones were identified as S. 
albus [44]. No significant difference was found in the incidence of staphylococci or 
Pityrosporum spp. between the acne and senile comedones. However, corynebacteria 
were found less frequently in the senile compared with acne comedones [44]. Both 
these studies showed that < 100% of the comedones are colonised by 
propionibacteria or staphylococci but the researchers failed to mention the avoidance 
of antibiotics (presampling) in their cohort of patients. Therefore, it is difficult to 
completely rule out the role of antibiotics affecting the bacterial colonisation in these 
studies. 
 
 
Subsequently, Marples et al. [45], in an attempt to quantify the microbial population 
of individual comedones, studied the microflora of open and closed comedones in 
15 patients and isolated C. acnes in 92% of the lesions at a geometric mean density 
of 8.2104 per comedone. Furthermore, aerobes (mainly CoNS) were recovered from 
85% of all lesions while yeasts were seen in all but one preparation. Similarly, 
Puhvel and Amirian [46] studied the bacterial ecology of 148 open comedones from 
the face and back of 38 acne patients and cultured anaerobic diptheroids 
(synonymous with propionibacteria) and aerobic cocci from 80% and 75% of the 
lesions, respectively. Seven per cent of the comedones were found to harbour neither 
of the two micro-organisms. The results of this study were in agreement with the 
findings of Shehadeh and Kligman, Ganor and Sacks and Marples et al. [43-45] who 
also showed that comedones are not universally colonised by P. acnes, supporting 
the argument that the presence of P. acnes is not a prerequisite for comedogenesis. 
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1.2.3.1.2 Microbial ecology of follicular casts/comedones isolated by the 
cyanoacrylate sampling technique 
A cyanoacrylate gel technique to isolate and enumerate micro-organisms from 
individual PSFs (without biopsy) involves the use of cyanoacrylate gel and a sterile 
glass slide/sampler which is pressed against the skin and then gently peeled away 
[53]. The procedure extracts the follicular material and its resident bacteria. This 
method has the disadvantage that incomplete removal of follicular material can occur 
[52]. Moreover, as the cyanoacrylate gel has been shown to have an antibacterial 
effect, this may affect the viability of the bacteria to some extent [53].  
 
 
In an attempt to evaluate the role of P. acnes in the initiation of comedogenesis, 
Lavker et al. [47] investigated the structural organisation and bacteriological profile 
of follicular casts (isolated by the cyanoacrylate method) and early comedones 
(sampled by a Schamberg extractor) in prepubertal and early pubertal individuals. 
Neither follicular casts nor comedones (collected from five children aged 9-11 years 
with early acne vulgaris) yielded P. acnes when cultured. Additionally, in 10 of the 
15 prepubertal children, cultures obtained from the forehead and cheek by the surface 
scrub technique also failed to yield any P. acnes. Furthermore, both light and 
electron microscopy failed to show any bacteria in the prepubertal follicular casts. 
Prepubertal follicular casts contained all of the abnormalities usually seen in 
follicular casts and biopsy material from patients with acne, which suggests that these 
casts represent potential comedones. The authors concluded that as these 
abnormalities occurred in the complete absence of bacteria, therefore bacteria are not 
essential for the formation of follicular casts or comedones [47]. Complete absence 
of P. acnes in the follicular casts was validated by various techniques and yielded 
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compelling evidence against the role of P. acnes in the initiation of comedogenesis.  
However, whether these prepubertal children did develop acne at puberty is 
unknown. A long-term study investigating the occurrence/prevalence of acne in this 
group would have been more informative in drawing conclusions as to the role of P. 
acnes in comedogenesis. 
 
 
1.2.3.1.3 Microbial ecology of comedones isolated by microdissection from skin 
biopsies 
In order to resolve the ongoing controversy of the role of P. acnes in the initiation of 
comedogenesis, Leeming et al. [41] studied the bacteriology of 59 comedones (29 
open; 30 closed), isolated by microdissection from skin biopsies, from the upper 
back of 49 patients with acne. Approximately 55% and 22% of the comedones were 
found to be colonised by propionibacteria and staphylococci, respectively. Likewise, 
Pityrosporum spp. colonised 74% of these lesions [41]. Comparing these results with 
the findings of their study on the microbial ecology of normal PSFs, no significant 
difference was observed in the population density of propionibacteria among normal 
follicles and comedones. However, micro-organisms (propionibacteria, staphylococci 
and Pityrosporum spp.) were found to colonise significantly more comedones. 
Moreover, the species of staphylococci and propionibacteria isolated did not differ 
significantly among normal follicles and comedones. Lastly, compared with 34% of 
the normal follicles, approximately 11% of closed while 7% of open comedones 
were found to be sterile [39, 41]. 
 
 
Because of the different sampling and culturing techniques used by various 
investigators it is difficult to compare all the microbiological data on comedones. 
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However, one consistent observation that can be made is the fact that there was not 
universal colonisation of these lesions by a single microbial agent. Secondly, some of 
the lesions have been found to be sterile [41, 46], again arguing against the role of 
micro-organisms in the initiation of comedogenesis. 
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Table 1.2: Studies on the microbial ecology of comedones 
 
Study 
(first 
author 
and year) 
Age range 
(years) 
Type of 
lesions 
sampled 
Number of 
lesions 
sampled 
Abstinence 
from 
antibiotics 
presampling 
(weeks) 
Sampling 
technique 
Culture medium/ 
incubation 
period for P. 
acnes 
Microbiology 
(percentage of lesions 
colonised/sterile) 
Conclusion 
 
Shehadeh 
(1963) [43] 
 
 Adolescent   
 boys and  
 girls 
 
Comedones 
 
71 (45 open; 
26 closed ) 
 
NM 
 
Extraction of 
lesion content 
by sharp acne 
stylet or 
pointed 
scalpel after 
wiping 
surface with 
70% isopropyl 
alcohol. A 
sopping 
sponge left on 
skin for 3 min 
 
Brain-heart 
infusion blood 
agar fortified by 
1% glucose/5 
days under 90% 
N2  and 10% CO2 
C. acnes 96 
C. acnes & S. albus 92 
S. albus 96 
Sterile 0 
 
Acne flora is a ‘stable 
biad’ consisting of C. 
acnes and S. albus. These 
organisms are extension of 
those colonising normal 
PSFs 
 
Ganor 
(1969) [44] 
 
NM 
 
 Open  
 comedones/   
 senile  
 comedones 
 
101 (51 acne 
comedones; 
50 senile 
comedones) 
 
NM 
 
Comedo 
extraction by 
acne stylet 
after wiping 
surface with 
70% alcohol 
and an 
alcohol- 
soaked gauze 
left on skin for 
3 min 
 
Glucose blood 
agar/7 days 
Acne comedones: 
Corynebacteria   65 
Staphylococci 51 
Yeasts 67 
Senile comedones: 
Corynebacteria   36 
Staphylococci 50 
Yeasts 60 
 
Comedonal microflora is 
probably of a secondary 
nature 
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Table 1.2 Continued 
 
Study 
(first 
author 
and year) 
Age range 
(years) 
Type of 
lesions 
sampled 
Number of 
lesions 
sampled 
Abstinence 
from 
antibiotics 
presampling 
(weeks) 
Sampling 
technique 
Culture medium/ 
incubation 
period for P. 
acnes 
Microbiology 
(Percentage of lesions 
colonised/sterile) 
Conclusion 
 
Marples 
(1973) [45] 
 
14-23 
 
Comedones 
 
150 (75 
open; 75 
closed ) 
 
3 
 
Comedo 
extraction by 
Schamberg 
extractor after 
wiping skin 
with 70% 
ethanol 
 
Marshall and 
Kelsey agar/7 
days 
C. acnes 92 
Aerobes (mainly 
coagulase-negative 
staphylococci)     85 
Yeasts 99 
 
Incidence of cocci, 
Pityrosporum and C. acnes 
is nearly 100% in 
comedones; the absence of 
a group, in a given 
comedone, is probably due 
to technical error 
 
Puhvel 
(1979) [46] 
 
16-30 
 
 Open  
 comedones 
 
148 
 
3 
 
Comedo 
extraction by a 
comedone 
extractor after 
wiping skin 
with 70% 
alcohol 
 
Brain-heart 
infusion agar 
supplemented 
with 1% 
dextrose/5 days at 
37°C under 90% 
CO2  and 10% N2 
 
Anaerobic diptheroids 80 
Aerobic cocci 75 
No anaerobic diptheroid or 
aerobic cocci 7 
 
The comedonal microflora 
is an extension of the 
normal follicular flora and 
is unrelated to the event of 
comedogenesis 
 
Lavker 
(1981) [47] 
 
5-10 (15)a 
9-11 (5)a 
 
 Follicular  
 casts/  
 comedones 
 
88 follicular 
casts 
28 
comedones 
 
NM 
 
Cyanoacrylate 
/comedo 
extraction by 
Schamberg 
extractor. 
Information 
about surface 
disinfection 
NM 
 
Brain-heart 
infusion agar with 
0.1% Tween-80/7 
days 
 
No P. acnes yielded 
 
Bacteria, particularly P. 
acnes, are not involved in 
the initiation of 
comedogenesis 
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Table 1.2 Continued 
 
Study 
(first 
author 
and year) 
Age range 
(years) 
Type of 
lesions 
sampled 
Number of 
lesions 
sampled 
Abstinence 
from 
antibiotics 
presampling 
(weeks) 
Sampling 
technique 
Culture medium/ 
incubation 
period for P. 
acnes 
Microbiology 
(percentage of lesions 
colonised/sterile) 
Conclusion 
 
Leeming 
(1985) [41] 
 
13-39 
 
Comedones 
 
59 (29 open; 
30 closed) 
 
6 
 
 Punch biopsy  
 with  
 microdissection  
 of PSFs from  
 unprepared skin 
 
Reinforced 
clostridial 
medium 
supplemented 
with 0.2% Tween- 
80/6 days 
 
Propionibacteria 55 
Staphylococci 22 
Pityrosporum spp. 74 
Sterile: 
closed comedones 11; 
open comedones 7 
 
The presence of micro- 
organisms is not essential 
for the initiation of 
comedogenesis 
 
P. acnes, Propionibacterium acnes; C. acnes, Corynebacterium acnes; S. albus, Staphylococcus albus; PSFs, pilosebaceous follicles; NM, not mentioned. 
aNumber of patients in each group in parentheses. 
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1.2.3.2 Microbiology of inflamed acne lesions 
 
Over the years, various researchers have investigated the microbial ecology of 
inflamed acne lesions, in order to test the hypothesis that the microflora of 
noninflamed and inflamed acne lesions may be different. 
 
 
1.2.3.2.1 Inflamed lesions (predominantly pustules) 
 
Shehadeh and Kligman [43] examined a total of 104 inflamed acne lesions (papule, 
pustule, nodule or cyst) from over 100 adolescent boys and girls, and found C. acnes 
and C. acnes along with S. albus in 79% and 61% of the lesions respectively. Five 
per cent of the papules as well as pustules were found to be sterile and were observed 
to contain very few organisms on Gram-stained smears. Likewise,  Marples and 
Izumi [48], investigated the bacteriology of pustular acne in 109 pustules from 27 
acne patients and found C. acnes in 73%, Gram-positive cocci in 60% 
(predominantly S. epidermidis), and Gram-negative rods (predominantly 
Enterobacter aerogenes) in 10% of these lesions. Furthermore, 12% of the pustules 
were found to be sterile, with microscopic examination of the Gram-stained smears 
substantiating the negative culture results. Brook et al. [49], who also studied the 
bacteriology of 32 pustular acne lesions, isolated only aerobes/facultative anaerobes 
(predominantly S. epidermidis) and anaerobes (predominantly Peptostreptococcus 
followed by Propionibacterium spp.) from 47% and 34% of the lesions, respectively. 
Moreover, mixed aerobes and anaerobes were seen in 18% of the lesions. The results 
from the study of Nishijima et al. [50] also yielded propionibacteria   (predominantly 
P. acnes) and S. epidermidis as the most common (but never 100%) micro- 
organisms, colonising acne pustules. All these studies were limited by the fact that 
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the duration of individual lesions was not given and it is possible that the 
antimicrobial effect of the host immune response could have been responsible for the 
sterility of a number of these lesions. Furthermore, provision of some essential 
information, such as avoidance of antibiotics, presampling, in a number of these 
studies, would have been more informative in drawing conclusions about the 
bacterial ecology of these lesions. 
 
 
1.2.3.2.2 Inflamed lesions (papules) 
 
A key shortcoming of the above studies, i.e. not mentioning the duration o f  
individual inflamed lesions, was finally remedied by Leeming et al. [51]. They 
studied the microbiology of inflammatory papules which have  been  inflamed for 
only short periods, and used microdissection from skin biopsies to isolate 52 ‘1 day’ 
and 19 ‘3 day’ papules from the upper back of patients with acne. They found 
propionibacteria and staphylococci to have a colonising population (i.e. 200 
organisms per papule) in only 71% and 23% of the papules, respectively. Moreover, 
‘3 day’ papules were observed to be colonised more frequently than ‘1 day’ papules, 
although this difference was not statistically significant [51]. Interestingly, bacterial 
cultures from 20% and 54% of the papules (including lesions with both high and low 
microbial densities) were negative for propionibacteria and staphylococci (along with 
other aerobes), respectively. Furthermore, 10% of ‘1 day’ papules were found not to 
be colonised by any micro-organism (Pityrosporum, Propionibacterium, or 
Staphylococcus spp.) while all the ‘3 day’ lesions were found to be colonised. The 
population density of propionibacteria and staphylococci in ‘3 day’ papules was 
almost 2 and 2.6 times greater than in ‘1 day’ lesions, respectively. No bacteria were 
observed on microscopic examination of the papules without associated bacterial 
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growth, further validating the negative culture results [51]. Comparing these results 
with the findings of their studies on the microbial ecology of normal PSFs and 
comedones, propionibacteria, staphylococci and Pityrosporum spp. were found to 
colonise significantly more lesions. However, no significant difference was noted in 
the bacterial and yeast colonisation rates among the comedones and the two types of 
papules. Moreover, there was no significant difference amongst the distribution of 
different species and subspecies colonising normal PSFs, comedones and inflamed 
lesions. Although a rising trend was seen in the bacterial population densities among 
the normal PSFs, comedones and inflamed lesions, with the highest being in the ‘3 
day’ papules, this was not found to be statistically significant [39, 41, 51]. The 
authors concluded that micro-organisms found in inflamed lesions are just an 
extension of those colonising comedones and that their presence is not necessary for 
the initiation of inflammation in acne. 
 
 
Similarly Till et al. [42], by using the sampling technique adopted by Leeming et al. 
[51], also studied the microbiology of acne papules and found propionibacteria 
(exclusively P. acnes) and staphylococci (exclusively S. epidermidis) in 60% and 
24% of the inflamed lesions, respectively. Malassezia serovar A was found in 32% 
while 10% of the inflamed follicles had no detectable viable micro-organisms. 
Comparing these findings with the results obtained from the normal PSFs, biopsied 
from the same cohort of patients, the inflamed lesions were found to have 
significantly higher density and prevalence of propionibacteria and Malassezia [42]. 
These results also supported the work of Leeming et al. [51] who suggested that the 
inflammatory response in the follicles is not always initiated by the micro-organisms. 
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Table 1.3: Studies on the microbial ecology of inflamed acne lesions 
 
Study 
(first author 
and year) 
Age 
range 
(years) 
Type of 
lesions 
sampled 
Number 
of lesions 
sampled 
Abstinence 
from antibiotics 
presampling 
(weeks) 
Sampling 
technique 
Culture medium/ 
incubation period 
for P. acnes 
Microbiology 
(percentage of lesions 
colonised/sterile) 
Conclusion 
 
Shehadeh 
(1963) [43] 
 
Adolesce 
nt boys 
and girls 
 
Papules, 
pustules, 
nodules or 
cysts 
 
104 
 
NM 
 
Extraction of 
lesion content 
by sharp acne 
stylet or 
pointed 
scalpel after 
wiping 
surface with 
70% isopropyl 
alcohol. A 
sopping 
sponge left on 
skin for 3 min 
 
Brain-heart infusion 
blood agar fortified 
by 1% glucose/5 
days under 90% N2 
and 10% CO2 
C. acnes 79 
C. acnes & S. albus 61 
S. albus 77 
Sterile papules 5 
Sterile pustules 5 
 
Acne flora is a ‘stable 
biad’ consisting of C. 
acnes and S. albus. 
These organisms are 
extension of those 
colonising normal PSFs. 
After rupture of the 
comedones, the bacteria 
aggravate the 
inflammatory reaction by 
secondary infection. The 
antibacterial action of the 
host immune response is 
responsible for the 
sterility of a number of 
these inflammatory 
lesions 
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Table 1.3 Continued 
 
Study 
(first author 
and year) 
Age 
range 
(years) 
Type of 
lesions 
sampled 
Number 
of lesions 
sampled 
Abstinence 
from antibiotics 
presampling 
(weeks) 
Sampling 
technique 
Culture medium/ 
incubation period 
for P. acnes 
Microbiology 
(percentage of lesions 
colonised/sterile) 
Conclusion 
 
Marples 
(1970) [48] 
 
15-24 
 
Pustules 
 
109 
 
Of 27 patients 
sampled, 21 
had not 
received 
antibiotics for 
at least 3 
weeks 
 
Skin wiped 
with 70% 
ethyl alcohol 
and pus 
collected by a 
sterile blood 
lancet 
 
Casein yeast extract 
lactate glucose 
agar/7 days in N2 
and CO2 
C. acnes 73 
Gram-positive cocci 
(predominantly S. 
epidermidis) 60 
Gram-negative rods 
(predominantly 
Enterobacter aerogenes)10 
Lipophilic diptheroids 8 
Sterile pustules 12 
 
Normal flora of the face 
and acne pustules is 
similar, comprising of C. 
acnes and Gram-positive 
cocci. The antibacterial 
action of the host 
immune response is 
responsible for the 
sterility of a number of 
these pustules 
 
Brook 
(1995) [49] 
 
12-35 
 
Pustules 
 
32 
 
4 
 
Expression of 
the lesion 
content after 
cleansing 
surface skin 
with 
povidone- 
iodine 
followed by 
alcohol swab 
 
Vitamin K1- 
enriched Brucella 
blood agar and 
thioglycolate 
broth/5 days on 
Brucella blood agar 
and 14 days on 
thioglycolate broth 
Only aerobes and 
facultative anaerobes 
(predominantly S. 
epidermidis)   47 
Only anaerobes 
(predominantly 
Peptostreptococcus spp.) 
34 
Mixed aerobes and 
anaerobes   18 
 
Bacteria other than P. 
acnes and 
Staphylococcus spp. may 
contribute to the 
inflammatory process in 
acne vulgaris 
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Table 1.3 Continued 
 
Study 
(first author 
and year) 
Age 
range 
(years) 
Type of 
lesions 
sampled 
Number 
of lesions 
sampled 
Abstinence 
from antibiotics 
presampling 
(weeks) 
Sampling 
technique 
Culture medium/ 
incubation period 
for P. acnes 
Microbiology 
(percentage of lesions 
colonised/sterile) 
Conclusion 
 
Nishijima 
(2000) [50] 
 
13-43 
 
Pustules 
 
24 
 
NM, although 
none of the 
patients had 
any previous 
oral and/or 
topical 
antimicrobial 
treatment for 
acne 
 
The contents 
of pustules 
squeezed out 
and collected 
using a 
comedonal 
extractor after 
cleaning skin 
with 70% 
ethanol 
 
Brucella HK agar 
medium 
supplemented with 
5% defibrinated 
horse blood/NM 
 
Propionibacteria 
(predominantly P. acnes) 
79 
S. epidermidis 83 
P. acnes and S. 
epidermidis   58 
 
S. epidermidis and P. 
acnes may be the 
representative bacteria in 
any acne lesion. Other 
bacterial species may be 
contaminants 
 
Leeming 
(1988) [51] 
 
13-39 
 
 Inflammat  
 ory papules  
 from the  
 back of  
 patients with  
 acne 
 
‘1 day’ 
papule   52 
 
 
‘3 day’ 
papule   19 
 
4 
 
 Punch biopsy  
 with  
 microdissection  
 of PSFs from  
 unprepared skin 
 
Reinforced 
clostridial medium 
supplemented with 
0.2% Tween-80/6 
days 
 
‘1 day’ papule: 
Propionibacteria 68 
Staphylococci 19 
Pityrosporum spp. 52 
Sterile 10 
 
‘3 day’ papule: 
Propionibacteria 79 
Staphylococci 32 
Pityrosporum spp. 68 
Sterile 0 
 
Micro-organisms found 
in papules are an 
extension of comedonal 
microflora and their 
presence is not essential 
for the initiation of 
inflammation in acne 
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Table 1.3 Continued 
 
Study 
(first author 
and year) 
Age 
range 
(years) 
Type of 
lesions 
sampled 
Number 
of lesions 
sampled 
Abstinence 
from antibiotics 
presampling 
(weeks) 
Sampling 
technique 
Culture medium/ 
incubation period 
for P. acnes 
Microbiology 
(percentage of lesions 
colonised/sterile) 
Conclusion 
 
Till (2000) 
[42] 
 
 Female    
 26-51  
 (10)a 
 Male        
 25-50  
 (10)a 
 Female    
 26-54     
 (6)a 
 
 Inflammat  
 ory papules  
 (duration  
 unknown) 
 
26 
 
6 
 
 Punch biopsy   
 with  
 microdissection  
 of PSFs 
 
Brain-heart infusion 
agar with 
furazolidone/7 days 
 
Propionibacteria 
(exclusively P. acnes) 60 
Staphylococci 
(exclusively 
S. epidermidis) 24 
Malassezia 32 
Sterile 10 
 
The presence of micro- 
organisms is not a 
prerequisite for the 
initiation of 
inflammation in acne. 
However, micro- 
organisms may be 
involved in the 
inflammatory process at 
some stage 
 
P. acnes, Propionibacterium acnes; C. acnes, Corynebacterium acnes; S. albus, Staphylococcus albus; S. epidermidis, Staphylococcus epidermidis; PSFs, 
pilosebaceous follicles; NM, not mentioned. aNumber of patients in each group in parentheses. 
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1.2.4 Summary of the microbiological data on normal and 
acne-affected skin 
Only a proportion of normal as well as acne-affected PSFs, whether inflamed or 
noninflamed, is colonised by any specific microbial agent. Further, the microflora of 
normal or acne-affected PSFs (inflamed and noninflamed) generally consist of three 
major genera of micro-organisms (Propionibacterium, Staphylococcus, and 
Malassezia) with P. acnes and S. epidermidis being the main colonising species 
among the propionibacteria and staphylococci, respectively. We propose that 
bacteria, particularly P. acnes, are not a requirement for comedogenesis. The 
evidence for this is provided by a number of studies which failed to yield P. acnes 
from a proportion of noninflamed acne lesions [41, 43-46]. The findings from the 
study of Lavker et al. [47], who failed to isolate P. acnes from any of the follicular 
casts or early comedones of prepubertal and early pubertal children respectively, 
further support this notion. Likewise, P. acnes is probably not necessary for the 
initiation of inflammation, as it is never isolated from 100% of inflamed lesions and 
various investigators also found a proportion of these lesions to be sterile [42, 43, 
48-51]. 
 
 
It has been postulated that the microenvironment of individual follicles, whether 
normal or acne-affected, is important for colonisation as well as the production of 
extracellular enzymes by the micro-organisms [54, 55]. Oxygen and carbon dioxide 
tension, water availability and follicular pH are some of the possible factors that 
might differ from one PSF to another and may determine colonisation and enzymes 
production by the micro-organisms [54].  Comparing the available data on the 
microbiology of normal follicles with the microbiological information obtained from 
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comedones and inflamed lesions by Leeming et al., it seems that the 
microenvironment of a proportion of microcomedones (earliest subclinical lesion) is 
more suitable for microbial growth. This leads to a significantly greater colonisation 
of these lesions compared with the unaffected follicles [39, 41]. This may explain 
why acne patients carry higher numbers of P. acnes at the skin surface [22]. The fact 
that Leeming et al. [51] found 10% of the ‘1 day’ papules not to be colonised by any 
micro-organism while all the ‘3 day’ lesions were found colonised suggest that these 
early lesions might be free from any microbial colonisation at the start of 
inflammation. This may partly explain the sterility of a significant proportion of 
inflamed lesions within acne patients as reported by various investigators. As ‘3 day’ 
papules were also found to have the highest microbial density (albeit a non- 
significant difference), it is plausible that an inflamed lesion may provide an enriched 
environment not only for the colonisation but also for the proliferation of cutaneous 
micro-organisms. This might explain why Till et al. [42] found a significantly higher 
density of micro-organisms in the inflamed lesions compared with normal PSFs. Of 
course, these effects will be only temporary and body will eventually get rid of these 
micro-organisms as the host defences become ascendant. The results from other 
studies on the microbial ecology of comedones and inflamed lesions could not be 
compared because of differences in the sampling techniques used by the researchers. 
 
 
Antibiotics such as tetracycline have been shown to have anti-inflammatory effects 
in addition to their antibacterial activity, which may in part explain the improvement 
delivered by these agents [56]. Indeed, subantimicrobial dose of doxycycline has 
been demonstrated to improve acne without causing a significant reduction in 
cutaneous microflora [57]. Similarly, although patients with severe acne produce 
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more antibodies to P. acnes than do normal controls [23, 58], the antibody titres of 
patients with mild to moderate acne have not been found to differ significantly 
compared with normal controls [58]. Furthermore, patients with severe acne do not 
harbour significantly larger numbers of P. acnes compared with individuals having 
less severe form [22, 59]. Thus, it is possible that the increased levels of antibodies 
to P. acnes in severe acne patients is due to an increased exposure of these 
individuals to the immunogen as a result of their pathological condition. Likewise, 
cell-mediated immunity (CMI) to P. acnes may be a contributing factor in the 
inflammatory response in acne but this has been found to occur late in the chain of 
events and does not necessarily initiate inflammation in all patients with acne [60]. 
Moreover, Gowland et al. [60] found only four of 22 patients with moderate acne 
and 12 of 22 patients with severe acne to have CMI to P. acnes. Additionally, they 
did not find any evidence of CMI to P. acnes in 13- to 14-year-old children with 
severe acne. This suggests that an exaggerated immune response (humoral or cell- 
mediated) to P. acnes cannot solely be held responsible either for the initiation of 
inflammation in inflamed acne lesions or for the variation in its severity. 
 
 
1.3 Conclusion 
 
Propionibacterium acnes is likely to be a bystander and not an active participant 
in the initiation of noninflamed and inflamed acne lesions. This, however, does not 
undermine the importance of P. acnes in acne pathogenesis. The following chapter 
will discuss the possible mechanisms leading to the development of a 
microcomedone and its transformation into an inflamed lesion and how P. acnes may 
be involved in this process. 
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BACKGROUND 2: Pathogenesis of acne: 
Pathways to comedogenesis and inflammation 
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2. Pathogenesis of acne: Pathways to 
comedogenesis and inflammation 
2.1 Introduction 
 
Despite extensive research, the pathogenesis of acne has still not been fully 
elucidated. The microcomedone is thought to be the precursor lesion that can then 
develop into a comedone and/or inflamed lesion. However the sequence of events 
and their possible mechanisms leading to a microcomedone development and its 
transformation into an inflamed lesion is still a subject of ongoing debate. 
Considering the microbiological data, which does not support a role for P. acnes in 
the initiation of noninflamed and inflamed acne lesions (see Chapter 1), t h i s  
chapter details a possible stepwise mechanism to explain this process and will help 
to identify various key factors that can be therapeutically targeted to improve acne. 
 
 
2.2 Genetic susceptibility 
 
The risk of acne vulgaris in relatives of patients with acne, as compared with 
controls, is significantly higher suggesting hereditary influences [61]. A large twin 
study based on 458 pairs of monozygotic and 1099 pairs of dizygotic twins also 
suggested a strong genetic basis for acne as 81% of the variance in acne scores was 
attributable to genetic factors and family history of the disease showed significant 
familial clustering [62]. Furthermore, an autosomal dominant pattern of inheritance 
for comedones has also been described in thirteen members of a family [63]. Despite 
all this evidence, strongly suggestive of hereditary influences in the pathogenesis of 
acne, limited research has been done to date to identify the genes responsible for this 
common disease. 
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2.2.1 The androgen receptor gene polymorphism 
 
Response to androgens is mediated through the androgen receptor, a member of the 
nuclear receptor superfamily [64]. The androgen receptor gene, located on the X 
chromosome at Xq11-12, contains 8-35 CAG repeats in its first exon that encode a 
polyglutamine tract in the amino-terminal transactivation domain of the androgen 
receptor protein [65]. In vitro, the transactivation activity of human androgen 
receptor correlates inversely with the CAG repeat length [66]. Compared with 
normal controls, a significantly lower mean number of CAG repeats has been 
demonstrated in male, but not female, Chinese acne patients [67, 68]. Moreover, 
Pang et al. [68] found Chinese men and women with CAG repeat length 23 and  
24, respectively, to have a significantly increased risk for acne than those men and 
women with higher number of repeats. A correlation between CAG repeat length 
and acne however could not be demonstrated by Sawaya and Shalita [69] in their 
non-Chinese cohort and may reflect in part the ethnic difference in the pathogenesis 
of acne. 
 
 
2.2.2 CYP17 gene polymorphism 
 
A polymorphism in the CYP17 gene (located on chromosome 10q24.3) is another 
possible contender that has been studied to explain the genetic basis of acne [70]. 
This gene encodes cytochrome P450c17 enzyme, an enzyme which plays an 
essential role in the synthesis of dehydroepiandrosterone (DHEA, a weak adrenal 
androgen and precursor of testosterone) [71]. A polymorphism caused by a single 
base change from T to C in the 5- untranslated region of the CYP17 gene (CYP17- 
34T/C) is thought to up-regulate its transcription, leading to increased levels of 
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P450c17 enzyme [70], which ultimately may result in increased DHEA synthesis. 
Compared with normal controls, Chinese male patients with severe acne have been 
found to have significantly increased frequency of the C allele as well as CC 
genotype [70]. The authors concluded that CYP17-34C/C homozygosity may 
increase the risk of severe acne in Chinese men. 
 
 
2.2.3 Polymorphism of other genes 
 
Polymorphisms in genes encoding cytochrome P450 1A1 (an enzyme involved in 
retinoids metabolism) [72], tumour necrosis factor (TNF)-[73, 74], polymorphic 
epithelial mucin (a glycoprotein secreted from the mammary, gastric, sebaceous, 
and sweat glands) [75], TNF receptor type 2 [76, 77], interleukin (IL)-1and IL-1 
receptor antagonist (IL-1Ra) [78], and toll-like receptor (TLR)-2 genes [77] are 
some of the other possible candidates that have been studied for their association 
with acne and/or its severity. It is possible that acne is a polygenic disorder in which 
different genes, each of which is not strongly active by itself, may act in 
combination leading to the development of acne in an individual [2]. 
 
 
2.3 Comedogenesis 
 
Hypercornification of the lower four-fifths (infrainfundibulum) of the pilosebaceous 
duct (Figure 2.1), leading to mechanical obstruction of the sebum outflow, is an 
important feature of acne which can be seen histologically as a microcomedone and 
clinically as a blackhead (open comedone) and whitehead (closed comedone) [2, 79, 
80]. Closed comedones have only a microscopic opening which keeps the contents 
of the distended follicles from escaping  (Figure  2.2) while open comedones have
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wide follicular orifices which allow the contents to escape to the surface (Figure 
2.3) [3]. Histological features of microcomedones can be seen in 28% of the 
pilosebaceous units sampled from the clinically normal skin of patients with mild 
acne [81]. Evaluation of biopsy specimens of papules obtained up to 72 hours after 
development has demonstrated a microcomedone in 52% of subjects, an open 
comedone in 27%, and a closed comedone in 9% [82]. This implies that the majority 
of inflamed lesions originate from microcomedones. Moreover, there is a 
significant correlation between the severity of acne and the number of 
microcomedones [81]. 
 
 
Comedogenesis can occur due to hyperproliferation of ductal keratinocytes, 
inadequate separation of the ductal corneocytes, or a combination of both factors 
[83]. Hyperproliferation has been confirmed by demonstration of an increase in the 
Ki-67 (monoclonal antibody reacting with a nuclear antigen expressed by cells  in 
the late G1, S, M, and G2 phases of the cell cycle) labelling of ductal keratinocytes 
[84]. This fact is further substantiated by the presence of keratins 6 and 16 (keratin 
markers of hyperproliferation) in comedones [85]. The limited data available 
investigating whether comedogenesis is due to increased intercorneocyte adhesion 
showed no primary abnormality of ductal desmosomes [86]. Various factors that 
may be involved in comedogenesis can be explained as follows. 
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Figure 2.1: Sebaceous follicle with pilosebaceous duct. Comedogenesis begins in the lower 
four-fifths (infrainfundibulum) of the duct. Adapted from Williams et al.[4]. 
 
 
 
 
 
 
 
 
 
Pilosebaceous duct 
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Figure 2.2: Closed comedone. Adapted from Leyden JJ [87]. 
 
 
 
 
 
 
Figure 2.3: Open comedone. Adapted from Leyden JJ [87]. 
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2.3.1 Androgens 
 
The role of androgens in acne vulgaris and the beneficial effect of antiandrogen 
therapy are well established. Acne is associated with seborrhoea [37, 38] which is 
under androgenic control. Male castrates and oophorectomised females produce 
significantly less sebum compared with matched controls [88]. Moreover, the 
administration of testosterone to castrated males, children, or postmenopausal 
women in whom sebum secretion is normally low, results in an increase in 
sebaceous gland activity [89, 90]. Lastly, antiandrogen therapy reduces SER and 
improves acne [36]. All these facts support the essential role of androgens in sebum 
stimulation and acne development. 
 
 
2.3.1.1 Serum androgens levels in acne 
 
Based upon the above observations it is logical to hypothesise that acne patients 
may have increased levels of circulating androgens and/or end-organ sensitivity to 
these hormones, which may account for the seborrhoea seen in acne patients. 
Thiboutot et al. [91] found mean serum levels of total testosterone, free testosterone, 
dihydrotestosterone (DHT), and dehydroepiandrosterone sulfate (DHEAS, a sulfated 
form of DHEA secreted primarily by the adrenal gland and a precursor of 
testosterone) to be significantly greater (but still within the normal range) in female, 
but not male, acne patients compared with normal controls. Similarly, Lucky et al. 
[92] also found higher serum levels of total testosterone, free testosterone, and 
DHEAS in female acne patients compared with normal controls. The association 
between female acne and high serum DHEAS levels has been confirmed in  a 
number  of  other  studies  [93-95],  however,  the  results  for  other  androgens have 
differed [94, 95]. 
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2.3.1.2 End-organ sensitivity to androgens in acne 
 
It is likely that high concentrations of adrenal and gonadal androgens, alone or in 
combination, may lead to the development of seborrhoea and acne vulgaris in an 
individual. However, there is a considerable overlap of serum androgens levels 
between normal and female acne patients and higher mean concentrations of serum 
androgens can not elucidate the development of acne in all individuals [92]. 
Moreover, it also does not explain the development of acne in male patients who do 
not have abnormally high androgens levels compared with controls [91, 96]. One 
possible explanation may be increased end-organ sensitivity of acne patients to the 
circulating androgens. The enzyme 5α-reductase (5α-R) is responsible for catalysing 
the conversion of testosterone to its potent metabolite DHT. This enzyme has two 
isoforms, type 1 and type 2, and the former predominates in the skin [97]. Increased 
activity of type 1 5α-R enzyme, leading to a higher DHT production, in the skin may 
be one of the possible ways by which patients with acne may demonstrate increased 
end-organ sensitivity to the androgens. Indeed, the conversion of testosterone to 
DHT has been demonstrated to be significantly higher in acne bearing skin 
compared with normal skin [98]. Furthermore, two subsequent studies also 
demonstrated the activity of 5α-R to be higher in the infrainfundibular keratinocytes 
[99] and sebaceous glands [91] of individuals with acne compared with normal 
controls. However, the difference was not statistically significant. This might be due 
to the small sample size of the studies. 
 
 
Similarly, acne patients may differ in their response to the androgens at the receptor 
level. Androgen receptors have been identified at many sites in the skin including 
sebaceous glands, pilosebaceous duct keratinocytes, fibroblasts and endothelial cells 
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[100, 101]. Schmidt et al. [102] demonstrated acne patients to have a significantly 
higher density of androgen receptors compared with healthy controls. This can be 
another possible mechanism by which acne patients may have increased end-organ 
sensitvity to the androgens. It is possible that one or more of the above factors may 
account for the development of seborrhoea and acne in an individual. 
 
 
It is prudent to mention here that although androgens have a proliferative effect on 
cultured human [103] and SZ95 sebocytes (an immortalised human sebocyte cell 
line) [104], they have only a minimal effect on SZ95 sebocyte differentiation [105, 
106]. Peroxisome proliferator-activated receptor (PPAR) ligands, on the other hand, 
have been shown to be the master regulators of lipid metabolism [105-107]. In 
addition to the androgen receptors, PPARs are abundantly present in human 
sebaceous glands [108] and can be important therapeutic targets in acne patients. 
 
 
2.3.1.3 Mechanism of androgens involvement in comedogenesis 
Androgens may lead to comedogenesis not just by causing seborrhoea (see Section 
2.3.2) but could also increase epithelial turnover in the pilosebaceous duct via their 
receptors on the ductal keratinocytes [100]. In addition, androgens have been shown 
to significantly stimulate the proliferation of keratinocytes co-cultured with beard 
dermal papilla cells via the production of insulin-like growth factor-1 (IGF-1) by the 
dermal papilla cells [109]. Thus, it is possible that androgens may also influence 
epithelial turnover in the pilosebaceous duct via the production of IGF-1, which acts 
as a paracrine growth factor. IGF-1 has also been shown to stimulate lipid 
production in human SEB-1 sebocytes by an increased expression of sterol response 
element-binding protein-1, a transcription factor that regulates numerous   
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genes involved in lipid biosynthesis [110]. This may further aggravate seborrhoea 
and as a consequence comedogenesis in acne patients. 
 
 
2.3.2 Sebum 
 
Human sebaceous glands secrete a mixture containing triglycerides, wax esters, 
squalene, cholesterol esters, and some free cholesterol [111]. As mentioned 
previously (Chapter 1, Section 1.2.2.1) FFA in skin surface lipids are derived from 
sebaceous triglycerides through the lipolytic action of P. acnes lipases [33]. An 
increase in sebaceous gland activity occurs between ages 7-10 years which 
corresponds with the time when the adrenal secretion of DHEAS begins to increase 
[112]. This is reflected by a change in the composition of skin surface lipids towards 
the adult pattern, i.e. wax esters begin to predominate over cholesterol and 
cholesterol esters [112]. Interestingly, acne development (predominantly 
comedonal) also begins at this time [93]. Rate of sebum excretion continues to 
increases in both sexes during adulthood, reaching a maximum between the ages of 
26 and 40. Thereafter, the rate declines in both sexes, particularly in females [113]. 
 
 
FFA have long been implicated in the pathogenesis of acne vulgaris [114]. Acne 
patients are known to have a low sebaceous linoleic acid (LA, C18Δ9,12) level 
[115], which returns to normal with a concomitant decrease in SER, after treatment 
with antiandrogens [116]. These results indicate that the proportion of LA (an 
essential fatty acid) in sebum is influenced by SER. In experimental animals, a low 
linoleate results in scaly skin and decreased epidermal barrier function [117]. A low 
sebaceous    LA    concentration   has   also    been    proposed   to cause follicular 
hyperkeratosis and decreased barrier function in acne patients [118]. It is, therefore,
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understandable that androgen-induced seborrhoea, in acne patients, may lead to a 
low sebaceous linoleate concentration as a consequence of increased SER, resulting 
in comedogenesis. Adding more weight to the LA theory is the fact that topical LA 
has been shown to cause a significant reduction in the size of microcomedones in 
acne patients [119]. 
 
 
2.3.3 Interleukin-1

Results from essential fatty acid deficient mice have shown mRNA levels for 
epidermal IL-1, IL-1β and TNF to be elevated several-fold over controls [120]. 
Disruption of the skin permeability barrier and the body’s attempt to repair it was 
postulated to be responsible for this increase. In humans, the major IL-1 species 
produced by keratinocytes is IL-1[121]. It is present in many comedones at levels 
that are likely to be biologically and pathologically relevant [122]. Furthermore, IL- 
1α has been demonstrated to cause hypercornification of the follicular infundibulum, 
which can be blocked by IL-1Ra [123]. Therefore, it is possible that low sebaceous 
LA levels, in acne patients, may cause disruption of the cutaneous permeability 
barrier of the pilosebaceous duct. This may lead to increased IL-1production by 
the ductal keratinocytes which could result in comedogenesis. 
 
 
In summary, it is highly probable that androgens may play an important role in 
comedogenesis. They may not only stimulate keratinocytes proliferation in the 
pilosebaceous duct via their receptors on the ductal keratinocytes but may also lead 
to seborrhoea by their direct and indirect action (via IGF-1) on the sebocytes. These 
two androgens mediated effects may, therefore, explain the development of 
comedones in acne patients. This may also explain the microbiological data which 
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suggests that comedogenesis can occur in the complete absence of P. acnes from the 
PSFs. 
 
 
2.3.4 Potentiation of comedogenesis after P. acnes 
 
colonisation 
 
As explicated in chapter 1, a favourable microenvironment of microcomedones may 
lead to a significantly greater colonisation of these lesions compared with the 
unaffected follicles. Moreover, it may also encourage production of extracellular 
enzymes by the micro-organisms. After colonisation, P. acnes can potentiate 
comedogenesis by various mechanisms. FFA in sebum, produced by the lipolytic 
action of P. acnes lipases on sebaceous triglycerides [33], have been found to be 
comedogenic in the rabbit ear model (a model for evaluating the comedogenic 
potential of a substance by its application to the external ear canal of rabbit) and 
suggests a possible mechanism by which P. acnes can influence comedogenesis 
[114]. However, it is important to note that the rabbit skin is ultrasensitive compared 
to the comedogenic potential of the human face. Because of this extreme sensitivity, 
mild or moderate comedogenic substances may have no clinical significance for 
human skin [124]. 
 
 
Propionibacterium acnes through its production of porphyrins may act as a catalytic 
agent in squalene oxidation [125]. Oxidised squalene has been found to be 
comedogenic in the rabbit ear model and this may be another possible mechanism 
by which the organism can be involved in comedogenesis [126]. It has also been 
proposed that P. acnes biofilm may act as a biological glue causing adhesiveness o f  
keratinocytes, thus aggravating comedogenesis [127]. 
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Propionibacterium acnes-stimulated keratinocytes have been shown to cause 
significantly higher production of IL-1α compared with unstimulated keratinocytes 
[128]. IL-1α, as mentioned above, has been shown to cause hypercornification of the 
follicular infundibulum and may therefore exacerbate comedogenesis in acne 
patients [123]. Ingham et al. [129], however, failed to demonstrate that cutaneous 
micro-organisms or their products directly up-regulated IL-1α release, in vitro, by 
the keratinocytes. Hence it is difficult to interpret these findings as supporting a 
comedogenic role for P. acnes. 
 
 
Both viable and formalin-killed P. acnes have been shown to augment sebum 
production and accumulation by increasing diacylglycerol acyltransferase activity in 
hamster sebocytes, in vivo and in vitro [130]. It is, thus, understandable that P. 
acnes, by increasing lipogenesis, can further aggravate LA deficiency in acne 
patients and as a result may aggravate comedogenesis. Lastly, P. acnes has been 
shown to increase the expression of IGF-1 in the epidermis of human abdominal 
skin explant [131]. This can then activate IGF-1 receptor, mostly located in the basal 
layer of the epidermis and also induced by P. acnes, leading to proliferation and 
abnormal differentiation of the keratinocytes through a paracrine pathway [131]. 
This can potentially be another mechanism by which P. acnes can potentiate 
comedogenesis. 
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2.4 Inflammation 
 
2.4.1 Subclinical inflammation 
 
As detailed in chapter 1, P. acnes is probably not necessary for the initiation of 
inflammation in inflamed acne lesions. This leaves us with the question what 
exactly initiates inflammation, if not P. acnes? Compared with the control follicles 
obtained from non-acne patients, clinically normal skin of acne patients has been 
shown to have increased numbers of CD4+ T helper cells and macrophages in the 
perifollicular and papillary dermis [132]. However, these cells were not activated 
and lacked expression of HLA (human leukocyte antigen)-DR. Furthermore, 
expression of vascular adhesion molecules (E-selectin and vascular cell adhesion 
molecule-1, VCAM-1) was also found to be up-regulated, with the dermal 
concentration of IL-1 reported to be three times higher in this clinically normal 
skin. Similarly, an increase in the concentration of IL-1in the interfollicular and 
perifollicular epidermis and down the follicle wall was also found. All these changes 
occurred in the absence of ductal hyperproliferation and abnormal differentiation in 
this normal looking skin of acne patients [132]. These data suggest that subclinical 
inflammation exists in the acne prone areas, even if it appears clinically normal, in 
people suffering with acne and that these inflammatory changes precede 
comedogenesis. 
 
 
Now what factors could be responsible for the subclinical inflammation in the 
clinically normal skin of acne patients? Based upon the results from essential fatty 
acid deficient mice model [120] it is possible that chronic barrier perturbation due to 
LA  deficiecy  in  acne  patients  may  lead  to  increased  production  and  release of 
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proinflammatory cytokines i.e. IL-1and TNF from keratinocytes in the follicular 
wall. The increased expression of IL-1will not only contribute to comedogenesis 
but, along with TNF, may also result in the non-specific subclinical inflammation 
demonstrated in the normal looking skin of these patients. More recently, 
upregulation of IL-6 and TNF-in cultured human sebocytes after addition of DHT 
has also been demonstrated [133]. As acne patients may have increased levels of 
circulating androgens and/or end-organ sensitivity to these hormones, the 
proinflammatory cytokines produced as a result of DHT action on sebocytes could 
also play an important role in the subclinical inflammation mentioned above. 
 
 
2.4.2 Clinical inflammation 
 
The transition from subclinical to clinical inflammation might depend on an 
imbalance between proinflammatory and anti-inflammatory pathways that can be 
activated as a result of this local stress (Figure 2.4). 
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2.4.2.1 Activation of the cutaneous equivalent of the central 
hypothalamic-pituitary-adrenal axis 
The hypothalamic-pituitary-adrenal (HPA) axis plays a crucial role in terminating 
the stress response and buffering tissue damage, in response to systemic stress 
[134]. This process involves production and release of corticotropin–releasing 
hormone (CRH) followed by production and secretion of proopiomelanocortin 
(POMC) derived peptides (adrenocorticotropic hormone, ACTH and -melanocyte 
stimulating hormone, -MSH). ACTH induces production and secretion of the 
powerful anti-inflammatory protein cortisol, which terminates the stress response 
and buffers tissue damage. The presence of CRH, its binding protein (CRHBP) and 
corticotropin-releasing hormone receptors type 1 (CRHR-1) and type 2 (CRHR-2) 
has been confirmed in human sebaceous glands, in vivo, suggesting that a complete 
CRH system exists in sebocytes [135]. Moreover, a functional CRH-POMC- 
corticosteroid axis organised similarly to the HPA axis has been demonstrated in 
epidermal melanocytes [136], dermal fibroblasts [137] and human hair follicles 
[138]. 
 
 
The CRH expression in the hypothalamic cells can be modulated by various 
proinflammatory cytokines (TNF-, IL-1and IL-6) [139]. These cytokines may 
also modulate its expression in the skin. Thus, the subclinical inflammation evident 
in the clinically normal skin of acne patients may lead to increased cutaneous 
production of CRH. Indeed, CRH expression has been found to be greatly increased 
in acne-involved skin compared with non-involved and normal skin [135]. As – 
MSH  peptides,  produced  locally,  as  a  result  of  this  CRH  stimulation of the 
cutaneous  CRH-POMC-corticosteroid  axis  also  modulate  the  expression  of    its 
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receptor (melanocortin-1 receptor, MC-1R) [138], this may explain the increased 
expression of MC-1R in the sebaceous glands of lesional skin of patients with acne 
vulgaris [140]. 
 
 
Although CRH can induce cutaneous inflammation by causing mast cell 
degranulation [141], it might also act as an anti-inflammatory agent by increasing 
the local production of steroids. Likewise, -MSH has also been shown to exert 
anti-inflammatory actions by inhibition of IL-1 mediated IL-8 secretion from SZ95 
sebocytes [142] and by suppressing TNF-and IL-1gene expression following an 
ischaemic cerebral event in mice [143]. Furthermore, it has also been demonstrated 
to induce the production of IL-10 by human peripheral blood monocytes in vitro 
[144]. IL-10 is a regulatory cytokine that acts to harness the release of several 
proinflammatory cytokines [145]. 
 
 
In brief, activation of the cutaneous CRH-POMC-corticosteroid axis may activate 
both proinflammatory and anti-inflammatory pathways that when working in 
conjunction with other proinflammatory pathways (discussed below) may determine 
the development of a clinically inflamed lesion. 
 
 
2.4.2.2 Substance P 
 
Substance P (SP), another important proinflammatory neuropeptide [146], has also 
been found to be over expressed in dermal nerves around the sebaceous glands of 
acne patients [147]. Recently, IL-1was found to up-regulate SP expression in the 
dorsal root neurons from mature rats [148]. This may be another proinflammatory 
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pathway that can be activated as a result of subclinical inflammation seen in the 
clinically normal skin of acne patients. 
 
 
2.4.2.3 Human -defensins 
 
Defensins are small mammalian antimicrobial peptides that form an integral part of 
the innate immune system [149]. They have been divided into two main subtypes, 
- and -defensins. In humans, the -defensins are found in granules of neutrophils 
and small intestinal Paneth cells whereas -defensins are mainly expressed in 
epithelial tissues [149]. To date, six human -defensins (hBD-1 to -6) have been 
identified [150-154]. Among them, hBD-1 to -3, are expressed in human skin [150- 
152]. Interestingly, hBD-1 is synthesised constitutively [155] whereas expression of 
hBD-2 and hBD-3 can be induced by micro-organisms and proinflammatory 
cytokines [151, 152]. 
 
 
In acne patients, hBD-2 is more strongly up-regulated than hBD-1 in the lesional 
skin when compared with healthy controls [156]. hBD-2 does not only possess 
antimicrobial activities (against Gram-positive and -negative bacteria but not P. 
acnes) [157, 158] but also acts as a chemoattractant for mast cells [159] and can 
induce histamine release and prostaglandin D2 production from these cells as well 
[160]. Moreover, hBD-1 and hBD-2 are also chemotactic for immature dendritic 
cells (DCs) and memory T cells via the chemokine receptor CCR6 [161]. hBD-2, 
like its murine counterpart, may further activate these chemoattracted dendritic cells 
via the TLR-4, leading to the production of proinflammatory cytokines IL-1, IL- 
1,  IL-6,  and  IL-12  [162]. Lastly, hBD-2 can chemoattract TNF-treated 
neutrophils via the CCR6 receptor [163]. Proinflammatory cytokines e.g. TNF-
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and IL-1 have been shown to modulate hBD-2 expression and, therefore, may 
explain its up-regulation in acne lesions [151, 164]. 
 
 
It is evident that various proinflammatory and anti-inflammatory pathways may be 
activated as a result of subclinical inflammation, seen in the clinically normal skin 
of acne patients. It is possible that an imbalance between these pathways may lead 
to the development of clinical inflammation in inflammatory acne. Interestingly, an 
in vitro study has shown that acne patients produce significantly less IL-10 from 
human peripheral blood monocytes, in response to P. acnes stimulation, as 
compared with healthy controls [165]. It is possible that the production of IL-10 by 
monocytes, in response to -MSH, in acne patients may also be impaired: this may 
be one of the anti-inflammatory pathways that can be defective in these patients. 
 
 
Our proposed mechanism signifies that the presence of P. acnes in PSFs is not 
necessary for the development of clinical inflammation in acne patients. This may 
therefore explain the sterility or absence of P. acnes from a significant proportion of 
inflamed lesions within acne patients as reported by various investigators (see 
Chapter 1). 
 
 
2.4.3      Potentiation of inflammation by P. acnes 
 
As explained above, clinical inflammation in an acne lesion may develop in the 
complete absence of P. acnes from the PSFs. However, micro-organisms (from 
colonised follicles) may further intensify this inflammation. Spongiosis of the PSF 
wall has been demonstrated to be an early feature of acne papules [82]. This may 
alter the permeability of the follicular wall. One outcome of this may be the
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diffusion of bacterial products (from colonised follicles) into the dermis, therefore, 
intensifying the inflammatory response. This may explain why neutrophils are seen 
predominantly in papules present for 24 hours and not at the initiation of 
inflammation [82]. Propionibacterium acnes and/or its products, after being released 
into the dermis, may intensify the inflammatory process by its antigenic [23, 58, 
166], enzymatic [167], chemoattractant [168, 169], and complement activation [170, 
171] activities. Furthermore, P. acnes’ secretory protein called Christie-Atkins- 
Munch-Peterson factor and acid sphingomyelinase, which is released from the host 
cells in the presence of P. acnes, are cytotoxic to keratinocytes and macrophages in 
vitro [172]. Propionibacterium acnes can also lead to the formation of reactive 
oxygen species (ROS), especially superoxide anions, by activation of the scavenger 
receptor CD36 on keratinocytes [173]. These may be other potential mechanisms 
explaining the involvement of P. acnes in inflammatory acne. 
 
 
2.4.3.1      P. acnes and toll-like receptors 
 
TLRs are a family of pattern recognition proteins that recognise pathogen-associated 
molecular patterns (PAMPs), which represent conserved molecular features of a 
given microbial class [174]. To date, ten functional TLRs (TLR-1 to -10) have been 
identified in humans [174]. Upon activation, TLRs mediate their effects by 
activation of the transcription factor, nuclear factor-kappaB (NF-κB), and mitogen- 
activated protein kinases (MAPKs) [174]. Activation of NF-κB leads to 
transcriptional induction of several cytokines/growth factors (e.g. IL-1, TNF-, IL- 
6, IL-10, granulocyte/macrophage colony-stimulating factor), chemokines (e.g. IL- 
8), adhesion molecules (e.g. VCAM-1), and hBD-2 genes [175-177]. TLRs are 
expressed on monocytes/macrophages (TLR-1, -2, -4, -5) [178], neutrophils (TLR-1, 
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-2, -4, -5) [178], DCs (TLR-1 to -5, -7 to -9) [179], and SZ95 sebocytes (TLR-2 and 
 
-4) [180]. Moreover, the expression of TLR-2 and TLR-4 in normal human 
epidermis [181] and TLR-2 expression on macrophages surrounding the PSFs in 
acne patients [182] has been demonstrated in vivo. 
 
 
The main ligand for TLR-4 is lipopolysaccharide (a component of the outer 
membrane of Gram-negative bacteria) [183] whereas TLR-2 recognises a broad 
range of PAMPs including peptidoglycan and lipoteichoic acid from Gram-positive 
bacteria [184], bacterial lipoprotein/lipopeptide [185], yeast cell wall particle 
zymosan [186], mycobacterial lipoarabinomannan [187], and 
glycosylphosphatidylinositol anchors from protozoan parasites [188]. Intriguingly, 
both these receptors can also recognise various endogenous ligands including heat- 
shock protein (HSP) 60 and 70 [189, 190]. 
 
 
Compared with normal controls, TLR-2 is more strongly up-regulated than TLR-4 
in the inflamed lesions of acne patients [181]. Propionibacterium acnes has been 
shown to up-regulate TLR-2 and TLR-4 expression in cultured keratinocytes, in 
vitro, and may therefore provide one possible explanation for their up-regulation 
in acne patients [181]. This in vitro data, however, does not mean that the up-
regulation of these TLRs is caused solely by P. acnes as their expression can also be 
modulated by proinflammatory cytokines e.g. IL-1, TNF-and interferon (IFN)-γ 
[178, 191, 192]. Certain strains of P. acnes have been shown to induce the 
expression of hBD- 2 and IL-8 in cultured keratinocytes via both TLR-2 and TLR-
4 activation in vitro [193]. Likewise, increased production of IL-12 and IL-8 by 
TLR-2 activation of primary human monocytes by P. acnes has been demonstrated 
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[182]. Activation of TLRs by various P. acnes associated ligands (e.g. 
peptidoglycan, GroEL (bacterial HSP60) [194], DnaK (bacterial HSP70) [194], 
lipoteichoic acid) may also explain other reports of increased production of 
proinflammatory cytokines/chemokines by keratinocytes (IL-1, TNF-, and 
granulocyte/macrophage colony-stimulating factor) [128], peripheral blood 
mononuclear cells (IL-1, TNF-, and IL-8) [195], and SZ95 sebocytes (CXCL8, 
synonymous with IL-8) [196] after P. acnes stimulation. It is therefore plausible 
that induction and activation of TLRs by P. acnes and the resultant production 
of hBD-2 (an antimicrobial peptide containing proinflammatory properties) and all 
the other proinflammatory cytokines/chemokines mentioned above, may also 
intensify inflammation in acne patients. 
 
 
2.4.4 Potentiation of inflammation by other intrafollicular 
contents 
Antibodies to keratin intermediate filament proteins have been demonstrated in the 
sera of healthy individuals as well as patients with various cutaneous diseases [197]. 
It is conceivable that these antibodies may also potentiate inflammation following 
altered follicular permeability/rupture. After rupture of the duct it is likely that other 
intrafollicular contents like FFA, keratin and hairs may also contribute to the 
inflammation. 
 
 
2.5 Resolution of acne 
 
This can be considered in the context of resolution of individual lesions and the 
disease as a whole. Comedones are temporary structures [79]. Based upon    changes 
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in the expression of Ki-67 and K16, it has been postulated that comedones undergo 
cyclical growth [198]. Cunliffe et al. [79] considered this cycling to be important in 
the development and resolution of comedones. Downie et al. [199], on the other 
hand, demonstrated that IL-1 and other cytokines (e.g. TNF- and IFN-γ) can 
inhibit lipogenesis and induce de-differentiation of human sebocytes into a 
keratinocyte-like morphology in vitro. This implies that IL-1may not only lead to 
comedogenesis but can also modulate its resolution-albeit temporarily. Factors 
associated with acne resolution have been minimally researched and remain 
obscure. Limited data suggest that the resolution is not related to reduction of 
sebum production as the SER amongst individuals with a past history of acne 
remains significantly higher compared with age-matched controls [200]. 
 
 
2.6 Conclusion 
 
Androgens, sebaceous lipid abnormalities, key cytokines such as IL-1, cutaneous 
CRH-POMC-corticosteroid axis, SP, and hBDs may play an important role in the 
aetiopathogenesis of noninflamed and inflamed acne lesions. Propionibacterium 
acnes, by virtue of its various pathogenetic factors, may aggravate both these lesions 
(Figure 2.5). Targeting P. acnes or one or more of the above factors may result in a 
clinical improvement in acne patients. 
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3. Effect of visible light on the microbiology of acne 
 
3.1 Introduction 
 
Light can work in various skin conditions by its photothermal, photochemical, 
photomechanical, and/or photoimmunological effects. Photothermal effects denote 
tissue damage secondary to generation of heat after absorption of photons of 
appropriate wavelengths by specific molecules, termed chromophores [201]. 
Absorption profiles of the key skin chromophores (e.g. melanin, haemoglobin, and 
water) are given in Figure 3.1. Selective photothermolysis refers to photothermal 
destruction of a target without causing damage to the adjacent tissues and depends on 
the following three variables: (i) a wavelength that is selectively absorbed by the 
target; (ii) a pulse duration that matches the thermal relaxation time (TRT; time 
required to lose 50% of the acquired heat) of the target; and (iii) delivery of sufficient 
energy to damage the target [202]. Photochemical effects occur when the light 
wavelength matches the absorption characteristics of a chromophore (endogenous or 
exogenous) within the tissue and produces a chemical response without a noticeable 
temperature rise. A common example of the use of an exogenous chromophore for 
photochemical effects is photodynamic therapy (PDT) [201]. Photomechanical 
effects require a very high power, short duration pulse (e.g. nanoseconds). 
Sufficiently high power densities remove electrons from the absorbing medium and 
produce a state of ionised matter known as plasma. The collapse of the plasma 
produces a shock wave which leads to fragmentation of the absorbing particle. These 
photomechanical effects are exploited in tattoo dye pigment destruction [201]. Light- 
induced immunological effects refer to the immunomodulatory consequences of light 
on cytokines and cells of immune system [203, 204]. An increase in transforming 
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growth factor (TGF)-β1 mRNA expression after nonablative pulsed-dye laser (PDL) 
therapy is one example of such effect [205]. Depending on the condition being 
treated, one or more of these light-tissue effects may contribute towards the 
success of this treatment modality. 
 
 
Light-based therapies for acne are becoming increasingly popular in dermatology. A 
number of laser and non-laser light sources have been used for this purpose. Two 
systematic reviews of 19 and 25 trials, respectively, concluded that optical treatments 
can improve acne in the short term, with the most consistent outcomes for PDT [206, 
207]. Comparing laser and non-laser light sources, the latter are advantageous in 
dermatology as they are portable, cheaper to purchase and maintain, and have a large 
illumination field [208]. 
 
 
The rest of this chapter introduces intense pulsed light (IPL) and 5-aminolaevulinic 
acid-based PDT followed by a discussion on the possible mechanisms of action of 
IPL/IPL-assisted PDT in acne, with emphasis predominantly on their anti-P. acnes 
effects. 
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Figure 3.1: Absorption coefficients of melanin, oxyhaemoglobin, and water. The emission 
spectrum of an IPL device has been overlaid. Adapted from Ash et al. [209]. 
 
 
3.2 Intense pulsed light 
 
IPL is a device that uses flashlamps and computer-controlled capacitor banks to 
generate pulsed polychromatic (500-1300 nm) high-intensity light [210]. Electrical 
energy stored in the capacitor bank is passed through xenon gas within a flashlamp 
leading to emission of bright light [210]. With the aid of different cut-off filters, a 
wide range of wavelengths are possible for IPL devices. A typical circuit diagram for 
a flashlamp power supply is given in Figure 3.2. 
Oxyhaemoglobin 
IPL Spectrum 
Water 
Melanin 
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Figure 3.2: Circuit diagram for a flashlamp power supply. Adapted from Ash et al. [211]. 
 
 
Based upon the method used to generate and deliver the energy, IPL devices can be 
classified into free discharge and constant current systems [211]. A free discharge 
system produces a rising/falling discharge slope as it applies a large electrical charge 
to the capacitor which then releases the entire stored energy directly through the 
flashlamp (Figure 3.3a). Most free discharge systems are unable to generate true 
long pulse durations to match the TRT of the target structure (e.g. hair follicle with a 
TRT of 25-55 ms) to cause selective photothermolysis [211]. Ash et al [211] found 
that in a free discharge system with a measured pulse duration of 15-17 ms, most of 
the useful energy was concentrated in only 3-4 ms while rest consisted of low energy 
infrared radiation. In order to resolve this problem, most free discharge IPLs deliver 
a train of shorter, high energy sub-pulses with variable on and off times to generate 
an average energy density (synonymous with fluence and defined as energy delivered 
per unit area measured in joules (J) cm-2) and overall pulse duration in the range of 
the TRT of the target chromophore (Figure 3.3b). This, however, does not produce 
stable  consistent  optical  energy  and  the  intensity  of  the  spectral  output  tails off 
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towards the end of the set of sub-pulses due to capacitor depletion. This may lead to 
sub-optimal clinical effects. Moreover, with too short a pulse duration a high 
proportion of the total energy will be delivered as shorter wavelengths which leads to 
epidermal heating necessitating use of cooling devices [211]. 
 
 
 
 
 
 
Figure 3.3: Time-resolved spectral output images of a single pulse and multi-pulse free 
discharge IPL device (a) A single pulse IPL device (Chromolite, Chromogenex Ltd) spectral 
image with a measured total pulse duration of 17 ms. Note the bulk of the useful spectral 
output concentrated into only a few ms (b) A multi-pulse free discharge IPL device 
(Lumina600, Lynton Lasers Ltd) spectral image producing long total pulse duration but with 
considerable spectral output shifts within the pulse train. Adapted from Ash et al. [211]. 
(b) 
(a) 
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A constant current IPL system differs from the free discharge system in the way in 
which the electrical energy is delivered from the capacitor to the flashlamp. In this 
system the electrical energy is delivered to the flashlamp, via a partial discharge 
capacitor, at a constant level throughout the pulse creating a square pulse discharge 
profile (Figure 3.4). This means that the optical energy is released throughout the 
duration of the pulse with only slight attenuation towards the end [211]. Significantly 
lower energies can be used to obtain equivalent clinical results compared with free 
discharge systems and if combined with appropriate cut-off filters the need for skin 
cooling may be obviated [211]. 
 
 
 
 
Figure 3.4: Time-resolved spectral output image of a single pulse constant current IPL 
device (iPulse, Cyden Ltd), with a measured total pulse duration of 50 ms, producing a 
constant optical discharge throughout the pulse. Adapted from Ash et al. [211]. 
 
 
By a combination of different wavelengths and other treatment parameters e.g. 
number and duration of pulses, delay between pulses, and fluence an IPL device can 
be adjusted according to the target structure, its depth, and the patient’s skin type 
[210].  This  versatility  makes  IPL  an  ideal  device  for  a  number  of    indications 
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including hair removal, rosacea, telengiectasias, pigmented lesions (e.g. melasma, 
lentigines), and port-wine stains [210]. For similar reasons it can be a useful addition 
to the therapeutic armamentarium for acne vulgaris. 
 
 
Side-effects of IPL treatment include pain during irradiation, transient erythema 
(common, starting immediately after treatment and may last for few hours up to 96 
h), oedema (may last up to 5 days), purpura, blistering, postinflammatory 
hyperpigmentation (PIH), and crusting [212-215]. Scarring occurs rarely and is 
almost always induced by overfluenced treatment or by crusting with subsequent 
scratching leading to bacterial infection [210]. Pain during irradiation can be helped 
by skin cooling [210]. 
 
 
3.3 5-Aminolaevulinic acid-based PDT 
 
PDT (an oxygen-dependent tissue reaction following photosensitisation and 
subsequent irradiation with light) [216] is also an exciting area of research for the 
treatment of acne. 5-aminolaevulinic acid (ALA) and methyl aminolaevulinate 
(MAL) are commonly used topical precursors of porphyrins for PDT in dermatology 
and will be briefly discussed here. MAL is a methylated ester of ALA that is 
hydrolysed to ALA before being converted to protoporphyrin IX (PpIX) via the 
haem metabolic pathway [217]. ALA is not itself a photosensitiser; PpIX is the 
active photosensitiser in ALA/MAL-PDT [217]. 
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3.3.1 Haem biosynthetic pathway 
 
The rate-limiting step of haem biosynthetic pathway is the conversion of glycine and 
succinyl-coenzyme A to ALA by the enzyme ALA synthase. This is controlled by 
haem via a negative feedback mechanism [218]. The final step of this pathway 
involves the incorporation of iron into PpIX, in the mitochondria, by ferrochelatase 
enzyme (Figure 3.5) [219]. Addition of exogenous ALA, thus bypassing the rate- 
limiting step, leads to accumulation of PpIX due to the limited capacity of 
ferrochelatase [219]. PpIX is a highly active photosensitising and fluorescent 
compound that accumulates selectively in certain tumours [218] as well as in the 
sebaceous glands, hair follicles, and the epidermis [220]. The body clears PpIX 
within 24-48 h, minimising the period of photosensitisation [216]. 
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Figure 3.5: The haem metabolic pathway. Exogenous application of 5-aminolaevulinic acid 
(ALA) overrides the negative feedback control with accumulation of protoporphyrin IX. 
Adapted from Peng et al. [219], Sakamoto et al. [221], and Kennedy and Pottier [218]. 
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3.3.2 Light sources 
 
Following bioconversion of ALA to PpIX, the latter can be activated by light of 
an appropriate wavelength. Porphyrins are tetrapyrrole molecules, with peak 
absorption in the blue light spectrum, the Soret band (405-415 nm). Moreover, 
weaker absorption bands (Q-bands) also exist in the green (~506 nm to ~540 nm), 
yellow (572-582 nm), and red spectra (628-635 nm) [217]. In the visible light 
spectrum, scattering and absorption generally decrease with increasing wavelength. 
Hence, although the strongest porphyrin absorption is in the blue spectrum, blue light 
penetrates poorly into the dermis [217]. In contrast, wavelengths within the yellow– 
red range penetrate deeper (230-750 μm) [222] and can be advantageous for PDT in 
acne vulgaris, as sebaceous glands that are located approximately 0.5-1.0 mm from 
the cutaneous surface [223] can be effectively targeted. 
 
 
A range of irradiation sources is available for use in PDT, including laser (e.g. argon 
laser, Nd:YAG laser, diode laser) and non-laser (e.g. tungsten filament halogen lamp, 
xenon arc lamp, metal halide lamp, light-emitting diode) light sources [208]. The 
reasons why incoherent light sources are preferable in dermatology have been 
mentioned above i.e. large illumination field, portability, and low cost. All these 
advantages along with the high versatility and short exposure time for IPL makes it a 
favoured device for PDT. 
 
 
3.3.3 PDT photochemistry and mechanism of action 
The chemical activation energy for PDT is provided when a photosensitiser absorbs a 
photon of light and is promoted from the ground state to the excited singlet state 
[224, 225]. The half-life of the singlet excited molecule is extremely short (10-6  to 
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10-9 seconds). Therefore, it either returns back to the ground state (resulting in 
fluorescence) or undergoes a spin conversion, via intersystem crossover, to the more 
stable and longer lived (10-3 seconds) triplet excited state [224]. The excited triplet 
can undergo type I and/or type II photochemical reactions with the surrounding 
molecules [224, 225]. 
 
 
Type I pathway involves the direct interaction of an excited triplet photosensitiser 
with a biomolecule, by electron or hydrogen atom transfer, producing radical forms 
of the substrate and/or photosensitiser [224]. These intermediates may react with 
molecular oxygen to form peroxides, superoxide ions, and hydroxyl radicals, which 
initiate free radical chain reactions [224]. Type II mechanism is mediated by an 
energy transfer process with spin-matched ground state molecular oxygen, leading to 
the formation of singlet oxygen (1O2) and to the return of sensitiser to its ground state 
[226]. The Type I pathway is highly concentration dependent, and plays a minor role 
in PDT due to the competition between substrates and oxygen for triplet 
photosensitisers [224]. 
 
 
1O2 is considered to be the primary chemical intermediate of PDT [224, 225] that 
reacts with lipids, proteins, and nucleic acids leading to cellular apoptosis [227, 228], 
necrosis [229], microvascular compromise [230, 231], increased expression of 
various proinflammatory cytokines (e.g. IL-1, IL-6, and TNF) [232-234], 
immunoparesis [235, 236] and hyperimmunity [237, 238]. 
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3.3.4 Variables affecting PDT results and side-effects 
 
Treatment variables that may affect PDT results and side-effects include the choice 
of photosensitiser and its concentration as well as contact time, temperature of the 
area being treated, wavelength(s) of light used in the treatment, its fluence and 
irradiance (the rate at which energy is delivered per unit area measured in W m-2 or 
mW cm-2), and the availability of molecular oxygen at the target site. The importance 
of molecular oxygen at the target site in PDT is evident from the fact that a reduction 
in oxygen level from 5% (normal tissue level) to 1% leads to a 50% reduction in 
PDT effect [239]. 
 
 
Compared with ALA, MAL has been shown to be more lesion specific [240, 241], 
penetrates deeper [242, 243], and is associated with less severe side-effects [241]. As 
lower concentrations of photosensitiser have shallower depths of penetration [243] 
and may not effectively destroy deeper structures, higher concentrations are 
advantageous in PDT. Moreover, PpIX production is related to the contact time of 
the ALA/MAL with the skin and higher amounts are formed with long application 
times [240, 244]. However, comparing long (3 h) [241, 245-247] with short (30-60 
min) [248, 249] application times, the latter are associated with milder side-
effects and lower patient drop-out rate and may therefore be preferable. 
 
 
The advantage of using longer wavelengths of light has been discussed above 
(Section 3.3.2). There is a wide variation in the light dose and irradiance (fluence 
rate) used in PDT. Light delivery at lower irradiance is preferable as it results in an 
enhanced   photodynamic   effect   due   to   tissue   re-oxygenation   [250,   251].  As 
mentioned previously,  light  absorption  also  leads  to  heat  generation. Generally,
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fluence rates above 150 mW cm-2 will give hyperthermia [252]. Mild hyperthermia 
(41.5-42.5 °C) can increase tumour pO2 by two to threefold and may be useful in 
PDT [253]. 
 
 
3.3.5 Adverse effects 
 
Adverse effects after ALA/MAL-PDT for acne include varying degree of pain (very 
common and helped by skin cooling), erythema (common, starting immediately after 
treatment and may last for 1-2 h up to 20 weeks), oedema (starting immediately after 
treatment and may last up to 7 days), blistering (rare), acute acneiform eruption 
(papules, pustules, nodules starting 3-4 days post-treatment, lasting 4 days to 3 
weeks, after high fluence red light PDT with 3 h ALA incubation), exfoliation, sterile 
pustular eruption (starting on the second or third day post-treatment, lasting 3 days, 
after 3 h MAL/ALA incubation), crusting (developing a few days after treatment), 
pruritus, and PIH (lasting 4-32 weeks) [241, 245-249, 254-258]. Scarring is very rare 
and has only been reported once [241]. 
 
 
3.4 Possible mechanisms of action of IPL/IPL-assisted 
PDT in acne 
As mentioned in chapter 1, it is known that P. acnes produces porphyrins, 
particularly coproporphyrin III [13]. Light (of appropriate wavelength) can activate 
these porphyrins, producing ROS, which may lead to bacterial destruction. There is 
in vitro data to support this hypothesis [14-16]. The addition of ALA increases 
endogenous porphyrin production by P. acnes and in vitro data shows that this 
augments its photodynamic eradication [14, 16].  Based upon these data and the
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various possible ways by which P. acnes may influence acne (Chapter 2, Figure 
2.4), it is believed that this bactericidal effect is responsible for the beneficial 
outcome of light treatment in acne patients. As the published observations on the 
specific effect of IPL or IPL-assisted PDT on the microbiology of acne are few, the 
rest of this chapter describes studies investigating the effect of incoherent light 
(pulsed and nonpulsed), including PDT, on P. acnes colonisation/density vs. clinical 
efficacy. This will be followed by other possible ways by which IPL or IPL-assisted 
PDT may improve acne and, again, will be discussed in the context of known effects 
of pulsed and nonpulsed incoherent light on various pathogenetic factors for acne. 
 
 
3.4.1 Microbiological effect vs. clinical efficacy of incoherent 
light (including PDT) in acne 
The current literature surrounding the microbiological effect vs. clinical efficacy of 
incoherent light therapy in acne will be discussed under the various methods that 
were adopted by various investigators to determine the outcome of light treatment on 
P. acnes colonisation/density (Table 3.1). 
 
 
 
3.4.1.1 Studies on the efficacy of incoherent light and assessment of its 
effect on P. acnes colonisation via culture and polymerase chain 
reaction 
Omi et al. [259], in their attempt to assess the efficacy of phototherapy and its effect 
on cutaneous microflora, carried out bacterial cultures (from acne comedones or 
cysts) and polymerase chain reaction (from skin surface; no detail given about the 
sequenced gene) in acne patients, treated with a high-intensity blue light (410-420 
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nm, irradiance 200 mW cm-2, fluence not stated) twice weekly for 4 weeks. 
Moreover, ultrastructural changes in the dermis and sebaceous glands were also 
examined, on skin biopsies, in 8 patients after 4 treatments via electron microscopy. 
They reported a 64.7% improvement in acne lesions after 8 sessions of light therapy. 
No change in P. acnes colonisation (in comedones/cysts or skin surface) w a s  
detected pre- and post-treatment; however, damaged P. acnes was observed at the 
ultrastructural level in one of their eight cases. Although, an interesting  study, 
looking at the density rather than colonisation of P. acnes pre- and post-treatment 
might have yielded more information about the possible mechanism of action of blue 
light in acne. A significant reduction in the density of P. acnes could have partly 
explained the beneficial effect of this treatment modality in these patients. This 
shortcoming of the present study was remedied by a number of other investigators 
who tried to correlate the clinical efficacy of visible light therapy with its effect on 
the density of P. acnes. 
 
 
3.4.1.2 Studies on the efficacy of incoherent light and indirect 
assessment of its effect on P. acnes density via porphyrin 
fluorescence 
Porphyrins produced by P. acnes give rise to orange-red fluorescence seen under 
Wood’s light [260]. The intensity of this fluorescence has been shown to be 
proportional to the P. acnes population [261]. Digital fluorescence photography has 
been used to evaluate the suppressive effects of anti-acne agents on P. acnes [262] 
and, therefore, various investigators have used this technique to investigate the 
possible mechanism of action of optical therapies in acne. 
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Hongcharu et al. [245] found red light-assisted ALA-PDT (550-700 nm, fluence 150 
J cm-2) to cause a statistically significant improvement in inflammatory acne for 10 
weeks after a single treatment and for at least 20 weeks after multiple treatments. 
Concomitantly, a significant reduction in porphyrin fluorescence was noticed for 20 
weeks in both the groups. The authors concluded that a reduction in P. acnes counts 
may be one of the potential mechanisms by which ALA-PDT can improve acne. 
Similarly, Tzung et al. [263] found blue light (420 20 nm, fluence 40 J cm-2) to be 
effective in the management of mild to moderate acne in their Taiwanese cohort; 
however, therapeutic effectiveness was reported not to be related to the change in 
fluorescence intensity. It is though prudent to mention here that no information was 
provided about post-treatment fluorescence intensity in the published study and it is 
difficult to ascertain whether or not there was any change from the pre-treatment 
value. The authors concluded that blue light has as yet unknown effects, in addition 
to P. acnes killing, by which it can improve acne. However, no evidence for P. 
acnes killing by the blue light was provided. 
 
 
Subsequently, Yeung et al. [264] in a single-blind, randomised controlled, split-face 
study treated patients with moderate inflammatory acne with full-face 0.1% 
adapalene and half-face IPL (530-750 nm, fluence 7-9 J cm-2) +/-  MAL-PDT. 
Neither MAL-PDT nor IPL was found to significantly improve inflamed acne 
lesions; however, a significant improvement in noninflamed lesions was seen in the 
MAL-PDT (38%) and IPL (44%) groups at 12 weeks after the last treatment. 
Moreover, the investigators did not find a significant difference in porphyrin 
fluorescence between the three groups. As no statistically significant improvement in 
inflamed acne lesions was found in the IPL or MAL-PDT groups, it is difficult to
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predict whether this lack of efficacy was due to inability of these optical therapies to 
kill P. acnes or insufficient anti-inflammatory/sebostatic effects of the IPL 
parameters used in this trial. 
 
 
It is difficult to compare the results of above-mentioned studies because of 
methodological differences. It can be argued that ALA-PDT using red light at a high 
fluence (150 J cm-2), as used by Hongcharu et al. [245], may lead to a reduction in 
porphyrin fluorescence (an indirect assessment of P. acnes density) and can improve 
acne. However, it is important to mention here, that by using bacteriologic culture, P. 
acnes has been shown to repopulate very quickly (within 10 days) after stopping 
benzoylperoxide (BPO) [262]. The fact that Hongcharu et al. [245] found a 
significant reduction in porphyrin fluorescence for 20 weeks after ALA-PDT is 
therefore surprising and casts doubt on the validity of these results. Bacterial counts 
from cultures would have been more informative in drawing conclusions as to the 
role of ALA-PDT using red light at the above fluence on P. acnes density. 
 
 
3.4.1.3 Studies on the efficacy of incoherent light and assessment of its 
effect on P. acnes density via propionibacteria culture 
The specific quantitative measurement of P. acnes on the skin is more likely to be 
accurate than the indirect assessment by porphyrin fluorescence and has been used 
by various investigators to elucidate the possible mechanism of action of optical 
therapies in acne. Shalita et al. [265] treated 10 acne patients (forehead or cheek) 
with twice weekly visible light in the violet-blue range (407-420 nm, irradiance 90 
mW cm-2, fluence not stated). Cultures for P. acnes were taken from both the treated 
and untreated symmetric area at baseline and after the 2nd, 4th, and 6th  treatment. Only 
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patients with a baseline P. acnes density of > 105 colonies cm-2 (6 out of 10 patients) 
demonstrated a significant reduction in P. acnes counts after the 6th treatment. The 
authors did not correlate this information with the clinical outcome in this cohort, 
however, reported a 68% mean reduction in inflamed lesion counts after 8 bi-weekly 
light treatment (407-420 nm, irradiance 90 mW cm-2, fluence not stated) to the face 
or back of 35 other patients with mild to moderate papulo-pustular acne. Although a 
frequently cited study (with at least 35 citations), attributing the efficacy of blue light 
phototherapy to its anti-P. acnes effects, the results should be interpreted  with 
caution due to the fact that essential information about methodology (including 
details about ethical approval, recruitment, inclusion/exclusion criteria, and sampling 
as well as culturing technique for P. acnes) and the statistical tests used was not 
given. Moreover, information about clinical outcome in patients who showed a 
reduction in P. acnes density vs. those who did not would have been more helpful in 
determining whether the reported anti-microbial effect of blue light therapy was 
necessary for its clinical efficacy or not. 
 
 
Horfelt et al. [256], in his attempt to determine the optimal light dose and mechanism 
of action of red light-assisted ALA-PDT (600-730 nm, fluences 30, 50, and 70 J cm- 
2, irradiance 50 mW cm-2) in patients with mild to severe acne demonstrated that the 
lower light dose is as effective as the higher dose. However, they did not find any 
significant reduction in the P. acnes density over the 10-week follow-up period. It 
was concluded that the mechanism of action of PDT in acne does not depend upon a 
reduction in P. acnes counts. 
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Subsequently, Ammad et al. [266] used a single-blind, uncontrolled study design to 
assess the efficacy of blue light phototherapy (415-425 nm, irradiance 70-90 W cm-2, 
fluence not stated) and its effect on P. acnes density in the treatment of acne vulgaris. 
They found blue light to be effective in the management of inflammatory acne, 
however, in accordance with the findings of Horfelt et al. [256] this beneficial effect 
was not found to be related to a reduction in P. acnes density. Similarly, Horfelt et al. 
[255] found single low dose red light phototherapy (635 nm, fluence 15 J cm-2, 
irradiance 63 mW cm-2) to be as effective as MAL-PDT in the treatment of moderate 
to severe facial acne. However, no significant decrease in the P. acnes density was 
observed in any group, thereby, adding to the list of publications favouring the anti- 
acne effects of visible light therapy to be independent of its influence on the 
cutaneous microflora. 
 
 
3.4.1.4 Summary of the microbiological effect vs. clinical efficay of 
incoherent light (including PDT) in acne 
Evidence on the effect of incoherent light, including PDT, on P. acnes density in 
acne patients is contradictory. In fact, except for the studies of Hongcharu et al. [245] 
and Shalita et al. [265], with their limitations discussed above, none of the other 
studies showed any significant effect on P. acnes colonisation/density (via bacterial 
culture or porphyrin fluorescence) post-treatment in acne patients. However, as all 
the studies except one used nonpulsed light sources [245, 255, 256, 259, 263, 265, 
266], no definite conclusions can be made regarding the effect of IPL or IPL-assisted 
PDT on the P. acnes density in acne patients. Further studies, such as that presented 
in this thesis, will be required to clarify this issue. Similarly, as none of the studies 
used nonpulsed blue light for PDT, its effect on P .acnes density in acne patients 
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remains to be explored. While a reduction in P. acnes density in acne patients is 
desirable and may clinically improve acne, the beneficial effects of light therapy in 
these patients can be seen independent of this occurrence. It is possible that 
incoherent light, with or without a photosensitiser, may improve acne by virtue of its 
immunomodulatory and/or sebostatic effects. 
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Table 3.1: Studies on the microbiological effects vs. clinical efficacy of incoherent light (including PDT) in acne 
 
Reference 
(first 
author 
and year) 
 
Study 
size (n) 
 
Study design 
 
Interventions 
 
Photosensitiser 
(contact time) 
 
Light source 
 
Irradiation 
valuesb 
No. of 
treatments 
and 
interval 
 
Clinical efficacy 
 
Porphyrin fluorescence 
{Assessment interval} 
 
Microbiology 
{Assessment interval} 
 
Hongcharu 
(2000) 
[245] 
 
23 
 
RCT, single- 
blind 
 
ALA-PDT, 
ALA alone, 
light alone, 
untreated 
control 
 
20% ALA (3h) 
 
Red light, 
550-700 nm 
 
150 J cm-2 
 
2 groups: 1 
treatment 
and 4 
treatments 
1 week 
apart 
 
Statistically significant 
improvement in 
inflammatory acne for 
10 weeks after a single 
treatment and for at least 
20 weeks after multiple 
treatments with ALA- 
PDT. Multiple ALA- 
PDT treatment sites 
showed more 
improvement than single 
treatment (p < 0.001) 
 
Statistically significant 
reduction in porphyrin 
fluorescence for 20 weeks 
after a single treatment and 
multiple treatments with 
ALA-PDT. No significant 
difference between the two 
groups 
 
{Baseline, 2, 3, 10, and 20 
weeks after the last 
treatment} 
 
ND 
 
Shalita 
(2001) 
[265] 
 
10 
 
Controlled trial 
(blinding and 
randomisation 
details not 
available) 
 
Violet-blue 
light, 
untreated 
control 
 
NA 
 
Violet-blue 
light 
(CureLight 
Ltd.), 407- 
420 nm 
 
Treated for 
20 min at 
an 
irradiance 
of 90 mW 
cm-2 
 
Fluence 
NM 
 
6, twice a 
week 
 
No clinical evaluation 
performed on this cohort 
of 10 patients. However, 
a 68% reduction in 
inflamed lesion counts 
was reported for another 
group of 35 acne patients 
after 8 bi-weekly 
treatment with the same 
light source. No 
statistical analysis given 
for these 35 patients 
 
ND 
 
A significant ↓ (> 1 log, p 
< 0.05) in the P. acnes 
density was seen in 6 out 
of 10 patients after 6 
treatments. These 
patients had a baseline P. 
acnes density of > 105 
colonies cm-2 
 
{Baseline, and after the 
2nd, 4th, and 6th treatment} 
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Table 3.1 Continued 
 
Reference 
(first 
author 
and year) 
 
Study 
size (n) 
 
Study design 
 
Interventions 
 
Photosensitiser 
(contact time) 
 
Light source 
 
Irradiation 
valuesb 
No. of 
treatments 
and 
interval 
 
Clinical efficacy 
 
Porphyrin fluorescence 
{Assessment interval} 
 
Microbiology 
{Assessment interval} 
 
Omi 
(2004) 
[259] 
 
28 
 
Open, 
uncontrolled 
 
Blue light 
only 
 
NA 
 
Blue light 
(ClearLightTM 
), 410-420 nm 
 
Treated for 
15 min at 
an 
irradiance 
of 200 mW 
cm-2 
 
Fluence 
NM 
 
8, twice a 
week 
 
A 64.7% ↓ in acne 
lesions after 8 treatments 
(p < 0.01). Improvement 
sustained for 2 months 
after the last treatment in 
6 out of 9 patients 
 
ND 
 
No change in P. acnes 
colonisation detected pre- 
and post-treatment via 
bacterial culture or 
polymerase chain 
reaction 
 
{Baseline and after 8 
treatments} 
 
Tzung 
(2004) 
[263] 
 
31 
 
RCT, split-face, 
single-blind 
 
Blue light, 
untreated 
control 
 
NA 
 
Blue light (F- 
36 W/Blue V, 
Waldmann), 
420 20 nm 
 
40 J cm-2 
 
8, twice a 
week 
 
After 8 treatments: 
significant improvement 
in global acne severity 
score with blue light vs. 
control (52% vs.12%, p 
< 0.001). Improvement 
sustained for at least 1 
month after the last 
treatment 
 
Therapeutic effectiveness 
was not found to be related 
to fluorescence intensity 
change (p = 0.812) 
 
{Before and at the end of 
the treatment} 
 
ND 
 
  Horfelt    
  (2007) 
  [256] 
 
15 
 
Open, 
uncontrolled 
 
Various 
fluences of 
red light (30, 
50 and 70 J 
cm-2) 
compared 
with each 
other 
 
20% ALA (3 h) 
 
Red light 
(Waldman 
PDT 1200 
lamp), 
600-730 nm 
 
30, 50, and 
70 J cm-2 
 
50 mW cm- 
2 
 
1 
 
No statistical analysis. 
Acne response same for 
30 and 50 J cm-2. 7 out 
of 9 patients’ facial acne 
improved by global 
severity score of at least 
one (out of four) at week 
10 after the treatment 
 
ND 
 
No significant ↓ in P. 
acnes density for up to 
10 weeks after treatment 
with 50 J cm-2 
 
{Baseline, 1, 2, 3, and 10 
weeks after treatment} 
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Table 3.1 Continued 
 
Reference 
(first 
author 
and year) 
 
Study 
size (n) 
 
Study design 
 
Interventions 
 
Photosensitiser 
(contact time) 
 
Light source 
 
Irradiation 
valuesb 
No. of 
treatments 
and 
interval 
 
Clinical efficacy 
 
Porphyrin fluorescence 
{Assessment interval} 
 
Microbiology 
{Assessment interval} 
 
Yeung 
(2007) 
[264] 
 
30 
 
RCT, split-face, 
single-blind 
 
All 
participants 
used 0.1% 
adapalene gel 
and were 
randomised to 
two split-face 
treatment 
groups; IPL 
assisted 
MAL-PDT 
vs. IPL alone; 
and IPL vs. 
control 
(adapalene- 
only group) 
 
16% MAL (30 
min) 
 
IPL (Ellipse 
Flex), 
530-750 nm 
 
7-9 J cm-2 
 
4, 3 weeks 
apart 
 
Inflamed lesions: 
 
Significant ↓ in the 
adapalene-only group at 
4 weeks (72%, p = 0.01) 
and 12 weeks (88%, p = 
0.01) after the last 
treatment. No significant 
↓ in the MAL-PDT or 
IPL groups 
 
 
Noninflamed lesions: 
 
Significant ↓ in the 
MAL-PDT (38%, p = 
0.05) and IPL (44%, p = 
0.01) groups at 12 weeks 
after the last treatment. 
No significant change in 
the adapalene-only 
group 
 
Porphyrin reduction > 50% 
at 4 weeks after the last 
treatment: MAL-PDT 
(27%) vs. IPL (17%) vs. 
adapalene-only (0%). No 
significant difference 
between the three groups 
 
{Baseline, before each 
treatment and 4 and 12 
weeks after the last 
treatment}a 
 
ND 
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Table 3.1 Continued 
 
Reference 
(first 
author 
and year) 
 
Study 
size (n) 
 
Study design 
 
Interventions 
 
Photosensitiser 
(contact time) 
 
Light source 
 
Irradiation 
valuesb 
No. of 
treatments 
and 
interval 
 
Clinical efficacy 
 
Porphyrin fluorescence 
{Assessment interval} 
 
Microbiology 
{Assessment interval} 
 
Ammad 
(2008) 
[266] 
 
21 
 
Single-blind, 
uncontrolled 
 
Blue light 
only 
 
NA 
 
Blue light 
(ClearLightTM 
), 415-425 nm 
 
Treated for 
14 min at 
an 
irradiance 
of 70-90 W 
cm-2 
 
Fluence 
NM 
 
8, twice a 
week 
 
After the 8th treatment: ↓ 
inflamed lesions 
13.87%, ↓ noninflamed 
lesions 10.23%. p < 0.05 
for inflamed lesions only 
 
ND 
 
No significant ↓ in P. 
acnes density after the 8th 
treatment (p = 0.66) 
 
{Baseline and after the 
8th treatment} 
 
  Horfelt  
  (2009) 
[255] 
 
23 
 
Open, 
nonrandomised, 
split-face 
controlled study 
 
MAL-PDT, 
light alone 
 
MAL cream 
160mg/g (3h) 
 
Red light 
(Aktilite® CL 
128 lamp), 
635 nm 
 
15 J cm-2 
 
63 mW cm- 
2 
 
1 
 
Global acne severity 
score, papules/pustules 
and noninflamed lesions 
showed a statistically 
significant ↓ in both 
groups at 10 and 20 
weeks follow up (p < 
0.05). No significant 
difference between the 
groups for any of these 
parameters 
 
Fluorescence imaging only 
used for the assessment of 
photobleaching after 
irradiation. No data for the 
follow-up visits reported 
 
No significant ↓ in P. 
acnes density for up to 20 
weeks after treatment at 
any site 
 
{Baseline, 1, 10, and 20 
weeks after treatment} 
 
n, number of participants at the start of trial; NA, not applicable; ND, not done; NM, not mentioned; PDT, photodynamic therapy; RCT, randomised controlled 
trial; ALA, 5-aminolaevulinic acid; MAL, methyl aminolaevulinate; IPL, intense pulsed light; P. acnes, Propionibacterium acnes; ↓, reduction. aResults only 
reported for week 4 after the last treatment. bFluence (J cm-2) and irradiance (mW cm-2) where stated. 
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3.4.2 Other potential mechanisms of action of incoherent 
light (including PDT) in acne 
3.4.2.1 Photoimmunological effects 
 
Light may be beneficial in acne because of its immunomodulatory properties. 
Shnitkind et al. [267] demonstrated narrow-band blue light (420 nm) to inhibit IFN-γ 
and TNF-α induced production of the proinflammatory cytokine IL-1α in two 
immortalised keratinocyte cell lines. Moreover, the expression of intercellular 
adhesion molecule-1 was also reduced. Ultraviolet B synergistically increased the 
effect of blue light. 
 
 
IPL (570 nm cut-off filter, triple pulses of 7 ms with a pulse interval of 70 ms, 
fluence 75 J cm-2) has been demonstrated to up-regulate TGF-β1 expression in 
human skin fibroblasts, in vitro [268]. Similarly, IPL-assisted ALA-PDT (555-950 
nm, fluence 8 J cm-2, ALA contact time 6 h) has been shown to up-regulate TGF-β1 
expression in cultured HaCaT cells [269]. TGF-β is an immuno-regulatory cytokine 
that can lead to inhibition of T lymphocytes proliferation and differentiation. 
Moreover, it also inhibits activation of macrophages and their production of 
proinflammatory cytokines, and can prevent maturation of dendritic cells [270]. In 
addition, it is also a potent inhibitor of keratinocytes proliferation [271]. Therefore, 
increased expression of TGF-β can be one of the mechanisms by which IPL/IPL- 
assisted PDT may improve acne. 
 
 
Byun et al. [269] showed increased expression of IL-10 in cultured HaCaT cells after 
treatment with IPL (555-950 nm, fluence 8 J cm-2). IL-10 induction has also been 
demonstrated in skin explants of PDT-treated (630 nm) mice [233].  As previously
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explained (Chapter 2, Section 2.4.3.1), TLRs mediate their effects by activation of 
the transcription factor, NF-κB, and MAPKs [174]. MAPKs subsequently potentiate 
the activity of another transcription factor, activator protein (AP)-1 [272]. Moreover, 
TLR-2 and TLR-4 are up-regulated in inflamed lesions of acne patients [181]. In line 
with these observations, AP-1 and NF-κB activation has been found to be markedly 
increased in inflamed acne lesions, compared with normal skin, and was 
accompanied by significant increases in mRNA levels for genes regulated by NF-κB 
(IL-8, IL-1β, IL-10, TNF-α) and AP-1 (matrix metalloproteinases (MMP)-1, -3, -9) 
[273]. IL-10 has been shown to inhibit activation of NF-κB, in vitro [274, 275], and 
its induction in acne-affected skin may suppress TLR-mediated signalling and could 
improve acne. IL-10 likewise inhibits MHC (major histocompatibility complex) class 
II and co-stimulatory molecule B7-1/B7-2 expression on monocytes and 
macrophages, resulting in suppression of their antigen-presenting function [145]. 
Moreover, it also negatively regulates costimulatory signals on Langerhans cells 
(LCs) [276]. Up-regulation of IL-10 may therefore represent another possible 
mechanism by which IPL/IPL-assisted PDT may positively impact acne. 
 
 
Comparable to UVB reactions in skin, red light-assisted ALA-PDT (630 + 3 nm) has 
 
been shown to decrease the number of epidermal LCs in a murine model [277]. This 
local immunosuppression caused by reduced epidermal LCs could also potentially 
improve acne. 
 
 
3.4.2.2 Effect on sebaceous glands 
 
As mentioned earlier, IPL has been successfully used to treat telengiectasias and 
port-wine stain [210]. The mechanism, as in lasers, involves selective absorption    of 
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light by haemoglobin in the blood vessels. The absorbed light is converted to heat 
leading to coagulation of the abnormal vessels [278]. Thus IPL, like pulsed-dye laser 
which has been used to treat sebaceous gland hyperplasia [279], can potentially 
damage sebaceous gland as a result of photocoagulation of its blood supply. 
Similarly, the fact that PpIX accumulates selectively in sebaceous glands  after 
topical ALA application has been successfully used to treat sebaceous gland 
hyperplasia with ALA-PDT irradiated with IPL (500-1200 nm with a 550 nm cut-off 
filter, ALA contact time 30-60 min, fluence 32 J cm-2, 3.5/3.5 ms pulse duration, 20 
ms delay between pulses) [280]. In terms of acne, a decrease in sebaceous glands 
size along with reduction in SER has been demonstrated for up to 20 weeks after 
treatment with red light-assisted ALA-PDT (550-700 nm, fluence 150 J cm-2) [245]. 
Reduction in SER, due to sebaceous gland damage, may therefore represent other 
possible ways by which IPL-assisted PDT/IPL may improve acne 
 
 
3.4.3 Summary of the therapeutic targets for IPL/IPL-assisted 
PDT 
There is insufficient evidence to draw definite conclusions regarding the effect of 
IPL/IPL-assisted PDT on P. acnes density in acne patients. Further studies a r e  
needed to clarify this issue. IPL/IPL-assisted PDT may also work in acne via their 
photoimmunological, and/or sebostatic (as a result of photothermal/photodynamic 
damage to the sebaceous glands) properties. However, in vivo, the simultaneous 
activation of all these three mechanisms may not be necessary for the clinical 
efficacy of these treatments. 
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The clinical and laboratory arms of our study were designed to assess the clinical 
efficacy of IPL/IPL-assisted MAL-PDT vs. adapalene 0.1% gel (conventional acne 
treatment) in mild to moderate acne patients and to determine their effect on the 
counts of P. acnes. ALA-PDT has also been shown to cause photodynamic 
eradication of other cutaneous micro-organisms (e.g. S. aureus and CoNS 
specifically S. epidermidis), in vitro [281], and therefore our laboratory arm also 
evaluated the effect of above treatments on S. aureus and CoNS, in vivo. These 
micro-organisms do not normally produce porphyrins; however excessive production 
and accumulation can be seen after incubation with ALA [281]. 
 
 
3.5       Hypothesis and Aims 
 
As mentioned earlier, two systematic reviews have concluded that optical therapies, 
including PDT, can improve acne at least temporarily [206, 207]. This has led us to a 
hypothesis that IPL and IPL-assisted MAL-PDT are effective treatments for acne and 
that their beneficial effect is due to their anti-P. acnes property by virtue of its 
porphyrin producing capability. Thus, a prospective, RCT was designed to determine 
the efficacy of IPL (administered as IPL-Placebo) and IPL-assisted MAL-PDT (IPL- 
MAL) vs. adapalene 0.1% gel in the treatment of acne and to identify their mode of 
action, looking specifically at the effect on surface density of P. acnes. Moreover, as 
mentioned above, the laboratory arm was further extended to evaluate the effect of 
these treatments on the surface densities of S. aureus and CoNS as well. 
 
 
3.5.1 Clinical study aims 
 
To evaluate the clinical efficacy of IPL-Placebo and IPL-MAL and adapalene 0.1% 
gel on their ability to reduce: 
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1) Inflamed lesion counts 
 
2) Noninflamed lesion counts 
 
3) Total lesion counts 
 
4) Leeds revised acne grading system score 
 
5) Visual analogue scale score 
 
6) Dermatology Life Quality Index score 
 
7) Family Dermatology Life Quality Index score 
 
8) Porphyrin fluorescence 
 
 
 
3.5.2 Laboratory study aims 
 
To determine whether IPL-Placebo and IPL-MAL exert the following effects on 
cutaneous micro-organisms: 
 
 
1) Reduce the density of P. acnes 
 
2) Change the density of CoNS and S. aureus 
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4. Methods and Materials 
 
4.1 The clinical study 
 
4.1.1 Rationale 
 
In accordance with previous studies assessing the clinical efficacy of optical 
therapies [247, 266, 282, 283], a global acne severity grade (the Leeds revised acne 
grading system) and lesion counts were used to assess the clinical outcome of the 
three treatments (IPL-Placebo, IPL-MAL, adapalene 0.1% gel) used in this trial. 
Likewise, a subjective global acne severity scale (the visual analogue scale) was used 
to account for the patient’s impression about the effectiveness of the received 
treatment [266]. The Dermatology Life Quality Index and Family Dermatology 
Life Quality Index questionnaires were used to assess the outcome of the three 
treatments on the quality of life (QoL) of the patients and their family 
members/partners, respectively. In keeping with the study of Yeung et al. [264], 
standardised clinical and fluorescent photographs were taken via the Canfield 
VISIA® Complexion Analysis system (Canfield Scientific Inc., USA). The clinical 
and fluorescent photographs were used for the assessment of Leeds revised acne 
grading system score and follicular porphyrin fluorescence pre- and post-treatment, 
respectively. As mentioned in chapter 3 (Section 3.4.1.2), P. acnes produced 
porphyrins give rise to orange-red follicular fluorescence under Wood’s light 
examination. As the intensity of this fluorescence has been shown to be proportional 
to the P. acnes population, the digital fluorescent photographs were used as an 
indirect way of evaluating the suppressive effects of above three treatments on this 
micro-organism. 
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Based upon the results of two split-face studies in which improvement was also seen 
in untreated half of the face, raising the possibility of a systemic effect of light 
treatment, we opted for a parallel group study design [282, 284]. The Energist 
ULTRA VPLTM (Energist Ltd. Swansea, UK), a CE-marked IPL device currently 
being used in our department, was used as the light source in the trial. As elucidated 
in chapter 3 (Section 3.3.4), MAL was preferred over ALA in this trial because of its 
greater lesion specificity, deeper penetration, and a better side-effect profile. 
 
 
4.1.1.1 Lesion counts 
 
Lesion counting involves recording the number of noninflamed and inflamed acne 
lesions and is an objective way of determining the response to a specific treatment 
[285]. Although time consuming, it is more accurate than acne grading. Moreover, 
lesion counting does not only distinguish small differences in therapeutic response 
but the effect of treatment on individual lesions can also be estimated [285]. It was 
for all these reasons lesion counting was chosen to evaluate the response to the 
various treatments used in this trial. 
 
 
4.1.1.2 Leeds revised acne grading system 
 
An acne grading system is a quick and subjective method of determining the severity 
of acne [285]. However, it does not distinguish small differences in therapeutic 
response [285]. In clinical trials, an acne grading system can be used along with 
lesion counts to get an overall picture of a treatment’s efficacy. Moreover, it can also 
be used to select the patients with the correct level of acne for a treatment under 
investigation [286]. 
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Several systems for grading the severity of acne currently exist [285]. The Leeds 
revised acne grading system (LRAGS/Leeds) [286] is a rapid and reproducible 
grading scale for inflammatory acne that relies on assessment of acne severity using 
photographic standards for 3 sites: the face, back, and chest. The criteria used to 
assess severity are extent of inflammation, range and size of inflamed lesions, and 
associated erythema. The grading system displays a series of colour photographs of 
facial and truncal (back and chest) acne producing 12 colour pictorial grades (1-12) 
for facial acne and 8 grades (1-8) for acne affecting the back or chest. In the grading 
system, grade 1 represents mild acne while grades 12 and 8 signify severe facial and 
chest or back acne, respectively. As the LRAGS allows for retrospective evaluation, 
via comparison of the patients’ photographs taken during the trial period with the 
photographic standards, this grading system was chosen for the study. 
 
 
4.1.1.3 Visual analogue scale 
 
Visual analogue scales (VAS) can be used to measure subjective experience and 
archetypally consist of a 10 cm line, with words descriptive of the maximal and 
minimal extremes of the parameter being measured, fixed at both ends [287]. They 
are user-friendly, require little motivation for completion by the patients, and allow 
the use of numerical values suitable for statistical analysis [287]. 
 
 
In order to get patient’s perspective regarding the treatment’s efficacy, a 10 cm VAS 
was used in this trial, where 0 represents ‘no acne, the best it could possibly be’ and 
10 ‘very bad acne, the worst it could possibly be’. Similarly, subjective evaluation of 
pain after IPL-Placebo and IPL-MAL was again measured by a 10 cm VAS, where 0 
represents ‘no pain’ and 10 ‘the worst ever pain’. 
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4.1.1.4 Quality of Life 
 
Skin disease can have a major impact on the QoL of patients [288] and their families 
[289]. Over the past two decades various generic scales e.g. Dermatology-specific 
Quality of Life instrument [290], Skindex [291], Dermatology Life Quality Index 
(DLQI) [292], Dermatology Quality of Life Scales [293], and Impact of  Chronic 
Skin Disease on Daily Life [294] have been described to measure the impact of skin 
disease on patients’ QoL. Similarly, the Family Dermatology Life Quality Index 
(FDLQI) [295, 296] is a validated dermatology-specific instrument that has been 
described to measure the secondary impact of patients’ skin disease on the QoL of 
family members. 
 
 
The DLQI is a self-administered and user-friendly questionnaire with a completion 
time of 1-3 min [292]. It was the first dermatology-specific QoL instrument [297] 
and remains the most commonly used health-related QoL outcome measure to date 
[298]. It has been validated for dermatology patients aged 16 years and above, and 
has been successfully used in various studies to demonstrate change in the patients’ 
QoL before and after treatment [298]. It was for all these reasons that prompted the 
use of this QoL tool in this trial. 
 
 
The DLQI consists of 10 items encompassing the impact of skin disease on different 
areas of patients’ life such as symptoms/feelings, daily activities, leisure, 
work/school, personal relationships, and the side-effects of treatment over the past 1 
week [292]. Each item is scored on a four-point scale; 0, not at all/not relevant; 1, a 
little; 2, a lot; 3, very much. Scores of each item (0-3) are summed to yield the total 
score, ranging from 0 (no impairment of life quality) to 30 (maximum impairment). 
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The FDLQI is the only generic dermatology-specific measure explicitly designed to 
measure the family impact of any type of skin disease [296]. It consists of 10 items 
encompassing the impact of patients’ skin disease on various aspects of QoL (e.g. 
emotional, physical well-being, relationships, peoples’ reaction, social life, leisure 
activities, burden of care, job/study, housework, and expenditure) of their family 
members/partners over the last 1 month [295]. Each item is scored on a four-point 
scale; 0, not at all/not relevant; 1, a little; 2, quite a lot; 3, very much. Scores of each 
item (0-3) are added to give a total score that ranges from 0 to 30; a higher score 
indicates greater impairment of QoL. 
 
 
4.1.1.5 Energist ULTRA VPLTM as an IPL source 
 
The Energist ULTRA VPLTM (Figure 4.1) is a variable pulsed IPL device equipped 
with a 530 nm and 610 nm interchangeable applicators. Both the applicators remove 
infrared wavelengths above 950 nm, thereby reducing non-specific epidermal 
heating. Moreover, the 530 nm and 610 nm applicators filter wavelengths below 530 
nm and 610 nm, respectively (Figure 4.2). This ensures delivery of the optimal 
wavelengths to the target chromophore. Wavelengths in the yellow-red range may be 
more effective, as a virtue of their deeper penetration into the skin, than blue light in 
the photodynamic eradication of P. acnes whose habitat is the PSF. Additionally, 
they may also damage the sebaceous glands which lie deep in the dermis. 
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Figure 4.1: The Energist ULTRA VPLTM  device with its 
touch-screen interface. 
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Figure 4.2: Spectral output of 530 & 610 nm applicators. Courtsey of Darren 
Thomas, Energist Ltd. Swansea, UK, © 2014. 
 
 
 
4.1.2 Clinical methods 
 
Ethical approval for this study was obtained from the South East Wales Research 
Ethics committee (reference number: 09/WSE03/40) and Research & Development 
approval was granted by the Cardiff and Vale NHS Trust (reference number: 
07/CMC/4136E). The study was also approved by the Medicines and Healthcare 
Products Regulatory Agency (reference number: 21323/0026/001-0001) and was 
conducted in accordance with the International Conference on Harmonisation’s Good 
Clinical Practice guidelines. 
530 nm applicator 
610 nm applicator 
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4.1.2.1 Subjects and recruitment 
 
Male and female volunteers aged 18-45 years with mild to moderate facial acne were 
eligible for the study. Patients were invited to enter the study through newspaper 
advertising, Cardiff University’s online notice board announcements and by poster 
advertisements at the halls of residence. Patients attending the dermatology 
department, University Hospital of Wales (UHW), for the treatment of acne were 
offered information about the study and the general practitioners (GPs) within the 
Cardiff locale were asked to directly refer appropriate patients. Posters about the 
study were also displayed in the GP surgeries so that interested subjects may also 
contact the research team directly. The trial period spanned from March 2010 to 
October 2011 with the first patient being enrolled into the study on March 9, 2010 
and the last patient completed follow-up on October 26, 2011. 
 
 
A standard screening questionnaire was used to assess general suitability of the 
patients. This was available online, for those who had access to the Cardiff 
University intranet, with the results being available to the investigators on an Excel 
datasheet. The same questionnaire was also used for any telephone enquiries. 
Patients whose suitability for the trial could not be ascertained on the basis of the 
screening questionnaire were given the option to meet the investigator. All 
prospective patients were given an information document detailing the study’s 
objectives and overall requirements. After they had been given sufficient time (at 
least 48 h) to read and understand the information document, all interested patients 
were asked to come for a baseline visit where conformity with the eligibility criteria 
was again ensured and a written informed consent was obtained. All the assessments
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and treatments were carried out in the dermatology department at Glamorgan House, 
UHW. 
 
 
Patients recruited to the trial were sequentially allocated a patient number and their 
data were collected on case report forms (CRFs). The patients’ anonymity was 
maintained, as patients were identified on CRFs by their initials and the allocated 
patient number. For any emergency a record of patient’s number, name and address 
was also maintained and kept separate from the CRFs. The data from each patient 
were eventually stored on an Excel data sheet for further analysis. 
 
 
During the course of the study, the patient could be discontinued for the following 
reasons: voluntary withdrawal, serious adverse event, suspected unexpected serious 
adverse event and noncompliance with the study protocol. The inclusion and 
exclusion criteria as detailed in the study protocol are listed below. 
 
 
4.1.2.1.1 Inclusion criteria 
 
1. Mild to moderate facial acne (face = area from hairline to jawline) with at 
least 15 inflamed and/or noninflamed lesions, but no more than 3 
nodulocystic lesions, thus, not exceeding Leeds grade 7 (for the face) 
2. Patients willing to have only their face treated 
 
3. Fitzpatrick skin phototypes I-IV 
 
4. Patients willing and able to provide written informed consent 
 
5. Patients who agree to avoid the use of sunbeds or undergo any ultraviolet 
light treatment for 4 weeks prior to entering the study and are willing to 
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minimise the amount of exposure to direct sunlight for the duration of the 
study 
6. Access to an active email account and willing to reveal their email account 
details to the study team in order to receive weekly reminders 
7. Patients considered to be reliable and expected to be compliant with the 
investigational products and protocol requirements 
 
 
4.1.2.1.2 Exclusion criteria 
 
1. Unable to give written informed consent 
 
2. Severe acne or scarring 
 
3. Pregnant women or those contemplating pregnancy 
 
4. Lactating females 
 
5. Use of anti-androgen containing contraceptives 
 
6. keloids or a tendency to heal with keloids 
 
7. Facial treatment in the previous year with collagen, dermabrasion and laser 
resurfacing 
8. Facial microdermabrasion within the past 3 months 
 
9. Treatment with alpha-hydroxyl acids within the past 3 months 
 
10. History of hypersensitivity to any of the study drugs or their excipients i.e. 
adapalene, Metvix TM (e.g. peanut oil, soya oil), Unguentum M® 
11. Photosensitivity disorders e.g. solar urticaria, porphyrias, systemic lupus 
erythematosus 
12. Allergy to porphyrins 
 
13. Epilepsy 
 
14. Oral photosensitisers within the past 4 weeks 
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15. Oral retinoid use within the past 12 months 
 
16. Use of vitamin A supplements > 2000 IU/day 
 
17. Use of systemic medications such as steroids, immunosuppressants, statins 
and preparations containing St. John’s worta 
18. Oral antibiotics and topical retinoids use within the past 4 weeks 
 
19. Treatment with IPL or lasers to the face within the last 12 months 
 
20. Psoriasis, rosacea, bacterial, viral, fungal, or other diseases of the facial skina 
 
21. Mild to moderate acne patients who never had any over the counter treatment 
 
22. Severe systemic diseases such as: impaired renal or liver function; regional 
enteritis or ulcerative colitis; a history of antibiotic-associated colitis; severe 
cardiovascular, neurological or any other disease that may interfere with the 
evaluation of the study medications 
23. Unavailability at any time during the course of the study i.e. 16 weeks 
 
24. Involvement in another clinical trial 
 
25. Patients living with anyone that is also taking part in this study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aPatients temporarily ineligible. Could be enrolled into the study after a wash-out period of 4 
weeks or after resolution of their illness. 
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4.1.2.2 Randomisation 
 
The randomisation was performed by the St. Mary’s Pharmaceutical Unit, Cardiff. 
The patients were randomly assigned by a computer-generated allocation sequence 
with a block size of 30 to three main groups: IPL-MAL group, IPL-Placebo group 
and adapalene group. The randomisation list was held within the pharmacy 
department of the UHW and unveiled at the end of the study. All the patients were 
randomised and treated within 30 days of the baseline visit (Figure 4.3). 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
< 30 days 
 
Weeks 1-16 
 
 
 
Figure 4.3: Study schema. IPL, intense pulsed light; MAL, Methyl aminolaevulinate. 
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4.1.2.3 Blinding and handling of trial medications 
 
Both patients and investigators remained blinded to the IPL-MAL and IPL-Placebo 
treatment allocation from the time of randomisation until database lock. However, 
the patients as well as investigators were aware of the treatment allocation in the 
adapalene group. This is contradictory to the main title of the trial which suggests it 
to be a completely double blind trial. Laboratory staff, however, remained blinded to 
the IPL-MAL, IPL-Placebo and adapalene treatment allocation throughout the trial. 
 
 
An unblinded trial nurse delivered the trial specific prescription to the pharmacy 
department of the UHW, where the treatment allocated to the patient was identified 
from the randomisation list and supplied to the unblinded nurse. Treatment in the 
IPL-MAL and IPL-Placebo groups was applied by the unblinded trial nurse 
throughout the trial and the treatment allocation was not discussed, at any time, with 
the patients or investigators. Emergency unblinding was possible through the 
pharmacy department, if deemed necessary, for reasons of patient safety. 
 
 
All the investigational medicinal products (IMP) used in the trial were supplied 
directly to the pharmacy department of the UHW. All the IMP were stored in the 
recommended storage conditions and appropriate temperature monitoring was 
performed especially for the MAL cream which is supposed to be stored at 2–8°C (in 
a refrigerator). 
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4.1.2.4 Treatment 
 
The IPL-MAL group received 16% MAL cream (Metvix®; Galderma UK Ltd, 
Watford) while Unguentum M® cream (Almirall Ltd, Uxbridge, UK) was used, as a 
placebo, in the IPL-Placebo group. MAL as well as Unguentum M® creams were 
applied as a 1-mm thin film to the face (avoiding the nose, lips, moustache area and 
areas immediately around the eyes) and covered with an occlusive dressing (3M 
Tegaderm; 3M Company, Bracknell, UK) for 60 min. All the patients sat in a 
darkened room during this time period. As explained in chapter 3  (Section 3.3.4), 
this contact time was chosen to minimise PDT-related side-effects as investigations 
using 3 hour incubation period [241, 245-247] have been associated with frequent 
and severe side-effects with a significant patient dropout rate compared with 
contact times of 30-60 min [248, 249]. Prior to the illumination, the patients washed 
their faces using a gentle cleanser (E45® Emollient Wash Cream; Forum Health 
Products Limited, Surrey, UK) followed by pat drying. 
 
 
The irradiated area corresponded to the facial area where MAL or Unguentum M® 
creams were applied under occlusion. Illumination was performed whilst patient 
relaxed on a couch with the backrest adjusted to an angle of +45°. The following 
irradiation parameters were used after application of a thin layer of ultrasound gel on 
the skin (for optical coupling): 610-950 nm cut-off filter, 50×10 mm spot size, 5-15 
pulses, 5 ms pulse duration, 20 ms delay between pulses, 20-40 J cm-2 fluence and 
two passes in conjunction with cold air cooling (SmartCoolTM; Cynosure, USA) 
(Figure 4.4). No topical anaesthetic agent was applied and non-overlapping pulses 
were delivered. The eyes were protected with goggles. Both IPL groups received 4 
treatments to the face with an interval of 2 weeks between each session (Figure 4.3). 
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Marked discrepancies have been demonstrated between the measured IPL devices 
outputs (e.g. fluence, pulse duration, pulse shape, spectral output) and those claimed 
by the manufacturers [299]. Therefore parameters claimed to be successful in one 
device might not demonstrate similar efficacy in another. Moreover, as limited 
information was available on the use of IPL for acne treatment in Fitzpatrick skin 
types I/II, the above settings were roughly based on those used by Babilas and 
colleagues [300]. They also used the Energist ULTRA VPLTM device in Fitzpatrick 
skin types II/III (610-950 nm cut-off filter, 15 pulses, 5 ms pulse duration, 20 ms 
delay between pulses, two passes, fluence 40 J cm-2) during MAL-PDT for actinic 
keratosis. The investigators reported similar efficacy but reduced pain with this 
device compared to a light-emitting diode (LED). 
 
 
Patients in the adapelene group applied a thin film of adapalene gel (Differin® Gel 
0.1% w/w; Galderma UK Ltd, Watford) to their faces, after washing it, nightly, 
avoiding the areas just around the eyes, nostrils and lips. Treatment in this arm lasted 
for 12 weeks (Figure 4.3). All the patients in this group were sent weekly emails to 
remind them regarding the daily application of adapalene. Compliance in this group 
was further ensured by weighing the adapalene tubes at follow-up visits. 
 
 
All the patients participating in the trial were provided a sunblock lotion (Delph® 
lotion; SPF 30; Fenton Pharmaceuticals Ltd, London, UK) to be used daily on the 
face for the entire duration of the study. Patients in the PDT arms were also advised 
to avoid sun exposure as much as possible for the first 48 hours after treatment. 
Moreover,   an   emollient   (Diprobase®    ointment;   Merck   Sharp   &   Dohme Ltd, 
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Hertfordshire, UK), to be used twice a day for a total of 5 days, was given to all 
patients in the PDT groups post-treatment. 
 
 
 
 
Figure 4.4: SmartCoolTM cooling device. 
 
 
 
4.1.2.5 Assessments 
 
All patients were evaluated at baseline, week 8, week 11, and week 16 of the trial. 
This amounted to a follow-up period, post-treatment, of 1 week, 4 weeks and 9 
weeks in the PDT groups whilst the maximum follow-up period, post-treatment, in 
the adapalene group was 3 weeks (Figure 4.3). Demographic data including each 
patient’s age, medical and medication history (including a detailed acne history), 
Fitzpatrick skin type, height, weight, history of smoking, and pregnancy test (females 
only) were recorded for all patients at baseline. 
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At baseline and subsequent visits the numbers of inflamed and noninflamed facial 
acne lesions were counted. Moreover, standardised clinical and fluorescent 
photographs were also performed. Leeds assessments were performed by 2 
dermatologists, blinded to all 3 arms of treatment and not involved in the study, by 
using the photographs taken at baseline and subsequent visits. 
 
 
As mentioned in section 4.1.1.3, a 10 cm VAS was used to assess patients’ own 
impression about their acne at baseline and follow-up visits. The impact of acne pre- 
and post-treatment on the quality of life of the patients was assessed, at each visit, 
using the DLQI questionnaire. Furthermore, the FDLQI questionnaire was used to 
assess the impact of acne, at baseline and week 16, on the quality of life of family 
members/partner of patients. 
 
 
Patients in the PDT groups had side-effects evaluated before the next treatment and 
at each follow-up visit. As mentioned previously (section 4.1.1.3), a 10 cm VAS 
was used to evaluate treatment-related pain in these groups. Side-effects in the 
adapalene group were assessed at week 8, week 11, and week 16. 
 
 
4.1.2.5.1 Acne lesion counts 
 
The facial area used for lesion counting extended from the hair to the jaw line 
(excluding the nose, lips, moustache area and areas immediately around the eyes). 
The numbers of different acne lesions (comedones, papules, pustules, nodules and 
cysts) were counted separately from the right and left forehead, both cheeks and the 
chin above the jaw line. Lesion counting was done, by gentle palpation of the non- 
stretched facial skin, whilst patient relaxed on a couch with the backrest adjusted to 
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an angle of +45°. A bright light source (Brandon Optica 288 Magnifier lamp; 
Brandon Medical Company Ltd, Leeds, England) containing a 22W fluorescent bulb, 
placed not more than 30cm from the patient, was also used during this assessment 
(Figure 4.5). Only lesions that could be palpated, whether inflamed or noninflamed, 
were included in the final count. 
  
 
 
 
 
 
 
Figure 4.5: Couch and light source used during assessment. 
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Brandon Optica 288 Magnifier lamp 
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4.1.2.5.2 Photography 
 
The Canfield VISIA® Complexion Analysis system (Figure 4.6) has a booth, chin 
cup and headrest to facilitate proper placement of the patient’s face, allowing for 
consistency throughout the study. Moreover, the system also uses an overlay feature 
to help align images, for consistency, at follow-up visits. 
 
 
Prior to photography, all the patients washed their face using a gentle cleanser (E45® 
Emollient Wash Cream) followed by pat drying. With the patient’s eyes closed, three 
standard close-up photographs (right, left, and central) were taken using white and 
ultraviolet (365 nm) light. 
 
 
The manual masking feature of VISIA® was used to draw a boundary (“analysis 
mask”) on the photographs to delineate areas (forehead, right, and left cheeks) where 
follicular (porphyrin) fluorescence was counted. The mask that was created at the 
first session was used for analysis of pictures at all later sessions ensuring 
consistency throughout the study. VISIA® software was used to store all the images 
and to count the number of follicular fluorescence in the above-mentioned delineated 
areas. 
 
 
4.1.2.6 Outcome measures 
 
The primary outcome parameter was reduction in lesion counts (inflamed and 
noninflamed) evaluated at weeks 8, 11, and 16. Secondary outcome parameters were 
reduction in total lesion counts, porphyrin fluorescence, microbial densities 
(discussed below), VAS, Leeds, DLQI, and FDLQI scores. 
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Figure 4.6: The Canfield VISIA® Complexion Analysis system consisting of a booth, 
chin cup and headrest. 
Headrest 
Chin cup 
108  
4.2 The laboratory study 
 
4.2.1 Rationale 
 
In accordance with previous studies [257, 266], the surface scrub technique of 
Williamson and Kligman [31] was used to investigate the effect of various treatments 
used in this trial on the cutaneous microflora of acne patients. As detailed in chapter 
2, P. acnes may aggravate inflammation and comedogenesis in acne patients and a 
reduction in its density due to irradiation with IPL (with or without a topical 
photosensitiser) may lead to an improvement in acne. As mentioned previously 
(Section 3.4.3), the effect of our treatments on S. aureus and CoNS densities was 
also investigated as in vitro data has shown a reduction in the densities of these 
micro- organisms following ALA-PDT [281]. 
 
 
4.2.2 Bacterial sampling from skin surface 
 
4.2.2.1 Sample collection 
 
The surface cutaneous microflora was sampled from a defined area (6.1cm2) 
demarcated by a sterile stainless steel ring on the skin (Figure 4.7). All the samples 
were taken from the right cheek about 4 cm lateral to the alar rim. One milliliter of 
sterile 0.1% Triton X-100 in 0.075 M phosphate buffer (pH 7.9) was pipetted into the 
steel ring which was held with firm pressure against the skin to create a water-tight 
seal. The skin was gently rubbed for 1 min using a sterile Teflon rod, after which the 
wash fluid was removed to a sterile sample bottle (amber). The sampling procedure 
was repeated at the same site and the two 1 ml samples combined in the same sample 
bottle (neat sample). Samples were sent to the microbiology laboratory, UHW for 
immediate processing. 
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Figure 4.7: Instruments used for sampling cutaneous microflora using 
the surface scrub technique of Williamson and Kligman. 
Sterile sampling bottle (amber) 
     Teflon rod   
Stainless steel ring with internal 
diameter of 6.1 cm2 
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4.2.2.2 Sample processing 
 
Samples were diluted with sterile saline to give a 100 and 1000-fold dilution. Fifty 
microliters of the undiluted, 100 and 1000-fold dilutions were then spiral plated 
using Whitley Automated Spiral Plater (Don Whitley Scientific Ltd., Shipley, UK). 
Counts are expressed as colony-forming units (CFU) cm-2 of skin. 
 
 
Enumeration of propionibacteria was performed by plating the sample on to 
reinforced clostridial agar (CM0151; Oxoid Ltd., Basingstoke, UK) containing 6 µg 
mL-1 furazolidone to inhibit the growth of staphylococci. Cultures were incubated at 
37°C for 7 days in an anaerobic chamber (Concept Plus; Ruskinn Technology Ltd., 
Bridgend, UK) under an atmosphere of 80% N2, 10% H2, and 10% CO2. 
 
 
Mannitol salt agar (PP0660; E&O Laboratories Ltd., Bonnybridge, Scotland) was 
used for the isolation of staphylococci and was incubated in air at 37°C for 48 hours. 
Moreover, samples were also plated on to Columbia agar with 5% defibrinated horse 
blood (PP0120; E&O Laboratories Ltd., Bonnybridge, Scotland) and incubated in air 
at 37°C for 48 hours. This is a general purpose medium suitable for the isolation of 
most organisms including many fastidious anaerobes. 
 
 
After appropriate incubation differential counts were made according to colony type, 
Gram stain and cell morphology. Differentiation of S. aureus from CoNS was done 
using a latex agglutination test (Staphaurex®; Remel, Lenexa, Kansas). This test uses 
coated (human fibrinogen and specific IgG) latex particles to identify S. aureus by 
the simultaneous detection of clumping factor and protein A. Biochemical tests 
(indole,  catalase  production)  were  used  for  the  basic  identification  of  P.  acnes. 
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Propionibacteria are generally catalase-positive with indole being produced by P. 
acnes but not P. granulosum or P. avidum [25]. 16S rRNA gene sequencing, a 
powerful method for investigating the phylogenetic relationship between bacteria 
[301], was used to identify propionibacteria at the species level where the micro- 
organisms were catalase-positive but indole-negative. Indole production by the 
propionibacteria was detected by smearing the growth from an actively growing pure 
culture onto a paper strip containing 1-2 drops of spot indole reagent (R21245; Oxoid 
Ltd., Basingstoke, UK). A colour change to blue within 30 seconds indicated a 
positive reaction. Similarly the presence of catalase in propionibacteria was detected 
by reacting colonies with 1-2 drops of hydrogen peroxide (289132; Sigma-Aldrich 
Ltd., Dorset, UK). A positive reaction resulted in formation of bubbles due to the 
release of oxygen. 
 
 
For the 16S rRNA gene sequencing of propionibacteria, bacterial genomic DNA was 
prepared by suspending a few colonies in 20% w/v Chelex-100 suspension (Cat no: 
142-2822; Bio-Rad Laboratories Ltd., Hemel Hempstead, UK) and heating it to 95°C 
for 10 min. The suspension was then cooled briefly at room temperature before 
centrifugation (Centrifuge 5424; Eppendorf UK Ltd., Stevenage, UK) at 13,000 
revolutions per minute for 10 min.1ul of the resulting supernatant, containing 
genomic DNA, was used as a template for amplification of the 16S rRNA gene by 
using the universal primers pA (AGAGTTTGATCCTGGCTCAG) and pH 
(AAGGAGGTGATCCAGCCGCA) [302]. Samples were initially heated at 94°C for 
2 min, followed by 30 cycles at 95°C for 45s, 55°C for 1 min, 72°C for 30s, followed 
by a final extension at 72°C for 5 min. PCR products were visualized by 
electrophoresis on 1% (w/v) agarose gels (Cat no: 16500-500; UltraPureTM   Agarose; 
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Invitrogen Life Technologies Ltd., Paisley, UK) and then purified with a PureLink® 
quick gel extraction kit (K2100-25; Invitrogen Life Technologies Ltd., Paisley, UK). 
The resulting DNA was sent to the Central Biotechnology Services (Cardiff 
University, School of Medicine, Heath Park, Cardiff, UK) for sequencing. The 
returned sequences were loaded into BioNumerics v5.10 database (Applied Maths, 
Sint-Martens-Latem, Belgium) and were screened using the Basic Local Alignment 
Search Tool (BLAST; http://www.ncbi.nlm.nih.gov/BLAST) to determine the most 
probable propionibacterium species. 
 
 
 
4.3 Statistical analysis 
 
Based upon the results from the study of Yeung et al. [264] it was calculated (by a 
statistician) that 30 subjects per treatment group to assess the improvement of 
inflamed lesion counts by 76.7±28.9%, 24.9±31.1%, and 49.2±27.4% for IPL-MAL, 
IPL-Placebo, and adapalene groups, respectively will give power of > 99% for 
comparing IPL-MAL vs. IPL-Placebo and 95% for IPL-MAL vs. adapalene. 
Similarly, 30 persons per group to assess the improvement of noninflamed lesion 
counts by 44.0±32.5%, 21.8±27.7%, and −9.8±47.1% for IPL-MAL, IPL-Placebo, 
and adapalene groups, respectively will give power of 80% for comparing IPL-MAL 
vs. IPL-Placebo and 90% for IPL-MAL vs. adapalene. The number of p e r s o n s  
needed per treatment group was increased to 40 to account for possible dropouts. 
Statistical advice was also sought for all the final analyses. Statistical analyses were 
done using SPSS version 20 and p < 0.05 was considered statistically significant. 
 
 
Treatment groups at baseline were compared with the Fisher’s exact test for sex, skin 
type, and antibiotics and retinoids use in the past. Where the Fisher’s exact test was 
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significant (topical antibiotics use in the past), column proportions were compared 
using the z-test. Quantitative variables were tested whether they come from a normal 
distribution and have equal variances. The variables propionibacteria and CoNS 
density as well as porphyrin fluorescence at baseline were log-transformed to achieve 
a normal distribution. As there were zero values for CoNS, the log-transformation 
was performed after adding 1 to the original values. There were minor deviations 
from the normal distribution, however, as ANOVA (analysis of variance) i s  
relatively robust to violations of the normality assumption, especially when samples 
are of equal sizes, a one-way ANOVA was performed for all variables except for S. 
aureus, DLQI, FDLQI, and Leeds grading where the Kruskal-Wallis test was 
performed. For porphyrin fluorescence and CoNS density, the Welch’s test was 
performed as the assumption of homogeneity of variances was not met. 
 
 
For each treatment group, intragroup comparisons with baseline were done for all the 
follow-up visits. For variables with a normal distribution of the paired differences 
(inflamed lesions, noninflamed lesions, VAS, DLQI), the paired-samples t-test was 
performed. Where a normal distribution of the paired differences could not be 
assumed (total lesion counts, porphyrin fluorescence, FDLQI), the Wilcoxon signed- 
rank test was performed. Where neither a normal nor a symmetric distribution of the 
paired differences could be assumed (CoNS, propionibacteria, and S. aureus 
densities, Leeds grading), the exact sign test was performed. 
 
 
For all variables (where applicable), week 8, 11, and 16 values were substracted from 
the baseline data (BL) and compared between the treatment groups. A one-way 
ANOVA was performed for inflamed lesions (BL−week 8, 11, and 16), noninflamed 
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lesions (BL−week 8, 11, and 16), porphyrin fluorescence (BL−week 8, 11, and 16), 
 
VAS (BL−week 8, 11, and 16), and DLQI (BL−week 16). The Kruskal-Wallis and 
Mann-Whitney tests were performed for total lesion counts (BL−week 8, 11, and 16), 
propionibacteria density (BL−week 8, 11, and 16), FDLQI (BL−week 16), Leeds 
grading (BL−week 8, 11, and 16), and CoNS density (BL−week 8, 11, and 16). For 
the DLQI (BL−week 8 and 11), the Welch’s test was performed as the assumption of 
homogeneity of variances was not met. The least significant difference post-hoc tests 
were also performed. For pain scores, the mean of week 1, week 3, week 5, and week 
7 was calculated and compared with an independent- samples t-test. No correction 
for multiple testing was done. 
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Results 
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5. Results 
 
5.1 The clinical effects 
 
Of the 512 patients screened, 37 were randomised to the study (Figure 5.1). This was 
lower than our target of 120 patients as the identification of suitable patients was 
much slower than anticipated, and recruitment was therefore stopped after 19 
months. In brief, two main factors contributed to the poor recruitment including: (i) 
duration of the trial (16 weeks), number of visits (8 and 5 visits for patients in the 
light groups and adapalene group, respectively) and length of baseline and follow-up 
visits (approximately 3 hours). Our target population was mostly young individuals 
who were either studying or working full time and found it difficult to commit to the 
abovementioned requirements because of their busy schedule; and (ii) reluctance of 
young acne patients to minimise direct sunlight exposure for the duration of study. 
Throughout the study, a variety of techniques were used in order to boost 
recruitment, with varying degrees of success (Table 5.1). 
 
 
Of the 37 patients randomised, 13 patients were allocated to IPL-MAL, 11 to IPL- 
Placebo and 13 to adapalene. Two patients in the IPL-MAL group left the study 
before any treatment whilst 1 patient in the IPL-Placebo group was lost to follow-up 
after the third treatment. Three patients in the adapalene group did not show up for 
any of the follow-up visits whilst one patient in the IPL-MAL group was lost to 
follow-up after week 11. Thirty patients completed the study and were analysed for 
the primary outcome (Figure 5.1). 
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 360 did not meet the eligibility criteria 
 80 considered to be eligible but refused to 
participate 
 34 considered to be eligible but could not be 
subsequently contacted via email or 
telephone 
Withdrew before randomisation 
(n=1) 
Reason for withdrawal: 
 Personal reasons 
Analysed for primary outcome 
Screened (n= 512) 
Via 
 Online questionnaire (n= 356) 
 Telephone enquiries (n= 156) 
Enrolled in study (n=38) 
Randomised (n=37) 
Completed all 4 treatments (n=11) 
Withdrew before any treatment (n=2) 
Reason for withdrawal: 
 Personal reasons (n=1) 
 Inability to comply with the 
study protocol (n=1) 
Completed all 4 treatments (n=10) 
Withdrew after 3rd  treatment (n=1) 
Reason for withdrawal: 
 Lost to follow-up 
Follow-up: 
Completed week 8   (n=11) 
Completed week 11 (n=11) 
Completed week 16 (n=10) 
Discontinued study  (n=1) 
Reason for withdrawal: 
 Lost to follow-up 
Follow-up: 
Completed week 8   (n=10) 
Completed week 11 (n=10) 
Completed week 16 (n=10) 
Completed the study (n=10) 
IPL-MAL (n=13) IPL-Placebo (n=11) 
Completed the study (n=10) Completed the study (n=10) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapalene (n=13) 
  
Received treatment (n=13) 
  
Follow-up: 
Completed week 8 (n=10) 
Completed week 11 (n=10) 
Completed week 16 (n=10) 
Discontinued study (n=3) 
Reason for withdrawal: 
 Contemplating 
pregnancy (n=1) 
 Personal reasons (n=1) 
 Lost to follow-up (n=1) 
 
 
                                                                                                                                          Completed the study (n=10) 
 
 
 
 
 
 
Figure 5.1: Flow chart. IPL, intense pulsed light; MAL, Methyl aminolaevulinate. 
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Table 5.1: Strategies employed to boost recruitment 
 
 
Strategies with good impact 
 
Amend protocol/procedure 
 
Some success 
Advertise in local papers Some success, but limited by lack of 
funds 
Regular emails regarding the trial to all the Cardiff 
University students and staff 
Some success 
Weekly announcements on Cardiff University’s 
online notice board 
Some success 
 
Strategies with little impact/unsure of impact 
 
Regular reminders to local general practitioners 
 
Unsure 
Regular reminders to clinicians at the University 
Hospital of Wales and nearby hospitals 
Unsure 
Distribution of pamphlets amongst the Cardiff 
University students during Freshers’ week 
Unsure 
Setting up a stall, periodically, in the University 
Hospital of Wales concourse 
Unsure 
Display of posters about the trial within Cardiff 
University and Cardiff Metropolitan University 
campuses 
Unsure 
Display of posters about the trial in the local 
General practitioners’ surgeries 
Unsure 
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5.1.1 Demographic and baseline characteristics 
 
Except for prior antibiotic use, the three treatment groups were similar with respect 
to the demographic and baseline characteristics (Table 5.2). The IPL-Placebo group 
had used topical antibiotics significantly more often than the adapalene group. This 
was a coincidence as the patients were randomly assigned to the three groups. 
 
 
Table 5.2:  Baseline demographic and disease characteristics 
 
 
Variable 
 
Adapalene 
(n = 10) 
 
IPL-MAL 
(n = 10) 
 
IPL-Placebo 
(n = 10)† 
 
P- 
value 
 
Age (years), mean + 
SD (range) 
 
24.0 + 5.9 
(19.0 - 39.0) 
 
23.0 + 3.2 
(20.0 - 29.0) 
 
24.0 + 5.0 
(19.0 - 33.0) 
 
0.868 
Sex, F/M (n) 6/4 7/3 5/5 0.893 
Height (cm), mean + 
SD (range) 
170.9 + 8.5 
(156.0 - 183.0) 
169.7 + 6.0 
(161.5 - 182.0) 
173.5 + 7.8 
(161.0 - 187.0) 
0.528 
Weight (kg), mean + 
SD (range) 
68.1 + 12.9 
(51.0 - 92.0) 
65.8 + 9.7 
(52.0 - 78.0) 
72.0 + 14.8 
(55.0 - 96.0) 
0.548 
Skin type, n (%) 
I 
II 
III 
IV 
 
0 (0) 
5 (50) 
4 (40) 
1 (10) 
 
2 (20) 
3 (30) 
3 (30) 
2 (20) 
 
0 (0) 
4 (40) 
6 (60) 
0 (0) 
 
 
 
0.387 
Current or ex-smokers, 
n (%) 
2 (20) 1 (10) 5 (50) 0.192 
Duration of acne 
(years), mean + SD 
(range) 
10.4 + 6.1 (4.0 - 26.0) 9.2 + 2.9 (5.0 - 13.0) 7.9 + 4.2 (3.0 - 15.0) 0.486 
Prior topical therapy, n 
(%) 
Antibiotics 
Retinoids 
 
 
1 (10) 
4 (40) 
 
 
5 (50) 
0 (0) 
 
 
7 (70) 
2 (20) 
 
 
0.035 
0.122 
Prior systemic therapy, 
n (%) 
Antibiotics 
Retinoids 
 
 
5 (50) 
1 (10) 
 
 
6 (60) 
0 (0) 
 
 
8 (80) 
1 (10) 
 
 
0.510 
1.000 
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Table 5.2 Continued 
 
 
Variable 
 
Adapalene 
(n = 10) 
 
IPL-MAL 
(n = 10) 
 
IPL-Placebo 
(n = 10)† 
 
P- 
value 
 
Acne lesions, mean + 
SD (range) 
 
Inflamed lesions 
(papules, pustules, 
nodules, cysts) 
 
Noninflamed lesions 
(open and closed 
comedones) 
 
Total lesion count 
(inflamed and non 
inflamed lesions) 
 
 
 
 
38.5 + 20.6 
(9.0 - 66.0) 
 
 
189.2 + 114.6 
(48.0 - 419.0) 
 
 
227.7 + 117.7 
(72.0 - 432.0) 
 
 
 
 
26.6 + 12.6 
(8.0 - 45.0) 
 
 
100.1 + 66.2 
(25.0 - 242.0) 
 
 
126.7 + 72.0 
(33.0 - 286.0) 
 
 
 
 
34.3 + 18.3 
(15.0 - 63.0) 
 
 
140.5 + 82.0 
(51.0 - 303.0) 
 
 
174.8 + 90.1 
(66.0 - 332.0) 
 
 
 
 
0.319 
 
 
 
0.104 
 
 
 
0.077 
 
VAS score (cm), mean 
+ SD (range) 
 
3.8 + 2.0 (1.0 - 7.0) 
 
4.0 + 1.5 (2.0 - 6.0) 
 
5.2 + 1.9 (3.0 - 8.0) 
 
0.195 
Leeds grade, median 
(range) 
1.5 (1.0 - 2.5) 1.0 (1.0 - 2.5) 1.3 (1.0 - 3.5) 0.430 
DLQI score, mean + 
SD (range) 
5.1 + 3.2 (2.0 - 11.0) 7.6 + 5.7 (1.0 - 18.0) 7.1 + 6.2 (1.0 - 17.0) 0.727 
FDLQI score, mean + 
SD (range) 
1.7 + 1.7 (0.0 - 5.0) 4.2 + 6.2 (0.0 - 21.0) 1.7 + 1.9 (0.0 - 4.0) 0.551 
Porphyrin fluorescence, 
median (range) 
539.5 
(221.0 - 2550.0) 
717.5 
(27.0 - 3688.0) 
548.0 
(263.0 - 2383.0) 
0.854 
 
†For the FDLQI score in the IPL-Placebo group n=9. IPL, intense pulsed light; MAL, methyl 
aminolaevulinate; VAS, visual analogue scale; DLQI, Dermatology Life Quality Index; FDLQI, 
Family Dermatology Life Quality Index. 
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5.1.2 Effect on noninflamed lesions 
 
Mean noninflamed lesion counts were reduced significantly in the adapalene group 
from 189.2 at baseline to 118.0 at week 16 (p = 0.007). No significant improvement 
was seen in the other two groups at any time (Table 5.3, Figure 5.2). 
 
 
For the change in noninflamed lesion counts from baseline, a statistically significant 
reduction of 37.6% was found in the adapalene group vs. 3.4% decrease in the IPL- 
MAL (p = 0.009) and 9.7% increase in the IPL-Placebo group (p = 0.001) at week 16 
(Table 5.4, Figure 5.3). There was no significant difference in the change in 
noninflamed lesion counts from baseline between the IPL-MAL and IPL-Placebo 
groups at week 16 (p = 0.197). 
 
 
 
 
 
 
 
 
 
 
Baseline 
 
Noninflamed lesion counts 
 
Adapalene (n = 10) 
 
IPL-MAL (n = 10) 
 
IPL-Placebo (n = 10) 
 
Mean + SD 
(range) 
 
P-value 
 
Mean + SD 
(range) 
 
P-value 
 
Mean + SD 
(range) 
 
P-value 
 
189.2 + 114.6 
(48.0 - 419.0) 
  
100.1 + 66.2 
(25.0 - 
242.0) 
  
140.5 + 
82.0 (51.0 - 
303.0) 
 
Week 8 156.1 + 106.4 
(38.0 - 382.0) 
0.076 87.7 + 46.9 
(28.0 - 
196.0) 
0.138 152.9 + 
77.5 (76.0 - 
274.0) 
0.531 
Week 11 154.2 + 110.1 
(27.0 - 402.0) 
0.063 105.1 + 60.4 
(25.0 - 
253.0) 
0.645 149.1 + 
87.4 (63.0 - 
298.0) 
0.639 
Week 16 118.0 + 74.4 
(38.0 - 267.0) 
0.007 96.7 + 48.8 
(29.0 - 
204.0) 
0.736 154.1 + 
88.6 (60.0 - 
319.0) 
0.478 
 
Table 5.3: Mean noninflamed lesion counts in the adapalene, IPL-MAL and IPL-Placebo 
groups at baseline, week 8, week 11, and week 16. IPL, intense pulsed light; MAL, methyl 
aminolaevulinate. 
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Figure 5.2: Mean noninflamed lesion counts at baseline, week 8, week 11, and week 16. Bar 
chart shows mean and standard deviation. IPL, intense pulsed light; MAL, methyl 
aminolaevulinate. 
 
 
 
 
  
Δ Noninflamed lesion counts 
 
Adapalene 
(n = 10) 
 
IPL-MAL 
(n = 10) 
 
IPL-Placebo 
(n = 10) 
 
P-value 
 
Δ Week 8 
Mean (range) 
 
33.1 
(−21.0 - 140.0) 
 
12.4 
(−28.0 - 46.0) 
 
−12.4 
(−120.0 - 98.0) 
 
0.125 
Δ Week 11 
Mean (range) 
35.0 
(−36.0 - 146.0) 
−5.0 
(−74.0 - 31.0) 
−8.6 
(−118.0 - 89.0) 
0.099 
Δ Week 16 
Mean (range) 
71.2 
(−23.0 - 172.0) 
3.4 
(−54.0 - 38.0) 
−13.6 
(−97.0 - 115.0) 
0.004 
 
Table 5.4: Mean difference from baseline in noninflamed lesion counts in the adapalene, 
IPL-MAL and IPL-Placebo groups at week 8, week 11, and week 16. IPL, intense pulsed 
light; MAL, methyl aminolaevulinate. 
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Figure 5.3: Difference from baseline in noninflamed lesion counts at week 16. Boxplot 
shows minimum, maximum, 25th and 75th percentiles, and median. + indicates the mean. IPL, 
intense pulsed light; MAL, methyl aminolaevulinate. 
 
 
5.1.3 Effect on inflamed lesions 
 
Mean baseline inflamed lesion counts in the adapalene, IPL-MAL and IPL-Placebo 
groups were 38.5, 26.6 and 34.3, respectively (Table 5.5, Figure 5.4). In the IPL- 
MAL and IPL-Placebo groups, maximum improvement was seen at week 11 with 
mean lesion counts of 21.1 and 29.7 giving a mean percentage decrease f rom  
baseline of 20.7% and 13.4%, respectively. On the contrary, maximum improvement 
in the adapalene group was seen at week 16 with a mean value of 28.3. These results, 
however, did not reach statistical significance. Likewise, no significant difference in 
the change in inflamed lesion counts from baseline was found between the three 
treatment groups at any time (Table 5.6). 
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Baseline 
 
Inflamed lesion counts 
 
Adapalene (n = 10) 
 
IPL-MAL (n = 10) 
 
IPL-Placebo (n = 10) 
 
Mean + SD 
(range) 
 
P-value 
 
Mean + SD 
(range) 
 
P-value 
 
Mean + SD 
(range) 
 
P-value 
 
38.5 + 20.6 
(9.0 - 66.0) 
  
26.6 + 12.6 
(8.0 - 45.0) 
  
34.3 + 18.3 
(15.0 - 63.0) 
 
Week 8 37.7 + 33.1 
(1.0 - 123.0) 
0.924 24.4 + 10.7 
(10.0 - 44.0) 
0.549 35.9 + 25.1 
(20.0 - 
104.0) 
0.793 
Week 11 33.4 + 31.0 
(5.0 - 110.0) 
0.506 21.1 + 14.8 
(8.0 - 54.0) 
0.211 29.7 + 26.3 
(10.0 - 
102.0) 
0.511 
Week 16 28.3 + 20.2 
(6.0 - 77.0) 
0.137 24.6 + 18.1 
(8.0 - 62.0) 
0.706 35.3 + 21.5 
(17.0 - 89.0) 
0.823 
 
Table 5.5: Mean inflamed lesion counts in the adapalene, IPL-MAL and IPL-Placebo groups 
at baseline, week 8, week 11, and week 16. IPL, intense pulsed light; MAL, methyl 
aminolaevulinate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: Mean inflamed lesion counts at baseline, week 8, week 11, and week 16. Bar 
chart shows mean and standard deviation. IPL, intense pulsed light; MAL, methyl 
aminolaevulinate. 
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Δ Inflamed lesion counts 
 
Adapalene 
(n = 10) 
 
IPL-MAL 
(n = 10) 
 
IPL-Placebo 
(n = 10) 
 
P-value 
 
Δ Week 8 
Mean (range) 
 
0.8 
(−60.0 - 25.0) 
 
2.2 
(−10.0 - 25.0) 
 
−1.6 
(−41.0 - 29.0) 
 
0.908 
Δ Week 11 
Mean (range) 
5.1 
(−47.0 - 45.0) 
5.5 
(−9.0 - 33.0) 
4.6 
(−39.0 - 40.0) 
0.995 
Δ Week 16 
Mean (range) 
10.2 
(−15.0 - 48.0) 
2.0 
(−26.0 - 35.0) 
−1.0 
(−26.0 - 23.0) 
0.318 
 
Table 5.6: Mean difference from baseline in inflamed lesion counts in the adapalene, IPL- 
MAL and IPL-Placebo groups at week 8, week 11, and week 16. IPL, intense pulsed light; 
MAL, methyl aminolaevulinate. 
 
 
5.1.4 Effect on total lesion counts 
 
In the adapalene group, mean total lesion counts were reduced significantly from 
227.7 at baseline to 193.8 (p = 0.010), 187.6 (p = 0.014) and 146.3 (p = 0.006) at 
weeks 8, 11, and 16, respectively (Table 5.7, Figure 5.5). No significant 
improvement was seen in the other two groups. 
 
 
For the change in total lesion counts from baseline, a statistically  significant 
reduction of 35.7% was found in the adapalene group vs. 4.3% decrease in the IPL- 
MAL (p = 0.011) and 8.4% increase in the IPL-Placebo group (p = 0.005) at week 16 
(Table 5.8, Figure 5.6). There was no significant difference in the change in total 
lesion counts from baseline between the IPL-MAL and IPL-Placebo groups at week 
16 (p = 0.210). 
126  
I 
400 
**p = 0.006 
*p = 0.014 
*p = 0.010 
300 
200 
100 
Adapalene 
PL-MAL 
IPL-Placebo 
0 
Baseline Week 8 Week 11 Week 16 
Visits 
 
 
 
 
 
 
 
 
 
Baseline 
 
Total lesion counts 
 
Adapalene (n = 10) 
 
IPL-MAL (n = 10) 
 
IPL-Placebo (n = 10) 
 
Mean + SD 
(range) 
 
P-value 
 
Mean + SD 
(range) 
 
P-value 
 
Mean + SD 
(range) 
 
P-value 
 
227.7 + 117.7 
(72.0 - 432.0) 
  
126.7 + 72.0 
(33.0 - 
286.0) 
  
174.8 + 90.1 
(66.0 - 332.0) 
 
Week 8 193.8 + 114.1 
(64.0 - 414.0) 
0.010 112.1 + 47.6 
(38.0 - 
215.0) 
0.250 188.8 + 91.4 
(97.0 - 378.0) 
0.570 
Week 11 187.6 + 118.7 
(52.0 - 422.0) 
0.014 126.2 + 60.3 
(33.0 - 
264.0) 
0.629 178.8 + 
100.3 (73.0 - 
333.0) 
0.770 
Week 16 146.3 + 82.5 
(54.0 - 295.0) 
0.006 121.3 + 47.4 
(37.0 - 
213.0) 
0.695 189.4 + 96.7 
(81.0 - 347.0) 
0.264 
 
Table 5.7: Mean total lesion counts in the adapalene, IPL-MAL and IPL-Placebo groups at 
baseline, week 8, week 11, and week 16. IPL, intense pulsed light; MAL, methyl 
aminolaevulinate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Mean total lesion counts at baseline, week 8, week 11, and week 16. Bar chart 
shows mean and standard deviation. IPL, intense pulsed light; MAL, methyl 
aminolaevulinate. 
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Δ Total lesion counts 
 
Adapalene 
(n = 10) 
 
IPL-MAL 
(n = 10) 
 
IPL-Placebo 
(n = 10) 
 
P-value 
 
Δ Week 8 
Mean (range) 
 
33.9 
(−5.0 - 156.0) 
 
14.6 
(−29.0 - 71.0) 
 
−14.0 
(−161.0 - 127.0) 
 
0.092 
Δ Week 11 
Mean (range) 
40.1 
(−32.0 - 167.0) 
0.5 
(−82.0 - 36.0) 
−4.0 
(−122.0 - 129.0) 
0.178 
Δ Week 16 
Mean (range) 
81.4 
(−18.0 - 185.0) 
5.4 
(−80.0 - 73.0) 
−14.6 
(−92.0 - 138.0) 
0.006 
 
Table 5.8: Mean difference from baseline in total lesion counts in the adapalene, IPL-MAL 
and IPL-Placebo groups at week 8, week 11 and week 16. IPL, intense pulsed light; MAL, 
methyl aminolaevulinate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: Difference from baseline in total lesion counts at week 16. Boxplot shows 
minimum, maximum, 25th and 75th percentiles, and median. + indicates the mean. IPL, 
intense pulsed light, MAL, methyl aminolaevulinate. 
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5.1.5 Effect on visual analogue scale 
 
Mean VAS scores did not differ significantly from baseline in the three treatment 
groups at any time (Table 5.9). Moreover, there was no significant difference in the 
change in VAS scores from baseline between the three groups (Table 5.10). 
 
 
  
VAS score (cm) 
 
Adapalene (n = 10) 
 
IPL-MAL (n = 10) 
 
IPL-Placebo (n = 10) 
 
Mean + SD 
(range) 
 
P-value 
 
Mean + SD 
(range) 
 
P-value 
 
Mean + SD 
(range) 
 
P-value 
 
Baseline 
 
3.8 + 2.0 
(1.0 - 7.0) 
  
4.0 + 1.5 
(2.0 - 6.0) 
  
5.2 + 1.9 
(3.0 - 8.0) 
 
Week 8 3.9 + 2.4 
(1.0 - 8.0) 
0.931 3.7 + 2.0 
(0.5 - 6.0) 
0.242 4.6 + 2.3 
(2.0 - 8.0) 
0.193 
Week 11 4.7 + 2.7 
(1.0 - 7.5) 
0.273 3.9 + 2.0 
(0.0 - 7.0) 
0.888 4.1 + 2.7 
(0.5 - 8.0) 
0.074 
Week 16 3.1 + 1.9 
(0.0 - 6.0) 
0.143 3.8 + 2.7 
(0.0 - 8.0) 
0.794 4.4 + 2.8 
(0.0 - 8.0) 
0.223 
 
Table 5.9: Mean VAS (visual analogue scale) scores in the adapalene, IPL-MAL and IPL- 
Placebo groups at baseline, week 8, week 11, and week 16. IPL, intense pulsed light; MAL, 
methyl aminolaevulinate. 
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Δ VAS score (cm) 
 
Adapalene 
(n = 10) 
 
IPL-MAL 
(n = 10) 
 
IPL-Placebo 
(n = 10) 
 
P-value 
 
Δ Week 8 
Mean (range) 
 
−0.1 
(−2.0 - 3.0) 
 
0.3 
(−1.0 - 1.5) 
 
0.6 
(−1.0 - 2.0) 
 
0.577 
Δ Week 11 
Mean (range) 
−0.9 
(−5.0 - 3.0) 
0.1 
(−4.0 - 2.0) 
1.1 
(−1.0 - 3.5) 
0.123 
Δ Week 16 
Mean (range) 
0.7 
(−2.0 - 3.0) 
0.2 
(−5.0 - 3.0) 
0.8 
(−1.0 - 4.0) 
0.750 
 
Table 5.10: Mean difference from baseline in VAS (visual analogue scale) scores in the 
adapalene, IPL-MAL and IPL-Placebo groups at week 8, week 11, and week 16. IPL, intense 
pulsed light; MAL, methyl aminolaevulinate. 
 
 
5.1.6 Effect on Leeds score 
 
As an example, photographs of three patients, one from each treatment arm, that 
were used for Leeds grading are given in Figures 5.7-5.9. Leeds scores did not differ 
significantly from baseline in the three treatment groups at any time (Table 5.11). 
Moreover, there was no significant difference in the change in Leeds grades from 
baseline between the three groups (Table 5.12). 
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Leeds grade 
 
Adapalene (n = 10) 
 
IPL-MAL (n = 10) 
 
IPL-Placebo (n = 10) 
 
Median 
(range) 
 
P-value 
 
Median 
(range) 
 
P-value 
 
Median 
(range) 
 
P-value 
 
Baseline 
 
1.5 
(1.0 - 2.5) 
  
1.0 
(1.0 - 2.5) 
  
1.3 
(1.0 - 3.5) 
 
Week 8 1.0 
(1.0 - 4.5) 
0.453 1.0 
(1.0 - 3.5) 
0.625 1.8 
(1.0 - 4.0) 
0.125 
Week 11 1.3 
(1.0 - 3.5) 
0.625 1.3 
(1.0 - 3.5) 
0.375 1.0 
(1.0 - 4.0) 
1.000 
Week 16 1.0 
(1.0 - 3.0) 
0.219 1.0 
(1.0 - 5.5) 
0.625 1.0 
(1.0 - 5.0) 
1.000 
 
Table 5.11: Median Leeds scores in the adapalene, IPL-MAL and IPL-Placebo groups at 
baseline, week 8, week 11, and week 16. IPL, intense pulsed light; MAL, methyl 
aminolaevulinate. 
 
 
 
 
  
Δ Leeds grade 
 
Adapalene 
(n = 10) 
 
IPL-MAL 
(n = 10) 
 
IPL-Placebo 
(n = 10) 
 
P-value 
 
Δ Week 8 
Median (range) 
 
0.25 
(−2.0 - 0.5) 
 
0.0 
(−1.5 - 0.5) 
 
−0.5 
(−1.5 - 1.0) 
 
0.167 
Δ Week 11 
Median (range) 
0.0 
(−1.0 - 0.5) 
0.0 
(−1.5 - 0.5) 
0.0 
(−1.0 - 0.5) 
0.254 
Δ Week 16 
Median (range) 
0.25 
(−0.5 - 1.5) 
0.0 
(−3.5 - 0.5) 
0.0 
(−1.5 - 1.0) 
0.144 
 
Table 5.12: Median difference from baseline in the Leeds grades in the adapalene, IPL- 
MAL and IPL-Placebo groups at week 8, week 11, and week 16. IPL, intense pulsed light; 
MAL, methyl aminolaevulinate. 
131  
 
 
 
 
Figure 5.7: Clinical photographs of a patient treated with adapalene (front and right/left views): (a-c) before treatment, (d-f) at week 8, (g-i) week 11 
and (j-l) week 16 visit. 
 
 
 
 
(b) (e) (h) (k) 
(a) (d) (g) (j) 
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Figure 5.7 Continued 
 
 
(c) (f) (i) (l) 
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Figure 5.8: Clinical photographs of a patient treated with IPL-MAL (front and right/left views): (a-c) before treatment, (d-f) at week 8, (g-i) week 11 
and (j-l) week 16 visit. IPL, intense pulsed light; MAL, methyl aminolaevulinate. 
 
 
 
 
(b) (e) (h) (k) 
(a) (d) (g) (j) 
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Figure 5.8 Continued 
 
 
(c) (f) (i) (l) 
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Figure 5.9: Clinical photographs of a patient treated with IPL-Placebo (front and right/left views): (a-c) before treatment, (d-f) at week 8, (g-i) week 
11 and (j-l) week 16 visit. IPL, intense pulsed light. 
 
 
 
 
(b) (e) (h) (k) 
(a) (d) (g) (j) 
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Figure 5.9 Continued 
 
 
(c) (f) (i) (l) 
137  
5.1.7 Effect on the Dermatology Life Quality Index 
 
In the adapalene group, the mean DLQI score fell significantly from 5.1 at baseline 
to 2.4 at week 16 (p = 0.031) (Table 5.13, Figure 5.10). Although there was a 
reduction in the DLQI scores in the IPL-MAL and IPL-Placebo groups at all the 
follow-up visits, this did not reach statistical significance. There was no significant 
difference in the change in DLQI scores from baseline between the three treatment 
groups at any time (Table 5.14). 
 
 
  
DLQI score 
 
Adapalene (n = 10) 
 
IPL-MAL (n = 10) 
 
IPL-Placebo (n = 10) 
 
Mean + SD 
(range) 
 
P-value 
 
Mean + SD 
(range) 
 
P-value 
 
Mean + SD 
(range) 
 
P-value 
 
Baseline 
 
5.1 + 3.2 
(2.0 - 11.0) 
  
7.6 + 5.7 
(1.0 - 18.0) 
  
7.1 + 6.2 
(1.0 - 17.0) 
 
Week 8 3.9 + 4.2 
(0.0 - 12.0) 
0.181 6.4 + 4.7 
(0.0 - 16.0) 
0.460 5.9 + 5.9 
(0.0 - 17.0) 
0.089 
Week 11 4.7 + 4.7 
(1.0 - 12.0) 
0.637 5.4 + 5.5 
(0.0 - 18.0) 
0.237 6.3 + 6.7 
(0.0 - 20.0) 
0.366 
Week 16 2.4 + 3.1 
(0.0 - 11.0) 
0.031 5.7 + 5.2 
(1.0 - 16.0) 
0.364 6.7 + 7.0 
(0.0 - 20.0) 
0.613 
 
Table 5.13: Mean DLQI (Dermatology Life Quality Index) scores in the adapalene, IPL- 
MAL and IPL-Placebo groups at baseline, week 8, week 11, and week 16.  IPL, intense 
pulsed light; MAL, methyl aminolaevulinate. 
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Figure 5.10: Mean DLQI (Dermatology Life Quality Index) scores at baseline, week 8, 
week 11, and week 16. IPL, intense pulsed light; MAL, methyl aminolaevulinate. 
 
 
 
  
Δ DLQI score 
 
Adapalene 
(n = 10) 
 
IPL-MAL 
(n=10) 
 
IPL-Placebo 
(n = 10) 
 
P-value 
 
Δ Week 8 
Mean (range) 
 
1.2 
(−3.0 - 7.0) 
 
1.2 
(−5.0 - 10.0) 
 
1.2 
(−1.0 - 6.0) 
 
1.000 
Δ Week 11 
Mean (range) 
0.4 
(−4.0 - 4.0) 
2.2 
(−6.0 - 12.0) 
0.8 
(−3.0 - 6.0) 
0.661 
Δ Week 16 
Mean (range) 
2.7 
(−2.0 - 9.0) 
1.9 
(−8.0 - 15.0) 
0.4 
(−4.0 - 4.0) 
0.493 
 
Table 5.14: Mean difference from baseline in the DLQI (Dermatology Life Quality Index) 
scores in the adapalene, IPL-MAL and IPL-Placebo groups at week 8, week 11, and week 
16. IPL, intense pulsed light; MAL, methyl aminolaevulinate. 
*p = 0.031 
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5.1.8 Effect on the Family Dermatology Life Quality Index 
 
Mean FDLQI scores did not differ significantly from baseline in the three treatment 
groups at week 16 (Table 5.15). Moreover, there was no significant difference in the 
change in FDLQI scores from baseline between the three groups (Table 5.16). 
 
 
  
FDLQI score 
 
Adapalene (n = 10) 
 
IPL-MAL (n = 10) 
 
IPL-Placebo (n = 9) 
 
Mean + SD 
(range) 
 
P-value 
 
Mean + SD 
(range) 
 
P-value 
 
Mean + SD 
(range) 
 
P-value 
 
Baseline 
 
1.7 + 1.7 
(0.0 - 5.0) 
  
4.2 + 6.2 
(0.0 - 21.0) 
  
1.7 + 1.9 
(0.0 - 4.0) 
 
Week 16 2.0 + 1.8 
(0.0 - 5.0) 
0.750 4.2 + 4.8 
(0.0 - 16.0) 
1.000 2.1 + 4.0 
(0.0 - 12.0) 
1.000 
 
Table 5.15: Mean FDLQI (Family Dermatology Life Quality Index) scores in the adapalene, 
IPL-MAL, and IPL-Placebo groups at baseline and week 16. A last value carried forward 
approach was used for the missing values in the three treatment groups at week 16. IPL, 
intense pulsed light; MAL, methyl aminolaevulinate. 
 
 
 
 
  
Δ FDLQI score 
 
Adapalene 
(n = 10) 
 
IPL-MAL 
(n = 10) 
 
IPL-Placebo 
(n = 9) 
 
P-value 
 
Δ Week 16 
Mean (range) 
 
−0.3 
(−3.0 - 1.0) 
 
0.0 
(−5.0 - 5.0) 
 
−0.4 
(−8.0 - 4.0) 
 
0.898 
 
Table 5.16: Mean difference from baseline in the FDLQI (Family Dermatology Life Quality 
Index) scores in the adapalene, IPL-MAL, and IPL-Placebo groups at week 16. IPL, intense 
pulsed light; MAL, methyl aminolaevulinate. 
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5.1.9 Effect on porphyrin fluorescence 
 
Median porphyrin fluorescence did not differ significantly from baseline in the three 
treatment groups at any time (Table 5.17). There was also no significant difference 
in the change in porphyrin fluorescence from baseline between the groups (Table 
5.18). As an example, fluorescent photographs of a patient treated with adapalene are 
given in Figure 5.11. 
 
 
 
 
 
 
 
 
 
 
Baseline 
 
Porphyrin fluorescence 
 
Adapalene (n = 10) 
 
IPL-MAL (n = 10) 
 
IPL-Placebo (n = 10) 
 
Median 
(range) 
 
P-value 
 
Median 
(range) 
 
P-value 
 
Median 
(range) 
 
P-value 
 
539.5 
(221.0 - 
2550.0) 
  
717.5 
(27.0 - 
3688.0) 
  
548.0 
(263.0 - 
2383.0) 
 
Week 8 443.5 
(194.0 - 
1286.0) 
0.922 490.0 
(62.0 - 
4551.0) 
0.846 401.0 
(114.0 - 
1946.0) 
0.922 
Week 11 574.0 
(179.0 - 
1666.0) 
0.922 564.5 
(94.0 - 
4259.0) 
1.000 777.0 
(241.0 - 
1854.0) 
0.695 
Week 16 574.0 
(215.0 - 
2075.0) 
0.496 557.5 
(56.0 - 
4600.0) 
0.770 448.0 
(159.0 - 
2289.0) 
0.695 
 
Table 5.17: Median porphyrin fluorescence in the adapalene, IPL-MAL and IPL-Placebo 
groups at baseline, week 8, week 11, and week 16. IPL, intense pulsed light; MAL, methyl 
aminolaevulinate. 
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Δ Porphyrin fluorescence 
 
Adapalene 
(n = 10) 
 
IPL-MAL 
(n = 10) 
 
IPL-Placebo 
(n = 10) 
 
P-value 
 
Δ Week 8 
Median (range) 
 
−77.5 
(−267.0 - 
2314.0) 
 
−12.5 
(−1143.0 - 
1999.0) 
 
−27.0 
(−676.0 - 
1607.0) 
 
0.848 
Δ Week 11 
Median (range) 
−51.5 
(−654.0 - 
1978.0) 
−110.5 
(−851.0 - 
1554.0) 
80.5 
(−521.0 - 
529.0) 
0.907 
Δ Week 16 
Median (range) 
11.5 
(−236.0 - 
694.0) 
−23.5 
(−1192.0 - 
1567.0) 
−8.0 
(−713.0 - 
1946.0) 
0.996 
 
Table 5.18: Median difference from baseline in porphyrin fluorescence in the adapalene, 
IPL-MAL and IPL-Placebo groups at week 8, week 11, and week 16. IPL, intense pulsed 
light; MAL, methyl aminolaevulinate. 
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Figure 5.11: Fluorescent photographs of a patient treated with adapalene (1) Enlarged view to show “analysis mask” and follicular fluorescence (2) 
front and right/left views: (a-c) before treatment, (d-f) at week 8, (g-i) week 11 and (j-l) week 16 visit. 
 
 
 
Boundary (“analysis 
mask”) which was used to 
delineate area for 
counting the number of 
follicular fluorescence at 
baseline and all follow-up 
visits 
Follicular (porphyrin) 
fluorescence 
(1) 
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(2b) (2e) (2h) (2k) 
Figure 5.11 Continued 
 
(2a) (2d) (2g) (2j) 
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Figure 5.11 Continued 
 
 
(2c) (2f) (2i) (2l) 
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5.1.10 Adverse events 
 
In the adapalene group, majority of the side-effects were reported at week 8 which 
improved, with the continued use of adapalene, at week 11 (Table 5.19). At week 8, 
skin dryness was the commonest reported side-effect (9/10) followed by exfoliation 
(4/10), erythema (3/10), worsening of acne (3/10, lasting 1-6 weeks) and skin 
tenderness (2/10), respectively. 
 
 
All the patients described a burning pricking pain during illumination in the IPL- 
Placebo and IPL-MAL groups. Mean VAS scores for pain were 2.74 (range 0.25- 
6.50) and 2.60 (range 0.25-5.50) in the IPL-MAL and IPL-Placebo groups, 
respectively. There was no significant difference in the mean pain scores between the 
two groups (p = 0.868). In the IPL-Placebo group, majority of the side-effects were 
reported after the second treatment (week 5) with oedema (2/10, lasting 1-2 days) 
being the commonest adverse event (Table 5.20). Cold sore and patchy alopecia in 
the beard area were reported by a patient each at weeks 5 and 11, respectively. 
Similarly, worsening of acne (starting few days after treatment and lasting 15-25 
days) was reported by a patient each at weeks 5 and 7. In the IPL-MAL group, equal 
number of side-effects were reported after the second and third treatments (weeks 5 
and 7) with two patients reporting oedema (lasting 2-3 days) and exfoliation (lasting 
2 days) at each visit (Table 5.21). Moreover, worsening of acne was reported by two 
patients (lasting 4-17 days) at week 5 and one patient (lasting 17 days) at week 7. 
One patient also reported blistering at week 7, which resolved without any sequelae 
after 5 days. 
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No scarring or pigmentary complications were seen in any patient treated with light. 
Most of the side-effects in the three treatment groups were mild to moderate and 
resolved completely by week 16. 
 
 
 
Adapalene (n = 10) 
 
Adverse event 
 
Week 8 
n (severity) 
 
Week 11 
n (severity) 
 
Week 16 
n (severity) 
 
Erythema 
 
3 (mild) 
 
1 (mild) 
 
0 
Dryness 9 (7 mild, 2 moderate) 8 (7 mild, 1 moderate) 0 
Pruritus 1 (mild) 0 0 
Exfoliation 4 (2 mild, 2 moderate) 1 (mild) 0 
Stinging 1 (moderate) 0 0 
Skin tenderness 2 (1 mild, 1 moderate) 1 (mild) 0 
Worsening of acne 3 (2 moderate) 1 (moderate) 0 
 
Table 5.19: Adapalene side-effects. 
 
 
 
 
IPL-Placebo (n = 10) 
 
Adverse 
event 
 
Week 3 
n (severity) 
 
Week 5 
n (severity) 
 
Week 7 
n (severity) 
 
Week 8 
n (severity) 
 
Week 11 
n (severity) 
 
Week 16 
n (severity) 
 
Dryness 
 
0 
 
1 
(moderate) 
 
0 
 
1 (mild) 
 
0 
 
0 
Oedema 1 (mild) 2 (mild) 0 0 0 0 
Exfoliation 0 1 (mild) 0 0 0 0 
Cold sore 0 1 (mild) 0 0 0 0 
Alopecia 0 0 0 0 1 (mild) 0 
Lip 
tenderness 
0 0 1 (mild) 0 0 0 
Worsening 
of acne 
0 1 (severe) 1 0 0 0 
 
Table 5.20:  IPL-Placebo side-effects. IPL, intense pulsed light. 
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IPL-MAL (n = 10) 
 
Adverse 
event 
 
Week 3 
n (severity) 
 
Week 5 
n (severity) 
 
Week 7 
n (severity) 
 
Week 8 
n (severity) 
 
Week 11 
n (severity) 
 
Week 16 
n (severity) 
 
Persistent 
erythema (> 
3 days) 
 
1 (mild) 
 
0 
 
0 
 
1 (mild) 
 
0 
 
0 
Dryness 0 1 (mild) 1 (mild) 1 (mild) 0 0 
Oedema 1 (mild) 2 (mild) 2 (mild) 1 (mild) 0 0 
Exfoliation 2 (mild) 2 (1 mild, 1 
moderate) 
2 (1 mild, 1 
moderate) 
3 (1 mild, 1 
moderate, 1 
severe) 
0 0 
Post- 
treatment 
pain 
1 (mild) 1 
(moderate) 
1 (mild) 0 0 0 
Migraine 1 
(moderate) 
0 0 0 1 
(moderate) 
0 
Scab 
formation 
0 1 (mild) 1 
(moderate) 
0 0 0 
Pruritus 0 1 
(moderate) 
1 
(moderate) 
1 (mild) 0 0 
Blisters 0 0 1 
(moderate) 
0 0 0 
Post- 
treatment 
burning 
0 0 0 1 (severe) 0 0 
Worsening 
of acne 
2 (1 mild, 1 
severe) 
2 (1 mild, 1 
moderate) 
1 
(moderate) 
0 0 0 
 
Table 5.21: IPL-MAL side-effects. IPL, intense pulsed light; MAL, methyl aminolaevulinate. 
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5.1.11 Summary of the clinical findings 
 
1. Adapalene  reduced  the  noninflamed  lesion  counts  by  37.6%  at  week 16, 
which was statistically significant when compared with the 3.4% decrease in 
the IPL-MAL (p = 0.009) and 9.7% increase in the IPL-Placebo group (p = 
0.001). 
 
 
2. The maximum improvement in the inflamed lesion counts of 20.7% and 
13.4% in the IPL-MAL (p = 0.211) and IPL-Placebo (p = 0.511) groups at 
week 11, respectively, was not statistically significant. In the adapalene 
group, a non-significant improvement of 13.2% (p = 0.506) and 26.5% (p = 
0.137) was seen at weeks 11 and 16, respectively. 
 
 
3. Adapalene reduced the total lesion counts by 35.7% at week 16, which was 
statistically significant when compared with the 4.3% decrease in the IPL- 
MAL (p = 0.011) and 8.4% increase in the IPL-Placebo group (p = 0.005). 
 
 
4. Adapalene reduced the DLQI score by 52.9% at week 16, which was 
significant at p = 0.031. However, this difference was not significant when 
compared with the 25% decrease in the IPL-MAL and 5.6% decrease in the 
IPL-Placebo group. 
 
 
5. There was no significant difference within or between the groups in the VAS, 
Leeds, and FDLQI scores pre- and post-treatment. 
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6. There was no significant difference within or between the groups in the 
porphyrin fluorescence pre- and post-treatment. 
 
 
5.2 Effect on cutaneous microflora 
 
5.2.1 Baseline characteristics 
 
The prevalence of propionibacteria, CoNS, and S. aureus at baseline in the three 
treatment groups are given in Table 5.22. At baseline, P. acnes was isolated from all 
the patients in the three treatment groups whilst P. granulosum was cultured from 
10% and 20% of the patients in the IPL-MAL and IPL-Placebo groups, respectively. 
Similarly, except for two patients in the IPL-MAL group, CoNS were ubiquitous in 
the three treatment groups. Conversely, S. aureus was isolated from 20% of the 
patients in the adapalene group only. Because of technical problems the laboratory 
staff were unable to separately count P. acnes and P. granulosum colonies and 
therefore only total propionibacteria count is given in the trial. The three treatment 
groups were similar with respect to the population densities of propionibacteria, 
CoNS, and S. aureus (Table 5.23). 
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Variable 
 
Adapalene 
(n = 10) 
 
IPL-MAL 
(n = 10) 
 
IPL-Placebo 
(n = 10) 
 
Propionibacterium 
acnes, n (%) 
 
10 (100) 
 
10 (100) 
 
10 (100) 
Propionibacterium 
granulosum, n (%) 
0 (0) 1 (10) 2 (20) 
Coagulase-negative 
staphylococci, n (%) 
10 (100) 8 (80) 10 (100) 
Staphylococcus aureus, 
n (%) 
2 (20) 0 (0) 0 (0) 
 
Table 5.22: Baseline prevalence of various micro-organisms in the adapalene, IPL-MAL, 
and IPL-Placebo groups. IPL, intense pulsed light; MAL, methyl aminolaevulinate. 
 
 
 
 
Variable 
 
Adapalene 
(n = 10) 
 
IPL-MAL 
(n = 10) 
 
IPL-Placebo 
(n = 10) 
 
P-value 
 
Propionibacteria, 
median CFU cm-2 
(range) 
 
2.6 × 104 
(9.8 × 103 - 
2.3 × 106) 
 
1.8 × 105 
(3.7 × 102 - 
1.0 × 107) 
 
2.7 × 104 
(3.0 × 103 - 
4.1 × 106) 
 
0.881 
CoNS, median CFU 
cm-2 (range) 
1.8 × 104 
(2.7 × 103 - 
1.2 × 105) 
6.4 × 103 
(0.0 × 100 - 
1.6 × 106) 
1.3 × 104 
(1.5 × 101 - 
7.3 × 104) 
0.369 
Staphylococcus aureus, 
median CFU cm-2 
(range) 
0.0 
(0.0 × 100 - 
3.3 × 103) 
a a 0.126 
 
Table 5.23: Baseline densities of various micro-organisms in the adapalene, IPL-MAL, and 
IPL-Placebo groups. aNo Staphylococcus aureus was isolated and therefore its value is 
constant (=0). IPL, intense pulsed light; MAL, methyl aminolaevulinate; CFU, colony- 
forming units; CoNS, coagulase-negative staphylococci. 
 
 
5.2.2 Effect on propionibacteria density 
 
A significant increase in the median density of propionibacteria from baseline was 
observed in the IPL-Placebo group at week 16 (p = 0.021) (Table 5.24, Figure 5.12). 
A non-significant increase was also seen in the adapalene group whilst a reduction 
occurred in the IPL-MAL group at all the follow-up visits. There was no   significant 
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difference in the change in propionibacteria densities from baseline between the three 
groups (Table 5.25). 
 
 
 
 
 
 
 
 
 
 
Baseline 
 
Propionibacteria density (CFU cm-2) 
 
Adapalene (n = 10) 
 
IPL-MAL (n = 10) 
 
IPL-Placebo (n = 10) 
 
Median 
(range) 
 
P-value 
 
Median 
(range) 
 
P-value 
 
Median 
(range) 
 
P-value 
 
2.6 × 104 
(9.8 × 103 - 
2.3 × 106) 
  
1.8 × 105 
(3.7 × 102 - 
1.0 × 107) 
  
2.7 × 104 
(3.0 × 103 - 
4.1 × 106) 
 
Week 8 6.5 ×104 
(1.4 × 103 - 
1.9 × 106) 
0.344 1.7 × 105 
(4.6 × 102 - 
1.6 × 107) 
0.344 2.9 × 105 
(1.2 × 104 - 
2.1 × 106) 
0.344 
Week 11 4.8 × 104 
(1.4 × 103 - 
4.9 × 106) 
0.344 1.3 × 105 
(2.7 × 104 - 
1.6 × 107) 
0.344 4.7 × 105 
(1.1 × 104 - 
7.1 × 106) 
0.344 
Week 16 8.1 × 104 
(2.2 × 103 - 
7.0 × 106) 
0.754 1.1 × 105 
(9.5 × 101 - 
1.1 × 107) 
1.000 1.6 × 105 
(9.1 × 103 - 
1.7 × 107) 
0.021 
 
Table 5.24: Median propionibacteria densities in the adapalene, IPL-MAL and IPL-Placebo 
groups at baseline, week 8, week 11, and week 16. IPL, intense pulsed light; CFU, colony- 
forming units; MAL, methyl aminolaevulinate. 
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Figure 5.12. Propionibacteria densities at baseline, week 8, week 11, and week 16. 
Boxplot shows minimum, maximum, 25th and 75th percentiles, and median. IPL, 
intense pulsed light; CFU, colony-forming units; MAL, methyl aminolaevulinate. 
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Δ Week 8 
Median (range) 
 
Δ Propionibacteria density (CFU cm-2) 
 
Adapalene 
(n = 10) 
 
IPL-MAL 
(n = 10) 
 
IPL-Placebo 
(n = 10) 
 
P-value 
 
8.3 × 103 
(−4.9 × 105 - 
5.3 × 105) 
 
−7.6 × 103 
(−5.5 × 106 - 
1.8 × 106) 
 
−1.3 × 104 
(−9.3 × 105 - 
2.4 × 106) 
 
0.468 
Δ Week 11 
Median (range) 
8.8 × 103 
(−2.6 × 106 - 
5.9 × 105) 
−2.6 × 104 
(−5.6 × 106 - 
1.0 × 106) 
−8.6 × 104 
(−2.9 × 106 - 
1.5 × 106) 
0.362 
Δ Week 16 
Median (range) 
−2.2 × 104 
(−4.8 × 106 - 
9.4 × 105) 
8.2 × 102 
(−6.9 × 106 - 
2.5 × 106) 
−4.6 × 104 
(−1.4 × 107 - 
1.4 × 106) 
0.658 
 
Table 5.25: Median difference from baseline in the propionibacteria densities in the 
adapalene, IPL-MAL and IPL-Placebo groups at week 8, week 11, and week 16. IPL, intense 
pulsed light; CFU, colony-forming units; MAL, methyl aminolaevulinate. 
 
5.2.3 Effect on coagulase-negative staphylococci density 
 
A significant increase in the median CoNS density from baseline was observed in the 
IPL-MAL group at week 8 (p = 0.039) (Table 5.26, Figure 5.13). A non-significant 
increase was also seen in the IPL-Placebo group whilst a reduction occurred in the 
adapalene group at all the follow-up visits. There was no significant difference in the 
change in CoNS densities from baseline between the three treatment groups (Table 
5.27). 
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Baseline 
 
Coagulase-negative staphylococci density (CFU cm-2) 
 
Adapalene (n = 10) 
 
IPL-MAL (n = 10) 
 
IPL-Placebo (n = 10) 
 
Median 
(range) 
 
P-value 
 
Median 
(range) 
 
P-value 
 
Median 
(range) 
 
P-value 
 
1.8 × 104 
(2.7 × 103 - 
1.2 × 105) 
  
6.4 × 103 
(0.0 × 100 - 
1.6 × 106) 
  
1.3 × 104 
(1.5 × 101 - 
7.3 × 104) 
 
Week 8 1.4 × 104 
(0.0 × 100 - 
1.1 × 105) 
0.344 2.7 × 104 
(0.0 × 100 - 
5.6 × 105) 
0.039 1.8 × 104 
(9.6 × 102 - 
9.0 × 104) 
0.344 
Week 11 1.2 × 104 
(0.0 × 100 - 
1.3 × 105) 
0.344 1.4 × 104 
(0.0 × 100 - 
9.1 × 104) 
1.000 2.2 × 104 
(1.7 × 103 - 
1.5 × 105) 
0.754 
Week 16 1.4 × 104 
(0.0 × 100 - 
2.7 × 105) 
0.344 2.6 × 104 
(0.0 × 100 - 
1.0 × 105) 
1.000 1.5 × 104 
(7.3 × 102 - 
7.8 × 104) 
0.754 
 
Table 5.26: Median coagulase-negative staphylococci densities in the adapalene, IPL-MAL 
and IPL-Placebo groups at baseline, week 8, week 11, and week 16. IPL, intense pulsed 
light; CFU, colony-forming units; MAL, methyl aminolaevulinate. 
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Figure 5.13: Coagulase-negative staphylococci (CoNS) densities at baseline, 
week 8, week 11, and week 16. Boxplot shows minimum, maximum, 25th and 75th 
percentiles, and median. IPL, intense pulsed light; CFU, colony-forming units; 
MAL, methyl aminolaevulinate. 
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Δ Week 8 
Median (range) 
 
Δ Coagulase-negative staphylococci density (CFU cm-2) 
 
Adapalene 
(n = 10) 
 
IPL-MAL 
(n = 10) 
 
IPL-Placebo 
(n = 10) 
 
P-value 
 
5.4 × 103 
(−10.0 × 103 - 
7.2 × 104) 
 
−4.5 × 103 
(−4.4 × 104 - 
1.0 × 106) 
 
−1.2 × 104 
(−2.5 × 104 - 
5.9 × 104) 
 
0.059 
Δ Week 11 
Median (range) 
5.3 × 103 
(−1.0 × 105 - 
4.8 × 104) 
5.1 × 102 
(−5.1 × 104 - 
1.5 × 106) 
−2.9 × 103 
(−7.5 × 104 - 
3.1 × 104) 
0.294 
Δ Week 16 
Median (range) 
3.2 × 103 
(−1.5 × 105 - 
6.9 × 104) 
−5.3 × 102 
(−5.7 × 104 - 
1.5 × 106) 
−3.2 × 103 
(−5.9 × 104 - 
1.2 × 104) 
0.860 
 
Table 5.27: Median difference from baseline in coagulase-negative staphylococci densities 
in the adapalene, IPL-MAL and IPL-Placebo groups at week 8, week 11, and week 16. IPL, 
intense pulsed light; CFU, colony-forming units; MAL, methyl aminolaevulinate. 
 
 
5.2.4 Effect on staphylococcus aureus density 
 
In the adapalene group, the median S. aureus density remained 0 at baseline and all 
the follow-up visits (Table 5.28). Staphylococcus aureus was not isolated from the 
IPL-Placebo group at any time point whilst a transient colonisation in the IPL-MAL 
group (median density 0) was seen at week 8 only. As there were no apparent 
differences in the median S. aureus densities between the groups, no intergroup 
comparison was done. 
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Baseline 
 
Staphylococcus aureus density (CFU cm-2) 
 
Adapalene (n = 10) 
 
IPL-MAL (n = 10) 
 
IPL-Placebo (n = 10) 
 
Median 
(range) 
 
P-value 
 
Median 
(range) 
 
P-value 
 
Median 
(range) 
 
P-value 
 
0.0 
(0.0 × 100 - 
3.3 × 103) 
  
a 
  
a 
 
Week 8 0.0 
(0.0 × 100 - 
6.1 × 102) 
1.000 0.0 
(0.0 × 100 - 
2.9 × 105) 
0.250 a 1.000 
Week 11 0.0 
(0.0 × 100 - 
1.8 × 103) 
1.000 a 1.000 a 1.000 
Week 16 0.0 
(0.0 × 100 - 
1.4 × 103) 
1.000 a 1.000 a 1.000 
 
Table 5.28: Median Staphylococcus aureus densities in the adapalene, IPL-MAL and IPL- 
Placebo groups at baseline, week 8, week 11, and week 16. aNo Staphylococcus aureus was 
isolated and therefore its value is constant (=0). IPL, intense pulsed light; CFU, colony- 
forming units; MAL, methyl aminolaevulinate. 
 
 
5.2.5 Summary of the effects on cutaneous microflora 
 
1. IPL-Placebo caused a significant increase in the density o f  
propionibacteria at week 16 (p = 0.021). There was no significant difference from 
baseline in the density of propionibacteria in the IPL-MAL or adapalene groups. 
Moreover, there was no significant difference in the change in propionibacteria 
densities from baseline between the three groups at any time. 
 
 
2. IPL-MAL caused a significant increase in the density of CoNS at week 8 
(p = 0.039). There was no significant difference from baseline in the density of 
CoNS in the IPL-Placebo or adapalene groups. Moreover, the difference in the 
change in CoNS densities between the groups was not significant at any time. 
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3. The median S. aureus density remained 0 in the adapalene group at all 
times. Moreover, it was only transiently isolated from the IPL-MAL group at week 8 
but was never cultured from the IPL-Placebo group. 
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6. Discussion 
 
6.1 Lesion counts 
 
The results from this study demonstrated that adapalene was superior to IPL-Placebo 
and IPL-MAL in reducing the noninflamed (adapalene 37.6% vs. IPL-MAL 3.4% vs. 
IPL-Placebo −9.7%) and total lesion counts (adapalene 35.7% vs. IPL-MAL 4.3% 
vs. IPL-Placebo −8.4%) at week 16. A maximum improvement of 20.7% and 13.4% 
in the inflamed lesion counts was observed in the IPL-MAL and IPL-Placebo groups 
at week 11, respectively. However, this improvement was transient, statistically not 
significant, and clinically not relevant when compared with the 13.2% change in the 
adapalene group. Contrary to the IPL-Placebo and IPL-MAL groups, the maximum 
improvement in inflamed lesion counts in the adapalene group (26.5%) was observed 
at week 16, however, statistical significance could not be achieved. Efficacy rates of 
46-74% [303-305] and 49-54% [303, 305] for noninflamed and total lesion counts, 
respectively, have been reported for adapalene and the results from this trial compare 
favourably with these. 
 
 
No clinically relevant effect on noninflamed lesions and a maximum improvement of 
13.4% in the inflamed lesion counts in the IPL-Placebo group in this trial is inferior 
to some of the other studies which have assessed the efficacy of IPL in the treatment 
of acne [264, 306, 307]. Choi et al. [306], in a randomised comparative single-blind 
split-face study, treated 20 patients with facial acne (skin phototypes III-V) with 4 
sessions of 585 nm PDL on one side of the face and IPL (Ellipse Flex System, 
Horsholm, Denmark; 530-750 nm, triple pulses, 2.5 ms pulse duration, 9 ms delay 
between pulses, two passes, fluence 7.5-8.3 J cm-2) on the contralateral side at 
fortnightly intervals.  They reported a maximum improvement in inflamed and
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noninflamed lesion counts of 66% and 43% at 4 and 8 weeks after the last IPL 
treatment, respectively (p < 0.05 for both). Similarly, El-latif et al. [307] in a 
randomised comparative open study, treated 50 patients (skin phototype IV) with 
mild to severe facial acne with either IPL or BPO 5% gel. The patients in the IPL 
group (530 nm filter, single pulse, 35 ms pulse duration, fluence 35 J cm-2) received 
weekly sessions for 5 weeks. The maximum improvement reported here in the 
inflamed lesion counts for the IPL group was 61.56%. Finally, as mentioned in 
chapter 3 (Section 3.4.1.2), the split-face study of Yeung et al. [264] in an Asian 
cohort of 30 patients showed a 44% decrease (p = 0.01) in noninflamed lesions 
following 4 treatments of IPL (Ellipse Flex System, Horsholm, Denmark; 530-750 
nm, 10 × 48 mm spot size, double pulses, 2.5 ms pulse duration, 10  ms delay 
between pulses, single pass, fluence 7-9 J cm-2), 3 weeks apart. However no 
significant improvement in inflamed lesion counts could be demonstrated. 
 
 
There are two main factors that might influence the therapeutic effectiveness of light- 
based treatments including PDT; (i) light source (e.g. lasers, pulsed and non-pulsed 
broad spectrum light) and its dosimetry (ii) photosensitiser (e.g. ALA or MAL) and 
its concentration along with contact time [308]. Altering any of these variables might 
yield different therapeutic results. The difference in IPL parameters might explain 
why we were unable to duplicate the results seen in the above studies. This might 
also explain the mixed results on inflamed lesion counts in the three trials mentioned 
above [264, 306, 307]. 
 
 
Similarly, a maximum improvement of 20.7% in inflamed lesion counts and the lack 
of a clinically relevant effect on noninflamed lesions in the IPL-MAL group of this 
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study is less than that reported by other investigators [264, 309]. Hong et al. [309] 
conducted a randomised investigator blinded split-face study to treat 20 patients with 
facial acne (skin phototypes IV-V). The patients received three MAL-PDT  sessions 
(3 h MAL) 2 weeks apart and were irradiated with red light on one-half of the face 
and IPL (Ellipse Flex System, Horsholm, Denmark; 530-750 nm, 10 × 48 mm spot 
size, double pulses, 2.5 ms pulse duration, 10 ms delay between pulses, single pass, 
fluence 8-10 J cm-2) on the other half. The authors reported a 72% and 46.3% 
statistically significant reduction in the inflamed and noninflamed lesion counts on 
the IPL side, respectively. Similarly, Yeung et al. [264] found a significant 
improvement in noninflamed lesion counts (38%) in the IPL-assisted MAL-PDT 
group (Ellipse Flex System, Horsholm, Denmark; 530-750 nm, 10 × 48 mm spot 
size, double pulses, 2.5 ms pulse duration, 10 ms delay between pulses, single pass, 
fluence 7-9 J cm-2; 30 min MAL); however, no significant improvement in inflamed 
lesions could be established. Again, the difference in IPL parameters between this 
study and those mentioned above may explain the variability of results. 
 
 
As explained in chapter 4 (Section 4.1.2.4), marked discrepancies have been 
demonstrated between the measured IPL devices outputs and those claimed by the 
manufacturers [299]. Therefore, parameters claimed to be successful in one device 
might not demonstrate similar efficacy in another. Moreover, as limited information 
was available on the use of IPL for acne treatment in Fitzpatrick skin types I/II the 
parameters used were based on those used successfully by Babilas et al. [300] who 
also utilised the Energist ULTRA VPLTM system (IPL device used in this trial) in the 
treatment of actinic keratosis. However, even arguing the fact that this study was 
underpowered, therefore not giving statistically significant results, a maximum
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improvement of 20.7% and 13.4% in inflamed lesion counts in the IPL-MAL and 
IPL-Placebo groups, respectively, is clearly less than the benefit reported in above 
studies [264, 306, 307, 309]. It is prudent to mention though that even if this study 
was adequately powered, the possibility of above results failing to achieve statistical 
significance cannot be ruled out. Being underpowered may also be argued as a 
possible explanation of why a 26.5% improvement in the inflamed lesion counts in 
the adapalene group at week 16 did not reach statistical significance. 
 
 
6.2 Leeds and VAS scores 
 
Evaluation by the Leeds and VAS scores did not reveal a clinically relevant 
significant improvement in acne severity in any of the treatment groups. Leeds 
grading is influenced by changes in the inflamed rather than noninflamed lesions 
[286]. Similarly, by default, VAS will be more influenced by the inflamed than the 
noninflamed lesions (which are better palpated than seen). As mentioned previously, 
an acne grading system does not distinguish small differences in therapeutic response 
and the same may also hold true for VAS [285]. The treatment groups in this study 
only showed modest improvement in inflamed lesion counts (albeit non-significant) 
and may therefore explain why a clinically relevant and statistically significant 
change could not be seen in acne severity in any of these groups. 
 
 
6.3 DLQI and FDLQI scores 
 
This study was also aimed at comparing the impact of adapalene, IPL-Placebo and 
IPL-MAL on the quality of life of acne patients and their families. A 52.9% 
statistically significant improvement in the DLQI score was observed in the 
adapalene group at week 16, however there was no significant difference between the 
164  
three groups. Without a significant change in acne severity, a decrease in the DLQI 
score in the adapalene group is quite interesting and might be explained by a better 
tolerability of the drug and/or its positive impact on patient’s symptoms. On the 
contrary, there was no significant improvement in the FDLQI scores in any group. 
This corresponds rather well with the fact that no clinically relevant and statistically 
significant change in acne severity was seen in any treatment group. 
 
 
6.4 Effect on cutaneous microflora 
 
The 100% and 93% prevalence of P. acnes and CoNS, respectively, in this trial at 
baseline is in agreement with the ubiquitous presence of these micro-organisms on 
normal human skin [25, 310]. Similarly, the 7% colonisation rate of S. aureus can be 
explained by its prevalence (< 10%) on normal human skin [311]. However, P. 
granulosum prevalence of 10% in this study is less than its previously reported value 
of 42.8% in acne patients [22]. It is important to mention here that Leyden et al. [22] 
used bacteriophage susceptibility to differentiate P. acnes from P. granulosum. 
However, as per the original study of Marples and McGinley [312], they did not 
attempt to further subdivide phage-resistant propionibacteria into P. granulosum  and 
P. avidum and labelled all such strains as P. granulosum. It is possible that some of 
these phage-resistant strains were P. avidum. Moreover, in contrast to the present 
study where bacterial samples were taken from the cheeks only, they obtained 
samples from two different sites; forehead and cheek. Regional variation in P. 
granulosum colonisation rates exist (with the highest prevalence on the alae nasi 
followed by ear, scalp, and forehead respectively) [25] and this along with the failure 
to differentiate P. granulosum and P. avidum might explain the higher prevalence of 
the former in their study. 
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This study found no significant change in the density of propionibacteria in the 
adapalene and IPL-MAL groups, however a significant increase was seen in the IPL- 
Placebo group at week 16. On the contrary, no significant change in the porphyrin 
fluorescence was found in any group. This implies that follicular porphyrin 
fluorescence as a sole method for assessing the change in propionibacteria density 
post-treatment may not be 100% reliable. This fact has been highlighted by Burkhart 
[313] who surmised that acne treatments may destroy/change the chemical structure 
of porphyrins, therefore changing its absorption and emission spectrum, and/or 
impair its production by P. acnes via altering some intracellular signalling pathway. 
This may affect follicular porphyrin fluorescence without a change in P. acnes 
density. While this hypothesis does not explain the lack of change in the porphyrin 
fluorescence in the context of a significant increase in the propionibacteria density in 
the IPL-Placebo group of this study, it emphasises (in the light of results from this 
study) the importance of using bacterial culture for determining the anti- 
propionibacteria activity of acne treatments. 
 
 
The CoNS densities did not differ significantly in the IPL-Placebo and adapalene 
groups whilst a significant increase was observed in the IPL-MAL group at week 8 
only. As S. aureus, at baseline, was only isolated from 2 patients in the adapalene 
group (median density 0) but not from the other two groups, no conclusions can be 
made regarding the effect of these treatments on this micro-organism. 
 
 
The results from this study are in agreement with those obtained by Horfelt et al. 
[255, 256] who did not find a significant difference in the P. acnes counts after 
MAL-PDT or ALA-PDT. Ammad et al. [266], did not find a significant difference in 
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the density of P. acnes after treatment with blue light and increased propionibacteria 
counts in the IPL-Placebo group of this study differed from these results. Similarly, 
increased CoNS density at week 8 in the IPL-MAL group was unexpected as ALA- 
PDT has been shown to significantly decrease S. epidermidis density in vitro [281]. 
The results from this study indicate that in vivo IPL/IPL-MAL treatment does not 
directly lead to the destruction of micro-organisms. Moreover, the observed 
unexpected findings may be explained by the follicular microenvironment theory 
elucidated in chapter 1 (Section 1.2.4). It is possible that IPL/IPL-MAL treatment (at 
the settings used in this trial) selectively changed the microenvironment of individual 
follicles making them more suitable to the growth of a specific micro-organism. 
Differential change in the follicular pH, by the variable anti-inflammatory properties 
of the two treatments (see Chapter 3, Section 3.4.2.1), might be one example of 
such alteration [55]. This might explain the selective increase in the densities of 
proprionibacteria and CoNS in the IPL-Placebo and IPL-MAL groups at weeks 16 
and 8, respectively, in this study. As no clinically relevant change in the inflamed 
lesion counts was seen in the IPL-MAL group at week 16, it is unlikely that an 
increase in the propionibacteria density in the IPL-Placebo group had any impact on 
its efficacy. Similarly, CoNS are not implicated in the pathogenesis of acne and a 
significant increase in the density in the IPL-MAL group at week 8 is unlikely to 
have influenced the efficacy of this treatment. 
 
 
6.5 Safety data 
 
This study showed no significant difference in the pain scores, during illumination, 
between the IPL-MAL and IPL-Placebo groups. This is contrary to the study 
conducted by Yeung et al. [264] in which 25% of the patients in the IPL-MAL group 
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withdrew from the trial because of significant stinging, burning and erythema after 
the treatment; however treatment with IPL was well tolerated. Similarly, in the study 
of Hong et al. [309], MAL-PDT with IPL was significantly more painful than red 
light after the second treatment. Light absorption leads to heat generation which 
contributes to PDT pain [244]. IPL-MAL treatment may have been well tolerated by 
the patients in this trial due to the cold air cooling that was used to prevent excessive 
heating of tissues, therefore, minimising PDT pain. Moreover, as previously 
mentioned (Chapter 4, Section 4.1.2.4), our IPL parameters were carefully chosen 
from a previous study [300] in which these settings were found to be less painful 
than a LED for MAL-PDT. 
 
 
Very few adverse events were reported by the patients in the IPL-MAL and IPL- 
Placebo groups with most of the side-effects being mild to moderate and resolved 
completely without any sequelae. Moreover, none of the patients developed PIH or 
scarring. This is in contrast to the side-effects reported by Yeung et al. [264] in 
which 2 patients in the IPL group whilst one in the IPL-MAL group developed PIH. 
PIH is more common in darker skin types [314] and its increased incidence in the 
study of Yeung et al. [264] (despite using a lower fluence) can be explained by the 
fact that they treated facial acne in patients with skin types IV-V whilst the cohort in 
this study included patients with skin types I-IV. Moreover, the use of cold air 
cooling in this trial prevented an excessive rise in epidermal temperature, which also 
helped to further minimise the complications [315]. In terms of adapalene side- 
effects, all but one experienced skin dryness followed by exfoliation, erythema and 
temporary worsening  of  acne  being  reported  by almost  one-third  of  the patients. 
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Again, all these adverse events were mild to moderate and resolved completely at the 
end of the trial. 
 
 
6.6 Summary 
 
Adapalene 0.1% gel proved to be more effective than IPL-Placebo and IPL-MAL in 
reducing noninflamed and total lesion counts at week 16. Moreover, it was also 
associated with a significant increase in the quality of life of patients. This study also 
found a modest improvement (albeit non-significant) in inflamed acne lesions in both 
the IPL-Placebo and IPL-MAL groups at week 11; however, ruling this out as a 
chance finding needs an adequately powered study. Treatment with IPL-Placebo and 
IPL-MAL was associated with a significant increase in the densities of 
propionibacteria and CoNS at weeks 16 and 8, respectively, which might be due to 
the induction of selective changes in the microenvironment of PSFs promoting the 
growth of a specific micro-organism. This suggests that, if a significant improvement 
in inflamed lesion counts can be confirmed in an adequately powered study, IPL- 
Placebo and IPL-MAL have anti-inflammatory and/or sebostatic effects rather than 
bactericidal properties. Recently, other investigators from our department have 
shown IPL to up-regulate TGF-β1 expression and activity (via nuclear translocation 
of its signalling transducer, Smad3) in vivo [316]. As explained in chapter 3 (Section 
3.4.2.1), TGF-β is an immuno-regulatory cytokine and its up-regulation may be one 
of the anti-inflammatory pathways by which IPL/IPL-MAL may improve acne. 
Similarly, IPL and IPL-assisted ALA-PDT have been demonstrated to significantly 
decrease SER in acne patients [317]. In a separate study on the cohort of this trial, 
the effect of IPL and IPL-MAL on the SER was also investigated and the results 
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when available might show the influence of these light-based treatments (at the 
parameters used in this trial) on sebaceous glands. 
 
 
6.7 Study critique 
 
1. Awareness of the treatment allocation in the adapalene group by the 
patients as well as investigators could have been a source of ascertainment 
bias in this study. Blinding of the treatment allocation in this group, by a 
placebo control, would have been preferable. However, this would have 
further increased the sample size of the trial, making useful interpretation 
of the results more difficult due to the recruitment difficulties we faced. 
 
 
2. This study was underpowered and therefore increased the probability of a 
type II error (failure to reject the null hypothesis when it is false). Hence, 
the results which are clinically relevant but statistically not significant 
should be interpreted with caution. 
 
 
3. The data from this study was evaluated by the per-protocol analysis rather 
than intention-to-treat (ITT) analysis and therefore included only those 
patients who completed the study without any major protocol violations. 
While an ITT analysis is considered ideal, the estimate of treatment 
efficacy using this approach is generally conservative because of dilution 
due to noncompliance. Therefore, to show the maximum possible 
improvement with the IPL parameters used in this trial a per-protocol 
analysis was chosen. This could be a potential source of bias in this trial 
[318]. 
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4. The follow-up period in this trial was short (9 weeks and 3 weeks for the 
light groups and adapalene group, respectively) and ideally should have 
been longer to assess the durability of response in the three treatment 
groups. In fact, a 44 weeks follow-up study was designed in conjunction 
with this project, but due to its length my participation was limited to that 
described in this thesis. 
 
 
5. The current study speaks only to the efficacy of a specific IPL treatment 
protocol and better results may be achieved by optimisation of the 
treatment parameters. 
 
 
6. The use of ultrasound gel on the skin to be treated can reduce reflection of 
the incident rays and enhance the delivery of energy to the targeted 
chromophore. However, heating of the gel, due to inadequate time 
between discharges, can create small bubbles in it which can impede light 
passage by light scattering [299]. This may potentially reduce the efficacy 
of light treatment. However, ultrasound gel was used by Choi et al. [306] 
and Babilas et al. [300] in their trials which demonstrated IPL and IPL- 
assisted MAL-PDT to be an effective treatment modality for acne and 
actinic keratosis, respectively. This means that a loss of efficacy due to the 
bubbling phenomenon, if any, is normally minimal. 
 
 
7. Discrepancies have been demonstrated between the measured IPL device 
outputs and the values displayed on the system or claimed by the 
manufacturers [299]. Our IPL machine was calibrated and serviced before 
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the trial, thereby reducing machine error as a cause of lack of significant 
clinical efficacy in our trial. 
 
 
8. One of the aims of this trial was to assess the effect of IPL and IPL- 
assisted PDT on the P. acnes density. However, as mentioned in chapter 5 
(Section 5.2.1), because of technical problems, the laboratory staff were 
unable to separately count P. acnes and P. granulosum colonies and 
therefore only total propionibacteria count was given in the trial. We 
believe that this did not influence our interpretation of the results as there 
was no significant reduction in the density of propionibacteria and P. 
granulosum was only isolated from 10% of the patients (IPL-MAL = 1, 
IPL-Placebo = 2). 
 
 
9. Disease-specific quality of life instruments have greater power to detect 
change by focusing on aspects of functioning that are most affected by the 
disease and tend to be of greatest importance to patients [319]. Using such 
an instrument (e.g. the Acne-Specific Quality of Life questionnaire) 
alongside the generic DLQI instrument could have been advantageous in 
the trial. 
 
 
6.8 Future studies 
 
Although, due to the underpowered nature of this study, no definite conclusions 
could be made regarding the efficacy of IPL and IPL-assisted MAL-PDT o n  
inflamed lesion counts, further research on the use of these treatment modalities in 
acne is still warranted.  This is largely due to reports from other investigators
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demonstrating these treatment modalities to be effective in acne management. 
Moreover, any future studies should aim to clarify the questions raised by this 
project, especially with respect to the possible mechanism of action of these 
treatment modalities in acne. We suggest the following changes for future studies: 
 
 
1. The treatment parameters should be further optimised to improve the 
clinical efficacy of these light-based treatments. Delivering smaller 
fluences in a train of 2-3 sub-pulses over a shorter time period, by 
decreasing the delay between pulses, could yield better results [306, 309]. 
 
 
2. Using a disease-specific quality of life instrument (e.g. the Acne-Specific 
Quality of Life questionnaire) alongside the generic DLQI instrument 
would give a more accurate estimate of the effect of these light-based 
treatments on the quality of life of acne patients. 
 
 
3. With the caveat of increasing the sample size, a placebo group would 
reduce the ascertainment bias in the adapalene arm. 
 
 
4. As shown in this study, enumeration of P. acnes by culture is more 
accurate than porphyrin follicular fluorescence for the evaluation of 
suppressive effect of anti-acne treatments on this micro-organism. Hence, 
either both or the former technique alone should be used in any future 
trials. 
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5. Keeping in mind the recruitment difficulties faced during this trial, a 
multicentre study might be more appropriate for any future attempt at 
comparing these light-based therapies with a conventional anti-acne 
treatment. 
 
 
6. The possibility of sebostatic properties of IPL-assisted PDT/IPL has been 
discussed in the thesis (Section 3.4.2.2) and any further study should also 
include quantitative sebum analysis which is possible using a SM 810® 
sebumeter (Courage + Khazaka Electronic, Köln, Germany) [108]. 
 
 
7. The anti-inflammatory properties of light-based treatments have been 
discussed (Section 3.4.2.1) and should also be investigated concurrently in 
any future studies. Reverse transcription-polymerase chain reaction can be 
used to assess the effect of IPL/IPL-assisted PDT on various cytokines e.g. 
TGF-β, IL-1, TNF-α, IL-10 [273]. Similarly, immunohistochemistry  can 
be used to assess the effect of these light-based treatments on other 
proinflammatory and anti-inflammatory molecules thought to be involved 
in acne pathogenesis e.g. SP, CRH, and hBD-2 [135, 147, 156]. 
 
 
6.9 Future of IPL and IPL-assisted PDT in acne 
management 
Despite the availability of numerous medical therapies for acne, issues of safety, 
compliance, and less than ideal efficacy help drive the search for alternative 
treatments for this common clinical problem. In light of these issues, IPL and IPL- 
assisted MAL-PDT were proposed as possible therapeutic alternatives and were
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compared with adapalene to find a place for these light-based treatments on the acne 
therapeutic ladder. Moreover, the effect of these treatment modalities was 
hypothesised to be due to their anti-P. acnes properties. In this thesis, the 
microbiology assessments suggest that in vivo IPL and IPL-MAL (at the treatment 
parameters used in this trial) do not have any bactericidal effects on P. acnes. 
Therefore any future attempt at elucidating the mechanism of action of these 
treatments should assess their effect on SER, various cytokines e.g. TGF-β, IL-1, 
TNF-α, IL-10, and other proinflammatory and anti-inflammatory molecules e.g. 
CRH, SP, and hBD-2 (see Chapter 2, Section 2.4.2) concurrently with 
microbiological assessment. 
 
 
Regarding the practical implications of the present study, it can be concluded that 
adapalene remains an effective first line treatment in mild to moderate facial acne. 
The present study has remained inconclusive (due to being underpowered) regarding 
the efficacy of IPL and IPL-MAL on inflamed acne lesions. However, the modest 
improvement seen with these treatments, as monotherapy, in this trial suggest that 
they are only marginally effective for inflammatory acne. This, in combination with 
the cost and time needed for these treatments, is likely to lead to patient 
dissatisfaction. All these facts should, therefore, be critically evaluated before 
embarking on any further research in this field.   
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Patient Information Sheet 
 
 
A comparison of the clinical efficacies of intense pulsed light, photodynamic 
therapy and adapalene  in the treatment of mild to moderate acne vulgaris 
 
Dear Sir or Madam, 
 
You are being invited to take part in a research study to see how well intense pulsed 
light (IPL) clears the spots (called ‘acne’) on your face. This light may be given alone 
or after using a cream called ‘methyl - aminolaevulinic acid’ (MAL). 
 
Before you decide, it is important for you to understand why the research is being 
done and what it will involve. Please take the time to read the following information 
carefully and discuss it with others like your family members or family doctor if you 
wish. 
 
Please do not hesitate to ask us any questions or to request more information as 
necessary. You may contact Dr. Suthananthan, Dr Shaheen or Sister Anne Thomas 
who are all working on this study. Their phone numbers and email addresses are on 
the last page of this leaflet. 
 Part 1 tells you the purpose of this study and what will happen to you if you 
take part. 
 Part 2 gives you more detailed information about the conduct of this study. 
Thank you for taking the time to read this. 
PATIENT INFORMATION SHEET- PART 1 
 
What is Intense Pulsed Light (IPL)? 
 
The visible or ‘white’ light that we see consists of all the colours of the rainbow. 
Laser machines produce only one colour of light. Intense Pulsed Light (IPL) is NOT 
a laser machine. Its light is made up of different colours or shades of the same 
colour of light.  This is referred to as being ‘broad-spectrum’. This light is produced 
in short bursts or pulses hence the term “intense pulsed light’’. 
 
IPL acts on (i.e. ‘targets’) specific things in the skin like pigments, chemicals and 
collagen. Depending on the machine settings, IPL can target the dark pigment found 
in hair, and hence it is useful in hair removal. It can also target the red pigment in 
blood and therefore can help to reduce the appearance of red spots and veins on 
the skin. 
 
IPL machines can give out blue, green, yellow and red light. The machine’s settings 
can be changed to produce only the colours that are most beneficial to you. In acne, 
blue light acts on chemicals called porphyrins. These porphyrins are made by the 
bacteria that cause acne. Through the action of blue light on these porphyrins, the 
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bacteria are either weakened or killed. Red light can go deeper in the skin than blue 
light, and in some studies it has been shown to reduce the number and size of the 
oil-producing glands. These oil-glands are also involved in causing acne. 
It is important to note that unlike sunlight, IPL machines have filters that remove 
ultraviolet (UV) light. Therefore the bad effects of UV light that cause skin wrinkling 
and cancer are removed. 
 
What is the purpose of the study? 
 
Over the past few years, doctors, mostly in Europe and the United States, have said 
that light therapy, with and without MAL cream, is helpful in treating acne. 
Nonetheless, the research that has been done in this area has been relatively little. 
Though useful, it has not properly addressed how well light works on its own or in 
combination with creams like MAL. Also, these studies do not say how well light 
treatments work compared to acne treatments that are already available through 
your doctor, like adapalene (Differin™). 
 
Why have I been chosen? 
 
You have been chosen because you have been identified by your doctor as having 
acne on your face or because you responded to one of our advertisements. 
 
Do I have to take part in the study? 
 
Participation in this study is entirely up to you. If you decide to take part, you will be 
given this information sheet to keep and asked to sign a consent form. If for any 
reason, you would like to withdraw from the study, after agreeing to join, you are 
free to do so at any time. Withdrawal will not affect your standard of care or ability to 
receive treatment from any hospital or your GP. 
 
Reports from this study will not contain any personal identifiable information about 
you. 
 
What will happen to me during this study? 
 
There will be three treatment groups: 
1. IPL and MAL cream together 
2. IPL and placebo (or ‘dummy’) cream 
3. Adapalene only 
 
All of these treatments have been used to treat acne. Therefore no matter which 
group you are placed in, you will receive real treatment. These groups are selected 
by a process that has no information about the persons involved; therefore your 
assignment will be purely by chance. 
 
If you are in either group 1 or group 2: A cream (which could be placebo or active 
treatment) will be put on your face for 60 minutes. You will be asked to wash it off 
after 60 minutes. Prior to the treatment with IPL, you will be required to wear 
goggles to protect your eyes. Then, a cooling gel will be put on your face. IPL will 
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then be administered onto your face through the cooling gel. IPL may cause a 
stinging or burning sensation. Some say that it feels similar to the sensation of an 
elastic band being snapped against the skin. The cool gel should help to reduce any 
discomfort you may experience. Only your face will be treated. 
 
The treatment and clinical review times vary between the treatment groups. Phase 1 
of the study lasts for 16 weeks. In phase 1, Patients in the IPL groups will have a 
total of 8 visits over this 16 week period whereas patients in the adapalene group 
will only attend 5 visits over the 16 week period. At the end of 16 weeks, we will ask 
patients in the IPL groups to keep an acne diary (how their acne is doing) for the 
next 44 weeks. No treatment will be given during this phase of the study. These 
patients from the IPL groups will be reviewed at 2 follow up appointments with the 
department during the subsequent 44 week period (Phase 2). 
 
Below is a simple diagram and notes that help us explain to you what will happen. 
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Day 1 
a. You read this information sheet 
b. Study explained to you 
c. Date given for appointment 
Baseline tests at UHW (3 hours) 
 After agreeing  to help with this study 
 Consent Form signed 
 Medical history taken 
 Fill out a simple form about how acne impacts your daily life 
(AQoL) and DLQI 
 Fill out a simple form about how your skin disease affects 
your family members (FDLQI) 
 Fill out a scale graded 0 to 10 based on your impression 
about the severity of your acne. 
 Assessment of oiliness of  your skin 
 Counting of spots on face 
 Photographs of your face 
 Skin swabs for bacteria 
 Appointment for treatment given 
You will be randomly allocated to 
a treatment group. 
IPL + MAL CREAM (2 HOURS) 
 
 
 4 treatments 2 weeks apart 
 The FDLQI will be repeated 
only at week 16 
 The rest of the baseline 
tests will be repeated at 
weeks 8, 11 &16. 
 
 
 
(8 visits over 16 wks) 
ADAPALENE GROUP 
 Use only 
Adapalene nightly 
to face for 12 
weeks. 
 The FDLQI will be 
repeated only at 
week 16 
 The rest of the 
baseline tests will 
be repeated at 
week 8,11 &16 
 
(5 visits over 16 weeks) 
IPL + PLACEBO CREAM 
(2 HOURS) 
 4 treatments 2 weeks 
apart 
 The FDLQI will be 
repeated only at week 
16 
 The rest of the 
baseline tests will be 
repeated at weeks 8, 
11 &16. 
 
(8 visits over 16 wks ) 
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What do I have to do? 
 
 
A. Please protect your face from getting tanned for the time that you are 
involved in this study. 
Being in the sun or on a sunbed causes your skin to produce more 
pigment, which we call a ‘tan’. Also, the pigments in sun-tanning lotions 
leave extra pigment in your skin. Darker skin types have more pigment 
too. As said before, IPL works by ‘targeting’ pigments in and on the 
skin. Hence, IPL treatment of your skin while you have a deep tan may 
result in much worse side-effects. For example, a bad ‘sun-burn’ effect, 
blisters, scarring, darkening or lightening of the skin that has been 
treated can happen. These side-effects are much less likely if you do 
not have a tan or use sun-tanning lotions. Therefore, please do not 
sunbathe while you are helping us in this study, even if you are wearing 
a sun protection cream. 
You can do this easily by staying out of direct sunlight during the course of 
this study. If you have to go outside, then wear a wide-brimmed hat and sun 
protection with a minimum sun protection factor (SPF) 30 on your face. We 
will provide you with Delph Sunblock Lotion that should be used for your face 
only. Please do not use any other sunblock on your face except for the one 
provided by the department. An emollient (to be applied twice a day for a 
total of 5 days) will be given to all patients in the IPL groups post treatment. 
 
As a result, before every treatment, please tell us if you may have recently 
had prolonged exposure to sunlight or have a tan. 
 
B. If you are placed in any of the IPL groups, you will have to be 
especially careful about protecting yourself from the sun for the first 2 
days after treatment. This is because you may have been given the 
MAL cream. MAL cream may make the sunlight act even more 
strongly on the skin for up to 48 hours after washing the cream off the 
skin. 
In these 2 days: 
1. From 11 am to 3 pm the sun’s rays are most damaging. Please avoid 
being in direct sunlight especially during these times. Staying indoors as 
much as possible is a good way to do this. 
2. Wear your sun cream, paying special attention to your face and neck. 
Re-apply it every 2 to 4 hours, because most of its protective effect 
wears off after this. Wearing the wide-brimmed hat as well helps. 
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C. Certain medications may cause you to be more sensitive to light. If you 
take any herbal supplements or medications before or after starting 
this project, please let us know. 
 
 
Otherwise, you should be able to work, travel and socialise as normal. 
 
What are the alternatives for treatment? 
 
Many treatments are now available from your local pharmacy or through your 
doctor. If you are using creams such as benzoyl peroxide, azelaic acid or 
nicotinamide on your face OR if you are on tablets for your acne e.g. minocycline, 
we will ask you to wait a little while until these have worn out of your system before 
entering you into this study. 
 
Please do not use any medication or medicated soaps, unless we have prescribed it 
for you. If you need other treatment for your skin e.g. steroids or antibiotics to be 
taken by mouth, please tell us about it as soon as possible. If you can, tell us before 
you start any treatment. Doing this helps us decide if it affects your IPL treatments. 
We may be able to suggest a suitable alternative for that medication while you are 
participating in this study. 
 
More information about acne and its treatment is available on the British Skin 
Foundation’s website at: 
http://www.britishskinfoundation.org.uk/standard.aspx?id=208 
 
 
What are the possible benefits of taking part? 
 
Your acne may get better. IPL is also used to help sun-damaged skin appear 
younger and more even-toned, with a smoother texture. Therefore, you may receive 
some of this benefit. Also, it is hoped that results from this study will help us to better 
understand the benefits (or otherwise) of this type of treatment. Hence, in the future, 
you would have helped doctors and patients decide if this is a good treatment option 
for them based on our findings. 
 
You will not pay for the special investigations required for this study. Your treatments 
will be provided at no cost to you throughout the period of the study.    
Transportation costs incurred through participation in this trial will be reimbursed at a 
fixed rate. This money will be paid to you at the end of your involvement in this 
study. 
 
 
What are the side-effects of any treatment received when taking part? 
 
Side effects of IPL: Looking at the studies done with IPL in the treatment of acne, 
many patients experienced little more than warmth, burning or tingling during 
treatment. Other effects include mild to moderate pain, redness and mild swelling of 
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the area for up to a week. Uncommonly, this area can become infected. Especially 
in darker-skinned individuals, temporary darkening or lightening of the treated area 
may occur. Blisters,crusting and scarring have been reported but are quite 
uncommon in all skin types. There may be temporary, long term patchy hair loss 
affecting the beard area in men. 
 
Side effects of IPL + MAL: First, we will give a brief explanation about how IPL + 
MAL works. 
 
Our red blood cells contain a red pigment called ‘haemoglobin’ that carries the 
oxygen around our bodies. Aminolaevulinic acid (ALA) is one of the first ingredients 
that our body uses to make the haemoglobin. This ALA can be sprayed or rubbed 
onto the skin and is allowed to absorb, making the skin more sensitive to light. Once 
light, such as IPL, is shone onto the skin, the areas that have absorbed the ALA will 
become inflamed and are destroyed. Thereafter, new healthy cells will grow to 
replace the destroyed ones. This whole process is called ‘photodynamic therapy’ or 
PDT. This technique is very useful in curing certain early and late skin cancers or 
even cancers inside the body when the patient takes the ALA by mouth.  PDT is 
also used to improve the appearance of aged skin. MAL is very much like ALA and 
behaves similarly when used on the skin. 
 
Since PDT works by causing inflammation and destruction of the cells that have 
absorbed the ALA, patients often experience a burning sensation while getting the 
light treatment that may last for a few hours and then resolve. Pain, redness, 
swelling, stripping of the skin, scab formation and temporary worsening of your acne 
commonly occur and may last for 1 to 2 weeks or sometimes longer. There is a 
small risk of scarring and darker skin types may experience discolouration of their 
skin, which often gets better with skin lightening treatment. We will use MAL for only 
60 minutes on the skin, which has been shown to cause milder side-effects. 
 
Other side effects that have been reported include: eczema (dry skin patches that 
may itch) where MAL is applied, wheals (hives), skin irritation, prolonged sensitivity 
to the sun, bleeding (if there is a wound), nausea, eye swelling, eye pain, 
headaches, tiredness and sensations of tingling and numbness. 
 
Side-effects of Adapalene: Usually patients have no problems with adapalene, but 
you may experience some burning, warmth, stinging, tingling, itching, redness, 
dryness, peeling, or irritation while you are using it.  Let us know immediately if 
these side effects are excessive, so that we can reduce your adapalene to every 
other day or a few days per week. These side effects should decrease after the first 
few weeks of treatment. 
Contact names and numbers are listed below if you are concerned in any way or 
have an emergency related to this study. 
 
What if I get pregnant or is there anything else I should know? 
 
The cream, adapalene, belongs to a group of drugs that are similar to vitamin A 
called ‘retinoids’. Retinoids may cause damage to an unborn child. Therefore, 
pregnant women  and women contemplating pregnancy will not be asked to join this 
201  
study. Therefore, if you are a female of childbearing age, you will be asked to do a 
pregnancy test before taking part to exclude the possibility of pregnancy. IPL 
treatments on the other hand, are unlikely to be harmful to the unborn child or have 
any negative effect on a man’s sperm causing damage to a foetus. 
 
Women who can become pregnant must consistently use effective birth control 
during the course of their treatment. Please use methods such as condoms rather 
than hormonal methods such as the pill or implants beneath the skin, since the 
hormones in them can affect the results of this study. 
 
If you become pregnant while in this study, please inform us as soon as possible 
using the contact information below. 
 
It is not known whether adapalene is secreted in human milk, therefore its use in 
breast feeding women should be avoided. Hence women who are breast feeding will 
not be asked to join this study. 
 
Due to the non-invasive nature of any of these treatments, it should not affect your 
life or private medical insurance. However, you should check with your provider to 
make sure that assisting us with this study does not affect your coverage. 
 
If we discover any other condition of which you were previously unaware, we will 
inform your GP and re-assess your ability to participate in this study. 
 
What happens when the research study stops? 
 
Unfortunately, IPL treatments for acne are not yet available on the NHS; therefore 
they are not routinely available to public patients. If you require further help for your 
acne after the end of the study, please return to your usual GP or dermatologist. 
 
During the follow-up phase of the study 44 weeks after the study, we will arrange for 
you to have 2 follow-up appointments in the Dermatology Department at the 
University Hospital of Wales. 
 
This completes Part 1 of the Information Sheet. If the Information in Part 
1 has interested you and you are considering participation, please 
continue to read the additional information in Part 2 before making any 
decision. 
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PATIENT INFORMATION SHEET- PART 2 
 
What if new information becomes available? 
 
Sometimes during the course of a research project, new information becomes 
available about the treatment being studied. If this affects the study, your research 
doctor will tell you about it and discuss with you whether you can or would like to 
continue in the study. If you decide to continue in the study, you will be asked to sign 
an updated consent form. 
 
What will happen if I don’t want to carry on with the study? 
 
You may stop your participation in the study at any time. This will not affect your 
standard of care or ability to receive treatment from any hospital or your GP. 
Your doctor may stop your participation in the study without your consent if you 
experience a serious adverse event, are found not to be eligible to participate in the 
study, need additional medication or do not follow study procedures. 
You can withdraw from treatment but keep in contact with us to let us know your 
progress. Information collected may still be used. Any identifiable samples that can 
still be identified as yours will be destroyed if you wish. 
 
What if something goes wrong? 
 
If you are harmed by taking part in this project, there are no special compensation 
arrangements. If you are harmed by someone’s negligence, then you may have 
grounds for legal action but you may have to pay for it. Regardless of this, if you 
wish to complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms should be available to you. 
 
Will my taking part in this study be kept confidential? 
 
All the information that is collected about you during the course of this research will 
be kept strictly confidential. Only staff members directly involved in your care will 
have access to it and these will be secured in a locked room within the department. 
 
Your file will be identified only by your study number and gender so that you cannot 
be recognised from it. Your GP would probably like to know about your participation 
in this study, but we will inform them only if you give us your permission to do so and 
provide your GP’s contact information. 
 
What about my photographs? 
These will be stored on a secure laptop owned by Cardiff University. It will be kept in 
the Dermatology Department and be accessible only to the members of the study 
team. This data will be encrypted. Back up copies will be held on the University 
Hospital of Wales’ FotoWeb site in a password protected area – this means that only 
select members of the study team will have a password allowing them to access this 
site. The photographs taken by the photography unit in the Dermatology Department 
will be stored on a secure server that is password protected. 
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After completion of the study, the data will be removed from the laptop and secured 
electronically on data disks for 15 years. After 15 years, the photographs will be 
destroyed via the confidential waste system. 
 
What will happen to the results of this study? 
 
The results of this study will be published in reputable medical journals and in an 
academic thesis. The results will not contain any personal identifiable information 
about you. 
 
Due to the nature of this study, we may use your photographs to illustrate the 
outcomes of your treatment in these publications and for teaching purposes. We will 
not use them without your permission. Therefore, you will be asked to give your 
consent for this separately. 
 
Who is organising and funding the research? 
 
Cardiff University, through the Department of Dermatology, is sponsoring and 
funding this study.  Your doctor is not being paid for including you in this study. 
 
Who has reviewed the study? 
 
To ensure your safety and that the highest research standards are being met, the 
Cardiff & Vale R&D Committee, South East Wales Research Ethics Committee and 
the Medicines & Healthcare Products Regulatory Agency have reviewed this study’s 
protocol and are satisfied that it is in accordance with the latest version of the ethical 
principles for human research. 
 
Contacts for Further Information 
If you have any queries, or experience injuries or adverse events related to this 
study please contact any of the persons below during work hours: 
 
Dr. Maria Gonzalez (Principal Investigator & Academic Supervisor) 
Work: (0)29 2074 4398 Email: gonzalezml@cardiff.ac.uk 
 
Sister Anne Thomas (Research Sister) 
Work: (0)29 2074 2672   Email: thomasag1@cardiff.ac.uk 
 
Dr. Chantal Suthananthan (Study Coordinator) 
Work: (0)29 2074 5875   Email: SuthananthanCA@cardiff.ac.uk 
 
Dr B. Shaheen (Study Coordinator) 
Work :( 0)2920746405 Email: shaheenb@cf.ac.uk 
 
 
Dr. Ausama Abou Atwan (Research Team Member) 
Work: (0)29 2074 2890 Email: atwanabouaa@cardiff.ac.uk 
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Address: 
Department of Dermatology, 
3rd Floor Glamorgan House 
School of Medicine, Heath Park 
Cardiff University, CF14 4XN 
Fax:  (0)29 2074 4312 
 
This is your copy. Thank you for agreeing to help with this study. 
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Consent Form 
 
 
 
CONSENT FORM 
 
 
CANDIDATE 
NUMBER 
PATIENT D.O.B (dd/mmm/yyyy) 
            
Title of Project: A comparison of the clinical efficacies of intense pulsed light, 
photodynamic therapy and adapalene in the treatment of mild to moderate acne 
vulgaris 
 
Name of Researchers: Dr. Maria Gonzalez, Dr C A Suthananthan, Dr B Shaheen, Dr. 
Marisa Taylor, Dr. A. A. Atwan 
 
 
 
 
Please initial box 
 
1. I confirm that I have read and understood the information sheet dated 
November 2nd 2010, Version 6 for the above study and have had the 
opportunity to ask questions. 
 
2. I agree to attend all clinics applicable to me as outlined in my information 
sheet. ( IPL Groups: 8 visits in Phase 1 and 2 visits in Phase 2; Adapalene 
Group: 5 visits in Phase 1) 
 
3. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving a reason. My legal rights and medical 
care will not be affected. 
 
4. I understand that sections of any of my medical notes may be looked at by 
those named above or from regulatory authorities where it is relevant to 
my taking part in research. I give permission for these individuals to have 
access to my records. 
 
5. I agree to my GP or family doctor being informed that I am taking part 
in this study. 
 
 
6. I agree for my photographs to be taken and stored as outlined in this 
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patient information sheet 
 
a. For use in this research thesis and my case notes 
 
b. For teaching purposes at the University Hospital of Wales 
 
c. For use in peer-reviewed medical publications 
 
 
 
 
7. I agree to take part in the above study 
 
 
 
 
 
 
 
 
  
Name of Patient Signature Date 
 
 
 
  
Name of Person taking consent Signature Date 
(if different from researcher) 
 
 
 
  
Researcher Signature Date 
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FURTHER CONSENT FOR ANALYSIS OF BACTERIAL SAMPLES 
 
 
Please initial box 
 
1. I consent to the taking of bacterial samples for the purpose of this 
research study. 
 
 
2. I consent to the tests listed here being done on my bacterial samples. I 
understand that the results will be used mainly for the purpose of the 
current study, but my doctors may use these results in another study. 
 
a. P. acnes counts & P. acnes typing. 
 
b. P. acnes drug sensitivities 
 
c. Culturing of any other pertinent bacterial species 
 
 
3. I agree to my sample being used for more unforeseeable tests as required 
in the future for this or other research. This may depend on the results of 
my culture results e.g. additional sensitivity testing may be required. 
 
a. I would like to be contacted before further tests as mentioned 
above are done on the stored sample for research purposes. 
 
b. I consent to further tests being done on the sample without being 
contacted. 
 
 
 
  
Name of Patient Signature Date 
 
 
 
 
 
  
Name of Person taking consent Signature Date 
(if different from researcher) 
 
 
 
  
Researcher Signature Date 
208  
Advertisements 
 
 Poster Advertisement 
 
 
 
Can you say ‘YES’ to these questions: 
 Do you have problems with facial acne? ( also 
known as spots) 
 Are you between 18 and 45 years of age? 
 Are you willing to be treated for your acne? 
 
If so, you may wish to take part in a research study which aims 
to compare an established acne treatment with a new available 
treatment. 
 
This research project will take place at the Department of 
Dermatology, University Hospital of Wales. 
 
For further details, please call: 
 
 
 
(Travel reimbursements up to £100 will be paid) 
Sister Anne Thomas 
(02920 742672) 
Or 
Dr C A Suthananthan 
(02920 745875) 
 
Department of Dermatology 
3rd  Floor Glamorgan House 
University Hospital of Wales 
Cardiff University 
CF14 4 XW 
DO YOU SUFFER FROM ACNE? 
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 Advertisement in English and Welsh for Cardiff University 
Online Notice Board 
 
 
DO YOU SUFFER FROM ACNE? 
 
Can you say ‘YES’ to these questions: 
 Do you have problems with facial acne? ( also 
known as spots) 
 Are you between 18 and 45 years of age? 
 Are you willing to be treated for your acne? 
 
If so, you may wish to take part in a research study which aims 
to compare an established acne treatment with a new available 
treatment. 
 
This research project will take place at the Department of 
Dermatology, University Hospital of Wales. 
 
To find out if you are suitable for this study, please answer a 
short questionnaire linked below. Once you have completed it, 
you will be contacted about your eligibility. Thank you very 
much for your interest in the study. 
Click HERE 
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A YDYCH YN DIODDEF O'R ACNE? 
 
A ydych yn gallu ateb 'YDWYF' i'r cwestiynau hyn: 
 Ydych chi'n cael trafferth gydag acne (plorod neu 
smotiau yw'r enw gan rai) ar eich wyneb? 
 A ydych rhwng 18 a 45 mlwydd oed? 
 A ydych yn fodlon cael triniaeth am acne? 
 
Os felly, efallai y byddech yn dymuno cymryd rhan mewn 
astudiaeth ymchwil sy'n anelu at gymharu'r dull sefydlog o drin 
acne â thriniaeth newydd sydd ar gael. 
 
Bydd y prosiect ymchwil hwn yn digwydd yn Adran 
Dermatoleg, Ysbyty Prifysgol Cymru. 
 
I weld a ydych yn addas ar gyfer yr astudiaeth, atebwch 
holiadur byr a ddolennir isod. Ar ôl i chi ei gwblhau, cysylltir â 
chi ynglŷn â'ch addasrwydd. Diolch yn fawr iawn am eich 
diddordeb yn yr astudiaeth. 
Cliciwch YMA 
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Questions in Online Questionnaire 
 
1. What is your email address? ……………………………….(Answer) 
2.   What is your postcode?.........................................................(Answer) 
3. What is your telephone number?.............................................(Answer) 
4.   How old are you?...................................................................(Answer) 
5. What is your first name?..........................................................(Answer) 
6.   What is your last name?............................................................(Answer) 
7.   Do you have facial acne?.........................................................(Y/N) 
8. Have you read the Patient Information sheet (PIS)?..................(Y/N) 
9. What happens when you are exposed to the sun? 
 
A: Always burns, does not tan 
B: Burns easily, tans poorly 
C: Tans after initial burn 
D: Burns minimally, tans easily 
E: Rarely burns, tans darkly easily 
F: Never burns, always tans darkly 
 
10. Are you allergic to the sun i.e. itchy rash, blister formation etc 
?..........................................................(Y/N) 
11. Have you had IPL before?...........................................................(Y/N) 
12. When were you last treated with IPL?..........................................(Answer) 
13. Have you had treatment for your facial acne?...................................(Y/N) 
14. What have you had for your facial acne?..........................................(Answer) 
15. When were you last treated for your facial acne?..............................(Answer) 
16. Do you have any skin problems affecting your face? Eg: psoriasis, eczema 
(Y/N) 
17. Do you have other medical problems?.............................................(Answer) 
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Screening Questions for Telephone Enquiries 
 
 
Title: A comparison of the clinical efficacies of intense pulsed light, 
photodynamic therapy and adapalene in the treatment of mild to 
moderate acne vulgaris 
 
DATE:    
 
 
SURNAME 
 
 
FIRST NAME 
 
 
HOME PHONE 
NUMBER 
 
 
MOBILE 
 
 
MAILING 
ADDRESS 
 
 
GENDER(M/F) 
 
 
AGE 
 
 
EMAIL: 
 
 
 
 
 
 
QUESTIONS 
 
(Please Tick) 
YES NO Comment 
Do you have facial acne?    
Have you read the Patient 
Information sheet (PIS)? 
   
What happens when 
you are exposed to the 
sun? 
 
A: Always burns, 
does not tan 
B: Burns easily, tans 
poorly 
C: Tans after initial 
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burn 
D: Burns minimally, 
tans easily 
E: Rarely burns, tans 
darkly easily 
F: Never burns, 
always tans darkly 
   
Are you allergic to the 
sun- i.e. itchy rash, 
blister formation etc? 
   
Have you had IPL 
before? 
   
When were you last 
treated with IPL? 
   
Have you had 
treatment for your 
facial acne? 
   
What have you had for 
your facial acne? 
   
When were you last 
treated for your facial 
acne? 
   
Do you have any skin 
problems affecting 
your face? Eg: 
psoriasis, eczema 
   
Do you have other 
medical problems? 
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The Family Dermatology Life Quality Index 
 
The Family Dermatology Life Quality Index ( FDLQI ) 
 
Name: …………………………… FDLQI Score 
Relationship with patient:  . ...……………………….. 
Patient’s diagnosis (if known): …....……………………… Date: 
...………… 
 
 The questions relate to the impact of your relative/partner’s skin disease on your 
quality of life over the last month. 
 Please read the questions carefully and tick one box for each. 
 
 
1. Over the last month how much emotional distress have you experienced due to 
your relative/partner’s skin disease (e.g. worry, depression, embarrassment, 
frustration)? 
Not at all/Not relevant   A little  Quite a lot  Very much 

2. Over the last month how much has your relative/partner’s skin disease affected 
your physical well-being (e.g. tiredness, exhaustion, contribution to poor health, 
sleep/rest disturbance)? 
Not at all/Not relevant   A little  Quite a lot  Very much 

3. Over the last month how much has your relative/partner’s skin disease affected 
your personal relationships with him/her or with other people? 
Not at all/Not relevant   A little  Quite a lot  Very much 

4. Over the last month how much have you been having problems with other 
peoples’ reactions due to your relative/partner’s skin disease (e.g. bullying, staring, 
need to explain to others about his/her skin problem)? 
Not at all/Not relevant  A little  Quite a lot  Very much 

5. Over the last month how much has your relative/partner’s skin disease affected 
your social life (e.g. going out, visiting or inviting people, attending social 
gatherings)? 
Not at all/Not relevant  A little  Quite a lot  Very much 

(Please turn over) 
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6. Over the last month how much has your relative/partner’s skin disease affected 
your recreation/leisure activities (e.g. holidays, personal hobbies, gym, sports, 
swimming, watching TV)? 
Not at all/Not relevant  A little  Quite a lot  Very much 

7. Over the last month how much time have you spent on looking after your 
relative/partner (e.g. putting on creams, giving medicines or looking after their skin)? 
Not at all/Not relevant  A little  Quite a lot  Very much 

8. Over the last month how much extra house-work have you had to do because of 
your relative/partner’s skin disease (e.g. cleaning, vacuuming, washing, cooking)? 
Not at all/Not relevant  A little  Quite a lot  Very much 

9. Over the last month how much has your relative/partner’s skin disease affected 
your job/study (e.g. need to take time off, not able to work, decrease in the number of 
hours worked, having problems with people at work)? 
Not at all/Not relevant  A little  Quite a lot  Very much 

10. Over the last month how much has your relative/partner’s skin disease increased 
your routine household expenditure (e.g. travel costs, buying special products, 
creams, cosmetics)? 
Not at all/Not relevant  A little  Quite a lot  Very much 


Thank you for completing the questionnaire. 
 
 
 
 
 
 
 
© MKA Basra, AY Finlay. Cardiff University 2005. 
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Dermatology Life Quality Index 
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The Leeds Revised Acne Grading System 
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